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Abstract 
 
During the blood stages of malaria, Plasmodium parasites remodel their 
vertebrate host cells by translocating hundreds of parasite-encoded proteins 
across an encasing double-membrane barrier that separates the parasite 
from the host cell cytosol1–6 via a putative export machinery termed PTEX1. 
Exported proteins have a variety of roles that have been linked to parasite 
growth and virulence. These include proteins containing the PEXEL motif 
(RxLxE/Q/D)1,2 as well as PEXEL-negative exported proteins (PNEPs)6. 
Whilst PTEX has been linked to the export of PEXEL-positive exported 
proteins, there has yet been no direct evidence that PTEX is responsible for 
the translocation of exported proteins. Previously, PTEX has been shown to 
comprise of three core components, those being PTEX150, HSP101 and 
EXP2. Two other proteins, namely TRX2 and PTEX88 had been tentatively 
assigned to PTEX but required validation that they are bona fide PTEX 
components.  
As a result of this study, it was confirmed that PTEX additionally 
comprises of TRX2 and PTEX88, and which the components of PTEX are 
essential or non-essential to parasite survival was also revealed. As a non-
essential PTEX component, TRX2 could be genetically deleted, although 
parasites transgenic parasites lacking TRX2 were significantly affected in 
their growth. As viable parasites harboring a TRX2 gene deletion could be 
recovered, the parasites ability to export proteins could be dissected. While 
the export of individual proteins or reported proteins did not appear to be 
compromised, the cumulative effect of protein export was, with TRX2 
deficient parasites showing a significant reduction in export of proteins to the 
infected erythrocyte surface. In contrast, knockdown of the essential protein 
 
HSP101, had significant consequences on protein export with both classes of 
exported proteins affected.  This indicates targeting of PTEX with anti-
malaria drugs should be against essential PTEX components.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table of Contents 
 
Title Page.i 
Declaration..ii 
Acknowledgement.iii 
List of publications....iv 
Abstract...v 
Table of Contents.....vi 
List of Tables................ix 
List of Figures.x 
List of Abbreviations....xii 
 
Chapter 1 ................................................................................................................... 1
Literature Review ....................................................................................................... 1
1.1 Introduction – The burden of malaria ................................................................ 2 
1.2 The life cycle of Plasmodium ............................................................................. 2 
1.2.1 Transmission of Plasmodium to the human host involves two hosts .......... 2 
1.2.2 Parasite invasion of the host erythrocyte .................................................... 3 
1.2.3 Parasite development within the erythrocyte .............................................. 4
1.2.3.1 Parasite growth during the asexual stages ......................................... 4 
1.2.3.2 Sexual stage development is essential for Plasmodium 
transmission to the mosquito .............................................................. 5 
1.2.4 Pathogenesis of malaria ............................................................................. 7 
1.3 Combating malaria – past, present and future treatments ................................ 8
1.3.1 Existing anti-malaria prophylaxis and treatment ......................................... 9 
1.3.2 The future of malaria treatment ................................................................ 11 
1.4 Remodeling of the host erythrocyte ................................................................. 11
1.4.1 Morphological and structural changes to the host erythrocyte ................. 12 
1.4.2 Protein export ............................................................................................ 15
1.4.2.1 Protein export and the role of the PEXEL/HT motif in protein 
export ................................................................................................ 16
1.4.2.2 PEXEL containing exported proteins ................................................ 17 
1.4.2.3 PEXEL Negative Exported Proteins (PNEPs) .................................. 20 
1.5 Protein translocation across the PVM ............................................................. 21
 
1.5.1 The Plasmodium Translocon of Exported Proteins (PTEX) ...................... 23 
1.6 Project aims and hypothesis ........................................................................... 28 

Chapter 2 ................................................................................................................. 30
Materials and Methods ............................................................................................. 30
1.7 Materials .......................................................................................................... 31
1.8 Methods ........................................................................................................... 32
1.8.1 Ethics statement ....................................................................................... 32 
1.8.2 DNA and protein sequence analysis ......................................................... 32 
1.8.3 Oligonucleotide Primers ............................................................................ 32 
1.8.4 DNA applications ...................................................................................... 32
1.8.4.1 DNA preparation ............................................................................... 32
1.8.4.2 Polymerase Chain Reaction (PCR) amplification ............................. 33
1.8.4.3 DNA digestion ................................................................................... 33
1.8.4.4 DNA ligation ...................................................................................... 33
1.8.4.5 Bacterial transformation .................................................................... 34
1.8.4.6 DNA sequencing ............................................................................... 34
1.8.4.7 Agarose gel electrophoresis ............................................................. 34 
1.8.4.8 Southern blot hybridisation ............................................................... 35
1.8.4.8.1 Preparation of membrane ........................................................... 35
1.8.4.8.2 Digoxigenin labeled DNA probes ............................................... 35
1.8.4.8.3 Hybridisation ............................................................................... 36
1.8.4.8.4 Detection .................................................................................... 36
1.8.4.8.5 Stripping probes from membrane ............................................... 37 
1.8.5 Plasmid constructs .................................................................................... 37
1.8.5.1 Epitope tagging ................................................................................. 37
1.8.5.2 PTEX gene deletion .......................................................................... 38
1.8.6 Protein applications ................................................................................... 39
1.8.6.1 Protein expression ............................................................................ 39
1.8.6.2 Protein purification ............................................................................ 39
1.8.6.3 Protein electrophoresis  .................................................................... 40
1.8.6.4 Western blot analysis ........................................................................ 40
1.8.6.5 Protein immunoprecipitations ........................................................... 41
1.8.6.6 Gel excision and Nano-LC-MS/MS ................................................... 42
 
1.8.6.7 Recombinant protein purification from maltose binding  protein 
 .......................................................................................................... 43
1.8.7 Plasmodium applications .......................................................................... 44
1.8.7.1 Infection of mice with P. berghei. ...................................................... 44
1.8.7.2 Preparation of DNA for P. berghei transfection ................................ 44
1.8.7.3 Preparation of schizonts for P. berghei transfection ......................... 45
1.8.7.4 Transfection and drug selection ........................................................ 45
1.8.7.5 Isolation of parasite DNA from whole blood. ..................................... 46
1.8.7.6 Cloning of transgenic parasites ........................................................ 47
1.8.7.7 Parasite growth curves ..................................................................... 47
1.8.7.8 Parasite virulence analysis ............................................................... 47
1.8.7.9 In vivo / in vitro growth assay ............................................................ 48
1.8.7.10 Generation of semi-immune sera ..................................................... 48
1.8.8 Immunofluorescence analysis of P. berghei ............................................. 48
1.8.9 Flow Cytometry ......................................................................................... 49
1.8.10 Statistical Analysis .................................................................................. 50 

Chapter 3 ................................................................................................................. 53
The conservation and characterisation of the Plasmodium Translocon of 
Exported Proteins ..................................................................................................... 53
1.9 Introduction ...................................................................................................... 54
1.10 Results ........................................................................................................... 55
1.10.1 PTEX components are expressed in P. berghei ..................................... 55
1.10.2 Generation of reagents to P. berghei PTEX components ....................... 56
1.10.2.1 Attempts to generate antibody reagents against PTEX150 and 
TRX2 ................................................................................................. 57
1.10.2.2 Peptide antibody development against TRX2 .................................. 60
1.10.2.3 Epitope tagging of PTEX components .............................................. 61
1.10.3 P. berghei PTEX orthologues localise to the PVM ................................. 63
1.10.4 P. berghei TRX2 and PTEX88 interact with other PTEX 
components .......................................................................................... 65
1.11 Discussion ..................................................................................................... 68 

Chapter 4 ................................................................................................................. 85
 
Dissecting the role of the PTEX components and assessing parasite growth 
and virulence ............................................................................................................ 85
1.12 Introduction .................................................................................................... 86
1.13 Results ........................................................................................................... 87
1.13.1 Generation of PTEX knockout constructs ............................................... 87
1.13.2 Analysis of P. berghei transfectants ........................................................ 88
1.13.3 The P. berghei TRX2 gene can be genetically deleted .......................... 90
1.13.4 Creation of clonal P. berghei TRX2 gene knock out parasites ............... 90
1.13.5 Attempts to complement the P. berghei TRX2 knockout parasites ........ 91
1.13.6 The loss of TRX2 affects P. berghei growth in vivo ................................ 93
1.13.7 Assessment of PbΔTRX2 growth in vitro ................................................ 95
1.13.8 Loss of TRX2 leads to alterations in parasite virulence .......................... 96
1.14 Discussion ..................................................................................................... 98 

Chapter 5 ............................................................................................................... 112
Functional evidence that PTEX is involved in parasite protein export ................... 112
1.15 Introduction .................................................................................................. 113
1.16 Results ......................................................................................................... 113
1.16.1 The deletion of P. berghei TRX2 deletion does not affect the 
export of the endogenous PEXEL proteins PBANKA_122900 & 
PBANKA_114540 ............................................................................... 113
1.16.2 P. berghei TRX2 knockout parasite lines expressing an 
episomally-expressed exported reporter protein ................................. 114
1.16.3 Generation of a P. berghei TRX2 knockout parasite line containing 
an integrated exported GFP reporter gene. ........................................ 116
1.16.4 Live-cell fluorescent imaging of wild type or TRX2 knockout 
parasites expressing an exported GFP reporter ................................. 118
1.16.5 Generation of parasites harboring an exported Nanoluc reporter 
construct ............................................................................................. 120
1.16.6 Measurement of global protein export in P. berghei using semi-
immune sera ....................................................................................... 122
1.16.7 Structural and morphological changes to P. berghei infected 
erythrocytes ........................................................................................ 125
1.17 Discussion ................................................................................................... 127 

 
Chapter 6 ............................................................................................................... 140
Discussion and future directions ............................................................................ 140
Chapter 7 ............................................................................................................... 150
Supplementary data ............................................................................................... 150 

Chapter 8 ............................................................................................................... 154
Appendix ................................................................................................................ 154 

Chapter 9 ............................................................................................................... 158
References ............................................................................................................. 158
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
List of Tables 
 
 
Chapter 1 
 
Table 1.1:  Comparison of the P. falciparum & P berghei exportome 
 
 
Chapter 2 
 
Table 2.1:  Oligonucleotides used in this study 
 
 
Chapter 3 
 
Table 3.1:  Comparisons between the P. falciparum and the orthologous P. 
berghei PTEX protein 
 
Table 3.2:  Reactivity of P. falciparum antibodies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
List of Figures 
 
 
Chapter 1 
 
Figure 1.1: The life cycle of the Plasmodium parasite. 
 
 
Figure 1.2: Schematic model of PTEX. 
 
 
Chapter 3 
 
Figure 1.1:  Schematic of the P. falciparum PTEX components and the 
orthologous proteins in P. berghei. 
 
Figure 3.2:  Anti-PfHSP101 and anti-PfEXP2 cross-react with P. berghei. 
 
 
Figure 3.3:  Expression of recombinant PTEX150 and TRX2 protein. 
 
 
Figure 3.4:  Cleavage of recombinant PTEX150 and TRX2 protein. 
 
 
Figure 3.5:  Sequence alignment between P. falciparum and P. berghei 
TRX2. 
 
Figure 3.6:  Generation of P. berghei transgenic parasites expressing 
epitope tags. 
 
Figure 3.7:  Expression of P. berghei transgenic parasites with epitope tags. 
 
 
Figure 3.8:  P. berghei PTEX components colocalise and have PV/PVM 
localization. 
 
Figure 3.9:  The five putative PTEX components form a complex in P. 
berghei, including PTEX88 and TRX2. 
 
Figure 3.10:  PbTRX2-HA interacts with unique protein species. 
 
 
Figure 3.11:  PbTRX2-HA associates with PTEX & non-PTEX proteins. 
 
 
Chapter 4 
 
Figure 4.1:  Construction of pB3-PTEX knockout constructs. 
 
 
 
Figure 4.2:  HSP101, PTEX150, EXP2 and PTEX88 are not amenable to 
gene deletion 
 
Figure 4.3:  Genetic disruption of TRX2 P. berghei. 
 
 
Figure 4.4:  Confirmation of the P. berghei TRX2 gene knockout 
 
 
Figure 4.5:  Construction of a P. berghei TRX2 complement plasmid. 
 
 
Figure 4.6:  Loss of TRX2 in P. berghei leads to reduced parasite loads in 
vivo. 
 
Figure 4.7:  Loss of TRX2 in P. berghei results in a longer parasite cycle in 
vivo. 
 
Figure 4.8:  Loss of TRX2 leads to altered growth phenotypes in vitro. 
 
 
Figure 4.9:  Loss of TRX2 in P. berghei leads to altered virulence and 
growth phenotypes in C57/Bl6 mice. 
 
 
Chapter 5 
 
Figure 5.1:  P. berghei TRX2 deletion does not affect the ability to export 
two identified endogenously expressed exported PEXEL 
proteins. 
 
Figure 5.2:  Generation of a P. berghei TRX2 knockout encompassing a 
GFP reporter. 
 
Figure 5.3:  Time-course of GFP expression and export in transgenic 
parasites. 
 
Figure 5.4:  Schematic of the constructs designed for episomal expression 
of Nanoluc in P. berghei. 
 
Figure 5.5:  Generation of semi-immune sera against P. berghei infection. 
 
 
Figure 5.6: Disruption of P. berghei TRX2 leads to reduced protein 
export on the erythrocyte surface. 
 
Figure 5.7: Disruption of P. berghei TRX2 leads to reduced protein export 
in synchronous infections. 
 
Figure 5.8:  Surface modification of infected erythrocytes 
 
 
 
List of Abbreviations 
 
Common scientific abbreviations 

Å  angstrom 
ATP   adenosine triphosphate  
BSA  bovine serum albumin 
DNA  deoxyribonucleic acid 
ER   endoplasmic reticulum  
GFP  green fluorescent protein 
HRP  horseradish peroxidase  
Hr/hrs  hour/hours 
Hsp   heat shock protein 
ICAM-1 intercellular adhesion molecule-1  
IFA   immunofluorescence analysis  
kb  kilobase(s) 
kDa  kilodalton(s) 
l  litre(s) 
M  Molar 
μg  microgram(s) 
mg  milligram(s) 
mL  millilitre(s) 
mM  millimolar 
min  minute(s) 
MW  molecular weight 
nm  nanomole(s) 
% (v/v) percent volume per volume 
% (w/v) percent weight per volume 
PAGE  polyacrylamide gel electrophoresis 
PBS  phosphate-buffered saline 
PCR  polymerase chain reaction 
rpm  revolutions per minute 
RT   room temperature 
s  second(s) 
SDS  sodium dodecyl sulphate 
SEM  standard error of the mean 
TBE   Tris-borate-EDTA buffer 
TIC   translocon at the inner membrane of chloroplasts 
TOC   translocon at the outer membrane of chloroplasts 
TOM   translocon at the outer membrane of mitochondria  
TIM    translocon at the inner membrane of mitochondria  
UTR  untranslated region 
 
Plasmodium parasite specific abbreviations 
 
ACT   artemisinin-based combination therapies  
EDV’s  electron-dense vesicles  
EMAP  erythrocyte membrane associated protein 1 
GBP  glycophorin-binding protein-130 
GPI   glycosylphosphatidylinositol  
HSP  heat shock protein 
HT   Host-Targeting Signal  
 
KAHRP  knob-associated histidine rich protein  
MAHRP-1 membrane-associated histidine-rich protein 1 
MAHRP2 membrane-associated histidine-rich protein 2 
mDHFR mouse dihydrofolate reductase 
NPPs   new permeation pathways 
PEXEL  Plasmodium EXport ELement  
Pf  Plasmodium falciparum 
Pb  Plasmodium berghei  
PfEMP1 P. falciparum erythrocyte membrane protein  
PIR   Plasmodium interspersed repeats 
PNEPs  PEXEL negative exported proteins 
PTEX  Plasmodium Translocon of EXported proteins  
PV   parasitophorous vacuole  
PVM   parasitophorous vacuole membrane  
RESA  ring-expressed surface antigen 
REX1   ring exported protein 1  
REX2   ring exported protein 2 
Rif  Repetitive interdispersed family 
SBP-1  skeleton-binding protein 1 
Stevor  subtelomeric variable open reading frames 

 

























 










Chapter 1 


Literature Review 






















 
 
1.1 Introduction – The burden of malaria 
Malaria is a global disease caused by infection with Apicomplexan 
protozoan parasites of the genus Plasmodium.  Multiple species of 
Plasmodium exist, five of which can infect humans: P. falciparum, P. vivax, 
P. malariae, P. ovale and P. knowlesi. The latter circulates in primates but 
has recently been observed to also infect the human host2,3.  Whilst P. vivax 
is widely distributed and causes a greater number of infections4, P. 
falciparum is the most virulent of the species, and is responsible for the 
majority of deaths caused by malaria5; accordingly, it is the focus of this 
review.  In 2012, an estimated 207 million malaria infections occurred, with 
627,000 (±150,000) deaths attributed to severe malaria, 90% of which 
occurred in sub-Saharan Africa. Most malaria infections occur in 
underdeveloped regions, with ~3.4 billion people at risk of infection6.  In 
addition to mortality and morbidity, malaria also causes an enormous 
financial impact on the economy, as a result of treatment costs and lost 
productivity.  
 
1.2 The life cycle of Plasmodium   
1.2.1 Transmission of Plasmodium to the human host involves two 
hosts  
The spread of the malaria parasite is attributed to the female Anopheles 
mosquito. Infection of a human host occurs when an infected mosquito takes 
a blood meal and subsequently injects extracellular sporozoites present in 
her salivary glands into the host (Figure 1.1i)7,8, where they migrate via the 
 	
bloodstream, passing through host cell barriers to the liver (Figure 1.1ii). 
There they bind to liver-specific heparan sulfate proteoglycans on the 
endothelial cell surface9,10 and glide along the endothelium.  The parasites 
then actively cross the capillary wall through Küpffer cells, and transmigrate 
through several hepatocytes before finally invading a hepatocyte and 
becoming encased within a parasitophorous vacuole (PV)11. At this stage of 
the malaria infection, no clinical symptoms are experienced. After parasite 
growth and mitotic division within the infected hepatocyte, a large schizont 
containing thousands of liver merozoites matures and ruptures, releasing 
infective merozoites into the bloodstream in vesicles called merosomes12. 
The released merozoites then invade red blood cells. 
 
1.2.2 Parasite invasion of the host erythrocyte  
The invasion of merozoites into erythrocytes (Figure 1.1iii) relies on an 
initial low-affinity association between glycosylphosphatidylinositol (GPI)-
anchored proteins on the surface of the extracellular merozoite and the 
erythrocyte surface.  Plasmodium parasites actively penetrate their host cell, 
which involves a highly coordinated cascade of events that lead to the 
sequential secretion of proteins from the apical organelles: micronemes, 
rhoptries and dense granules13,14. This includes specific interactions between 
host cell receptors and parasite ligands that are released from the 
micronemes and rhoptry, and the establishment of a tight junction at the 
parasite-host cell plasma membrane interface15.   Invagination is initiated and 
accomplished with the aid of the merozoite derived actin-myosin motor13, 
with the shedding of merozoite surface proteins as the parasite moves into 
 

the erythrocyte16. Upon invasion, the parasite becomes encased inside a PV 
which is bounded by the parasitophorous vacuole membrane (PVM)17,18. 
Once invasion is complete and the PVM is sealed, the dense granules are 
released into the PV space. At this stage, the parasite is equipped with its 
core organelles, including a nucleus, endoplasmic reticulum, a rudimentary 
Golgi, a single mitochondrion and an apicoplast19 . 

1.2.3 Parasite development within the erythrocyte 
1.2.3.1 Parasite growth during the asexual stages  
P. falciparum-infected erythrocytes are visible by microscopy in Giemsa-
stained blood smears, where they exhibit an indicative ring-shaped 
appearance shortly after erythrocyte invasion. The parasite then undergoes a 
period of growth during the trophozoite phase of its development while 
actively remodeling its host erythrocyte20 and consuming the erythrocytes 
cytoplasm21. For this, the food vacuole is a major parasite digestive organelle 
which degrades host-derived hemoglobin to obtain amino acids21,22. A by-
product of hemoglobin degradation, toxic ferriprotoporphyrin IX is produced 
which is then polymerized to crystalline hemozoin (malaria pigment)21, 
appearing as a distinct feature of the food vacuole of trophozoite and 
schizont parasites23-25. Whilst hemoglobin degradation by a multitude of 
peptidases26-28 is sufficient to provide some amino acids, exogenous amino 
acids for parasite growth are also required21. 
Further parasite adaptations to surviving the intra-erythrocytic stage 
include new induced structures and morphological alterations to the 
 
erythrocyte cytosol and the surface, which alters the rigidity of the host cell 
as well as its permeability, that enables the parasite to take up the necessary 
nutrients to support parasite growth. As discussed in section 1.4, these 
modifications are also important to parasite virulence and immune evasion.  
During the schizont stage, the parasite undergoes numerous rounds of 
binary division, until finally each schizont contains between 8 and 20 
daughter merozoites. Simultaneously, degradation of the erythrocyte 
membrane and subsequent osmotic swelling causes elastic instability of the 
membrane29 and complete membrane degeneration30-32, leading to parasite 
rupture and rapid ejection of merozoites33 into the bloodstream, which can 
then infect new erythrocytes18. The amplification of the erythrocyte stages 
and parasite rupture coincides with the symptomatic stages of infection. 
 
1.2.3.2 Sexual stage development is essential for Plasmodium 
transmission to the mosquito 
The asexual replication of the malaria parasite is responsible for the 
continual proliferation of the parasite, yet in order for disease transmission to 
occur between hosts, intraerythrocytic differentiation and development of 
highly specialized male and female gametocytes must take place (Figure 
1.1iv). Gametocytogenesis begins at approximately 7–15 days after blood 
stage parasites appear34, and is influenced by different kinds of stresses, 
including parasite density, host anemia, and  host immune response or drug 
treatment. Development into gametocytes is defined early at the invading 
merozoite stage35. Gametocyte maturation proceeds through five defined 
morphological stages; the first four adhere to host tissues and are 
 
sequestered in the hematopoietic system36. Mature, stage five gametocytes 
are released into the peripheral circulation34,37-39 and are taken up by a 
mosquito during her blood meal40,41. Once ingested, the male and female 
gametocytes undergo gametogenesis within the lumen of the mosquito 
midgut, after which, they undergo syngamy to fuse into a zygote that by 
meiosis, develops into the motile ookinete.  The ookinete transverses the 
peritrophic membrane, to ultimately reside in the extracellular space of the 
basal lamina.  Asexual sporogony occurs and after two weeks incubation, 
thousands of sporozoites are produced within this oocyst. Upon maturation, 
sporozoites are released, after which they attach and invade the salivary 
gland epithelium to form a transient vacuole. Here the sporozoites mix with 
mosquito saliva, where few enter the salivary duct and are injected into the 
next vertebrate host during the next feed to perpetuate the cycle of 
infection42.
 











 
Figure 1.1: Schematic of the life cycle of Plasmodium parasite. 
The malaria parasite life cycle involves two hosts. Transmission of the 
vertebrae host is attributed to the female Anopheles mosquito vector. i-iv 
refers to the phases of parasite development in the vertebrae host (see in 
text). ET: Early trophozoite (ring-like appearance), LT: Late trophozoite, S: 
Schizont.
 
1.2.4 Pathogenesis of malaria 
As outlined in section 1.4, during the erythrocytic stages of infection, major 
structural and morphological changes are made to the infected erythrocyte, 
leading to altered physical properties and impaired cell function43.  Infected 
erythrocytes become rigid with a rough surface, attributed to the protrusion of 
small electron dense knob-like structures44 that comprise of the knob-
associated histidine rich protein (KAHRP)45,46.  These protrusions act as 
platforms for anchoring the major virulence determinant and cytoadherance 
factor, P. falciparum erythrocyte membrane protein (PfEMP1)47,48.  This 
mediates an adhesive phenotype on the infected erythrocyte, which enables 
infected cells to bind to the microvascular endothelium by interaction with 
host cell receptors such as CD3649-51 in most organs, intercellular adhesion 
molecule-1 (ICAM-1) which is predominantly present in brain tissue, and 
chondroitin sulphate-A in the placenta52,53.  The adhesive phenotype of the 
infected erythrocyte plays an important role in immune avoidance. By 
sequestering in the microvasculature, the infected cells avoid passage 
through the spleen where splenic macrophages would normally recognise 
and destroy altered or damaged erythrocytes54. Infected erythrocytes can 
also adhere to uninfected cells in a process called rosetting55,56, via the CD36 
and platelet receptor (yet to be identified) with cell clumping likely to cause 
microvascular blockages and sequestration of infected erythrocytes leading 
to reduced microvascular blood flow and hypoxia57.  The release of 
Plasmodium toxin (GPI-toxin) also stimulates macrophages to release Tumor 
Necrosis Factor-α and other cytokines such as Interleukin-1 that contribute to 
the inflammatory process58.  Excess nitric oxide production is also induced, 
which diffuses through the blood-brain barrier leading to changes in synaptic 
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function and subsequently reduced consciousness59-61.  As a consequence 
of these mechanical and inflammatory events in the brain, seizures, paralysis 
and coma are common symptoms of severe cerebral malaria (CM)62, which 
can be fatal. While CM is a more common presentation of severe malaria 
where transmission intensity is low, severe anemia predominates where 
transmission intensity is high5. In addition to the destruction of infected and 
uninfected erythrocytes, anemia is also caused by inadequate host 
responses such as decreased erythrocyte production and/or suppression of 
the erythropoietic response resulting in ineffective erythropoiesis63. 
Furthermore, metabolic acidosis49 and acute respiratory distress syndrome 
are other complications arising from severe malaria symptoms
52
. 
 
1.3 Combating malaria – past, present and future treatments 
Individuals in Plasmodium falciparum endemic areas slowly develop 
natural semi-immunity to malaria after repeated exposure to Plasmodium 
infections64,65, yet complete protective immunity is never achieved. Adaptive 
protection against severe malaria results in a lower risk of clinical disease, as 
indicated by both the absence of an accompanying fever, and lower densities 
of parasitemia66. Knowledge of the acquisition and nature of protective 
immune responses against P. falciparum is presently limited, particularly 
among young children64, whom are most susceptible to severe malaria and 
subsequently endure the most fatalities 67,68 . Consequently, it is paramount 
that individuals are protected from infection through other means, or have 
access to cheap and effective treatments.  
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1.3.1 Existing anti-malaria prophylaxis and treatment 
 Basic prevention of transmission with the use of insecticide-treated 
mosquito nets and control of the mosquito vector by insecticide spraying has 
proved to be an effective method in reducing the number of new infections69. 
However, whilst the use of insecticide-treated bed nets and indoor residual 
spraying of insecticide70 has contributed to a reduction in infection rates, 
challenges arise with variances in compliancy49,71 and increasing resistance 
of the mosquito vectors to pyrethroids and to other insecticides, which 
overall, jeopardizes the global malaria control efforts6. As a consequence, 
further prophylaxis methods for prevention have been explored, with a 
vaccine the most desirable option, as it would provide a greater coverage 
and long-term protection against malaria.   
Attenuated, subunit, recombinant and DNA vaccines have all been 
investigated as strategies to prevent malaria infection or severity of disease.  
The multiple life cycle stages of the malaria parasite can provide targets for 
vaccine development, such as the pre-erythrocytic stages, where vaccines 
are directed against the invasive sporozoite. Alternatively, vaccines can be 
designed against the asexual blood stage where they may prevent 
erythrocyte invasion, destroy intra-erythrocytic parasites or reduce the 
virulence of the parasite and hence reduce malaria symptoms. Finally, 
vaccines against the sexual stage parasite to prevent intra-mosquito 
development is another strategy that can block transmission of malaria 
between human hosts72. However, to date, vaccine development against 
Plasmodium has proven to be extremely difficult due to the parasite’s ability 
to switch the antigens it expresses and the diverse polymorphisms exhibited 
in its antigens73.  For efficient eradication of malaria, a successful vaccine 
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would need to be at least 50% effective against severe disease and provide 
long lasting immunity against infection74. To date, the most successful 
vaccine candidate, targeting the central repeat region75 at the carboxy-
terminal of P. falciparum circumsporozoite protein76,77, and termed 
RTS,S/AS01, has been shown to reduce mild and severe disease after 
preliminary stage III clinical trials78. During 18 months of follow-up, 
vaccination of children and young infants with RTS,S/AS01 prevented many 
cases of clinical and severe malaria79. Children receiving three doses of their 
first vaccination between 5-17 months of age, had a 36% reduced incidence 
of severe disease, while infants first vaccinated at 6–12 weeks old had a 
decreased incidences of severe disease of 15%78. Despite this positive 
outlook, this vaccine is only partially protective against disease and wanes 
over time79, with the status of efficacy of RTS,S/AS01 at the phase 3 trial 
lower than that observed in a phase 2 trial involving infants80.  Thus, the 
RTS,S/AS01 vaccine alone is unlikely to reduce the global burden of malaria. 
Therefore, to have a significant impact, even if this vaccine were to be 
licensed, it would need to be used in conjunction with other prevention 
methods81.      
Once an infection is diagnosed, prompt administration of appropriate drug 
treatments can reduce the severity or clear a malaria infection.  However, 
past use of anti-malarial drugs has only been partially effective in controlling 
malaria and the high prevalence of multidrug-resistant P. falciparum 
parasites has given rise to its success as a pathogen.  Primary anti-malarials 
that had been effective in controlling malarial infections include chloroquine 
and sulphadoxine-pyrimethamine. However, resistance to both drug classes 
has developed in most P. falciparum endemic areas82, and as a 
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consequence, the use of artemisinin-based combination therapies is now 
recommended. The effects of artemisinin results in rapid parasite clearance 
with a longer-acting partner drug83 to multiple parasite stages83-85. However, 
the efficacy of artemisinins has become compromised, with artemisinin 
resistance recently emerging, characterised by slow parasite clearance
86,87
. 
 
1.3.2 The future of malaria treatment 
As parasites continue to exhibit multi-drug resistance to the last-line of 
treatments available, it is very clear that new strategies to combat the 
Plasmodium pathogen are needed.  In order to approach the development of 
vaccines and new drugs rationally, we require an in-depth understanding of 
malaria parasite biology and how Plasmodium parasites are able to 
successfully evade the host immune response to cause disease. One of the 
processes which is central to parasite virulence and survival is the parasite’s 
ability to remodel its host cell. Thus understanding the mechanisms by which 
the parasites achieves this may identify new molecular pathways that can be 
targeted by drugs or a vaccine to ultimately destroy parasites at the blood 
stages of growth or even to reduce the severity of the disease.  
 
1.4 Remodeling of the host erythrocyte 
Healthy erythrocytes are flexible, flattened, circular discs about 6-8μm in 
diameter88.  Mature erythrocytes lack cell organelles, an intracellular 
membrane system and a protein synthesis system. They consist of a 
cytoplasm within a plasma membrane, containing a high concentration of 
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hemoglobin, which binds and releases oxygen and carbon dioxide89. The 
plasma membrane is anchored to a network of proteins known as the 
spectrin membrane skeleton, which gives the erythrocyte its elasticity and 
flexibility to allow passage through blood vessels and thin capillaries90. 
Healthy erythrocytes circulate for three months, after which old or damaged 
cells are cleared by the liver’s reticuloendothelial system91. However, upon 
infection with Plasmodium parasites, the erythrocyte becomes drastically 
remodeled. This involves structural changes to the host cell (see section 
1.4.1) as well as the export of hundreds of parasite proteins (see section 
1.4.2) beyond the PV and across the PVM into the host cell.  These parasite 
proteins may either reside within the host cell cytosol as soluble proteins, or 
localise within or associate with novel parasite induced membranous 
structures in the host cell, while others are presented on the erythrocyte 
surface. To traffic proteins to these destinations, the parasite needs to 
employ its own protein export machinery to compensate for the lack of 
trafficking machinery in the naïve erythrocytes.   
 
1.4.1 Morphological and structural changes to the host erythrocyte  
There are several types of modifications that occur to the host erythrocyte 
once they become infected by Plasmodium spp. As part of the host cell 
modification process, for example, membranous structures appear in the 
cytoplasm of infected erythrocytes92. In P. falciparum, these structures are 
known as Maurer’s clefts, which are thought to function as a sorting 
compartment for parasite proteins transiting between the parasite and 
erythrocyte membrane93. While the origin of Maurer’s clefts remains 
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unknown, they may exist as independent structures or represent subdomains 
of the tubulovesicular network that extends from the PV93. The morphology of 
Maurer’s clefts is heterogeneous in size and structure, consisting of both 
branched membrane tubules and stacked disk-shaped cisternae94.  
Membranous structures have also been observed in other Plasmodium 
species such as P. berghei95,96 but whether these perform a similar function 
to Maurer’s clefts is unknown.  
The formation and maturation of Maurer’s clefts in P. falciparum has been 
examined in trafficking studies combined with 4D microscopy/tomography 
using integral Maurer’s cleft proteins fused to fluorescent proteins as 
markers. These experiments have shown that clefts are present much earlier 
than initially thought, appearing 2 - 4 hrs post invasion97, and that a set 
number of Maurer’s clefts are produced after invasion, with no new structures 
appearing over the remaining stages of parasite development97. This 
indicates that Maurer’s clefts are generated before most proteins destined for 
export have been synthesized. However, as proteins localise to the Maurer’s 
clefts after their formation, suggests that the major route of export for 
membrane proteins is not during cleft formation but via alternative 
pathways97 such as vesicles98 or soluble intermediates99. Further to this, 
Maurer’s clefts maintain a fixed position within the host cytoplasm due to 
tethers100 and thin attachments made between the erythrocyte membrane 
and PVM, although no continuous trafficking network to allow transport of 
proteins or molecules exists between the three compartments93,101,102. 
Parasite derived ‘dot-like’ structures termed J-dots103, are also distributed 
within the host cell cytoplasm in the early ring stage of the P. falciparum 
blood stage life cycle.  J-dots are also potentially membrane vesicles, but 
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these do not co-localise with the Maurer’s cleft marker, Skeleton-binding 
protein 1 (PfSBP1), nor do they share any other of the Maurer’s clefts 
antigenic determinants103. Proteins that have been shown to associate with 
J-dots include molecular chaperones and co-chaperones, which may 
facilitate the export and folding of other parasite-encoded proteins in the 
infected erythrocyte cytosol103,104.  
Another major structural change that has only been described in P. 
falciparum-infected erythrocytes is the development of electron-dense 
protrusions or knobs on the membrane surface105.  These structures are 
formed by KAHRP and erythrocyte membrane protein-2 (PfEMP2) also 
known as MESA, which localises to the cytoplasmic side of the erythrocyte 
membrane. The knobs are responsible for anchoring PfEMP1, and thus 
contribute to sequestration of infected erythrocytes and parasite virulence106, 
as outlined in section 1.2.4. Plasmodium species other than P. falciparum, 
such as rodent malaria P. berghei also cytoadhere to the endothelial lining in 
the microvasculature107,108, but none of these species harbour PfEMP1109 or 
KAHRP orthologues. Thus what parasite molecules mediates the binding to 
host ligands, such as CD36107 in these  species remains unknown.  
Other parasite induced structures observed in P. falciparum-infected 
erythrocytes include large electron-dense vesicles (EDV’s)110 approximately 
80 - 100nm in diameter, which form in the trophozoite stage and appear in 
low numbers . EDV’s contain PfEMP1 and PfEMP3 on their surface98,111 and 
fuse with the erythrocyte membrane110, suggesting EDVs may be involved in 
the delivery of integral membrane protein cargo to the erythrocyte 
membrane19. Similar structures, described as caveolae, have been observed 
in trophozoite stages of P. falciparum112 and other Plasmodium species, P. 
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vivax and P. cynomolgi113, indicating they may share a conserved 
function112,114. 
In addition to inducing new structures within the host erythrocyte, an 
increase in erythrocyte permeability also occurs following infection115. This 
stems from the parasite inducing new permeation pathways (NPPs) in the 
erythrocyte to facilitate the transport of small molecules such as 
monosaccharide sugars, amino acids, peptides, nucleosides, and 
monovalent inorganic anions and cations105,116 that the parasite requires as 
nutrients. Additionally, toxic waste bi-products such as lactate, are also 
excreted from the cell117.  
 
1.4.2 Protein export 
In addition to the structural modifications the parasite imparts on the host 
erythrocyte, the parasite also exports its own proteins into the host cell. In 
order for Plasmodium proteins to gain access to the host cell, they must 
traverse two separate membranes, the parasite plasma membrane and the 
PVM118.  The export pathway begins with co-translational targeting of 
parasite proteins to the endoplasmic reticulum (ER), followed by a classical 
eukaryotic secretion pathway to the parasite plasma membrane and release 
of proteins into the PV space119,120.  
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1.4.2.1 Protein export and the role of the PEXEL/HT motif in 
protein export 
Most parasite proteins destined for export contain a classical hydrophobic 
ER signal sequence at the N-terminal region, which facilitates co-
translational insertion in the ER118,119,121. Fusion of GFP to a classical signal 
sequence results in localisation of GFP to the PV120,121, whereas fusion of 
GFP to sequences lacking such N-terminal signal sequence remain in the 
parasite cytosol.  Varying forms of the signal sequence exist, however, some 
exported proteins such as glycophorin-binding protein-130 and ring-
expressed surface antigen (RESA), possess a recessed hydrophobic 
sequence, located more than 50 amino acids from the N-terminus. From the 
ER, proteins are trafficked via typical eukaryotic secretion to the parasite 
plasma membrane in secretory vesicles and fusion of these vesicles with the 
parasite plasma membrane releases soluble proteins into the PV. It is not 
known whether parasite proteins that contain a transmembrane domain(s), 
are inserted into the ER membrane or are maintained in a soluble form within 
trafficking vesicles and thus released directly into the PV space or inserted 
into the parasite plasma membrane, followed by extrusion122.  
Proteins destined for translocation beyond the parasite and into the host 
cell must be distinguished from those that localise to the PV or to other 
regions within the parasite that utilise the ER-secretory pathway. A highly 
conserved core set of five residues, RxLxE/Q/D, where x is any uncharged 
amino acid residue, was identified which specifically directs export. This motif 
has been termed the Plasmodium EXport ELement (PEXEL)123 or Host-
Targeting Signal (HT)124. Chimeric constructs comprising the N-terminal 
region of three soluble exported proteins containing the ER signal sequence 
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and PEXEL motif fused to GFP, were shown to be trafficked beyond the PVM 
into the erythrocyte cytosol, indicating these N-terminal regions are sufficient 
for protein export123.  
The PEXEL motif is proteolytically cleavage in the ER by the aspartic acid 
protease Plasmepsin V125-128,129.  Since Plasmepsin V processing occurs in 
the ER, it suggests that sorting of cargo to be exported occurs early in the 
secretory pathway125,127,129,130. Cleavage of the PEXEL motif occurs between 
residue three and four, after the leucine, resulting in a protein with a new N-
terminus (xE/Q/D)129-131, which is then N-acetylated (Ac-XE/Q/D)129. 
Mutations of the conserved arginine (R), leucine (L), or R/L/glutamine (E) to 
Alanine (A) abrogates N-terminal protein cleavage125, leading to retention of 
the protein in the ER127,131, as well as accumulation in the PV123,124. In 
contrast, mutation of the conserved fifth amino acid (E/Q/D) alone does not 
inhibit PEXEL cleavage or N-acetylation, indicating this residue is not 
essential for PEXEL processing125. However, while not important for 
cleavage, amino acid residues 4 and 5 appear to be important for efficient 
protein trafficking and export, signifying the N-terminus of the mature PEXEL 
is important for directing correct export to the host cell127,131-134. 
 
1.4.2.2 PEXEL containing exported proteins 
The discovery of the highly conserved PEXEL/HT motif in malaria 
parasites has enabled prediction of the proteins that are exported in 
Plasmodium species, including those that infect rodents, birds, apes and 
humans123,124,135,136. The prediction algorithm developed by Sargeant et al 
(2006)135, termed ExportPred, was used to predict the number of exported 
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proteins in the Plasmodium genus based on the presence of a signal 
sequence and a PEXEL motif. Of ~5000 P. falciparum proteins, 396 were 
predicted to be exported, and many of these proteins contain one or two 
predicted transmembrane domains.  Variation in the PEXEL motif has also 
been considered, including an export motif containing an arginine instead of 
a lysine (KxLxE/Q/D), or a relaxed PEXEL motif that includes an insertion of 
an amino acid between residues 4 and 5 (RxLxxE/Q/D)123,124. However, only 
RxLxE and a relaxed PEXEL motif (RxLxxE/Q/D) have been shown to be 
proteolytically cleaved by Plasmepsin V, whereas the putative PEXEL motif 
KxLxE/Q/D is not134. Based on further advances in the ExportPred (v2) 
algorithm, combined with gene modeling and annotation, the P. falciparum 
PEXEL exportome is now predicted to comprise of 463 proteins134.   
The PEXEL motif is also conserved amongst the Plasmodium species135 
being largely similar across eight different Plasmodium species examined to 
date (P. falciparum, P. reichenowi, P. vivax, P. knowlesi, P. gallinaceum, P. 
chabaudi, P. yoelii, and P. berghei)109,136. The most prominent difference in 
the PEXEL motif between the species is at the positively charged amino acid 
at position 1 of the PEXEL motif from arginine (R) to lysine (K)136. 
Based on the P. falciparum PEXEL motif algorithm, fewer PEXEL-positive 
proteins are present in non-falciparum species (Table 1.1). For example, P. 
berghei is predicted to export only around 75 PEXEL positive proteins into 
the host cell137. This is around six times smaller than the P. falciparum 
exportome. The large P. falciparum exportome, compared to other species is 
partly because of radiation and expansion of gene families in P. falciparum 
including those containing DnaJ domains138, the Plasmodium helical 
interspersed subtelomeric (PHIST) family135 and Stevors/Rifins. 
 
Approximately 75% of all the P. falciparum exported proteins belong to these 
protein families, whilst the remaining proteins (~200) are 
unrelated49,135,139,140. Also unique to P. falciparum, is the increased number of 
exported proteins required for the export of PfEMP1 to the parasite infected 
erythrocyte surface141. Multiple proteins have been identified (eg: SBP1, 
PFB0106c, MAL7P1.172, PF14_0758, and PF13_0076), that are required for 
the correct trafficking of PfEMP1 to its final destination at the erythrocyte 
surface140,142,143. 
Regardless of the size of their respective exportomes and differences in 
the number of PEXEL proteins, the presence of a functionally conserved 
PEXEL motif among Plasmodium species109,123,135,144,145, suggests that 
protein trafficking and host-cell remodeling is conserved among the 
Plasmodium spp. Further supporting this is the observation that exported 
proteins are present on the infected erythrocyte surface, as well as in 
vesicular-like membranous structures in erythrocytes infected with P. 
falciparum and other species such as P. berghei95,96,109,146,147. 
Table 1.1: Comparison of the P. falciparum & P berghei exportome 
 P. falciparum P. berghei  
PEXEL proteins    
- Protein families*1 >26 (eg: Rifin, Stevor) >5 (eg: Fam-b) 
- Unique protein *2 108 (eg: KAHRP) >75 (eg: SMAC) 
   
PNEP proteins    
- Protein families*3 >1 (eg: PfEMP1) >1 (eg: BIRs) 
- Unique protein *4 >15 (eg: SBP1) >20 
   
Total exported proteins ~463 ~350 
*1 PEXEL proteins that are members of protein families 
*2 PEXEL proteins that are unique and which do not belong to a protein family 
*3 PNEP proteins that are members of protein families 
*4 PNEP proteins that are unique and which do not belong to a protein family 
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1.4.2.3 PEXEL Negative Exported Proteins (PNEPs) 
Whilst the identification of the PEXEL motif has been a valuable prediction 
tool for exported proteins, there are known exported proteins that lack the 
classical PEXEL motif123, which are termed PEXEL negative exported 
proteins (PNEPs). This class of exported proteins contain no distinct 
structural features or a common motif that can be used to predict their 
export122,148. Initially only a handful of exported proteins were identified as 
PNEPS, including SBP-1149, membrane-associated histidine-rich protein 1 
(MAHRP-1150), MAHRP2100 and ring exported proteins (REX1)151 and 
REX2152. These proteins localise to Maurer’s clefts149-152 or tethers100, and 
some contain a single internal hydrophobic stretch148,152. However by 
searching for proteins with a similar expression profile to the known PNEPS, 
10 novel candidates were recently identified, indicating they are more 
numerous and diverse than initially anticipated139 and might play a more 
significant role in host cell remodeling122. Protein unfolding of PNEPs is also 
required for their translocation, which further suggests that these proteins 
follow the same pathway as PEXEL positive proteins139. While the rodent 
Plasmodium species contain fewer PEXEL proteins than in P. falciparum, 
they appear to export a larger repertoire of PNEPs109, (such as erythrocyte 
membrane associated protein 1. For example, the P. berghei genome 
encodes more than 120 PNEPs109, with ~100 PNEPs assigned to a family of 
proteins called the BIR proteins, belonging to the overarching Plasmodium 
interspersed repeat (PIR) superfamily, which can be found in other rodent 
Plasmodium species such as P. yoelli (YIR)153 or P. chabaudi (CIR)154 as 
well as P. vivax (VIR)155. In addition, the Pb-fam-a protein family in P. berghei 
contains 23 members, along with other unique PNEPs in this species, which 
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do not belong to either of these families. Thus, combined with PEXEL 
positive proteins, the P. berghei putative exportome, including PEXEL 
positive and PNEP exported proteins, comprises approximately 350 
proteins109.  
 
1.5 Protein translocation across the PVM 
The discovery of a common PEXEL motif between most exported proteins 
indicated that a common mechanism is used by the parasite to traffic and 
export proteins across the parasite membrane and PVM104. Whether the 
same can be said of PNEPs is unknown as is whether they use the same 
export pathway to PEXEL proteins or trafficked separately126..  
It has been hypothesised that for proteins to cross the PVM, either 
vesicular mediated transport is utilised by the parasite, although no evidence 
exists for this pathway, or alternatively, a translocon is present at the PVM. If 
parasite proteins cross the PVM via a translocon, it is anticipated that the 
proteins arriving in the PV are in an unfolded state to be competent for 
export156 and that energy is also required to cross this membrane. Support 
for the translocon hypothesis came from experiments showing that, exported 
proteins fused to mouse dihydrofolate reductase (mDHFR) that can be 
blocked from unfolding using the drug WR99210, remain trapped in the 
PV126,156. Moreover, depletion of ATP from the erythrocyte cytosol arrests 
protein transport in the PV157. 
To understand how Plasmodium parasites traffic proteins across the PVM, 
and to help identify a possible translocon, other translocation systems that 
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exist in nature which coordinate the delivery of multiple distinctive classes of 
protein substrates across various membranes to a range of 
destinations158,159, have been compared with the anticipation of finding 
similarities (e.g. chloroplast, mitochondria and bacteria secretion systems).  
All these translocons comprise of three core features: receptor(s) to 
recognise the cargo to be translocated, the pore-forming component that 
provides a portal for proteins to cross the membrane and a motor158-160 to 
provide energy for the translocation process. In addition, translocons also 
comprise of other structural proteins to hold the complex in a particular 
conformation, regulatory proteins that may serve diverse roles, such as 
aiding the assembly of the translocon or to maintain in an open competent or 
closed state.  
Protein substrates are directed to the translocon pore by the receptor 
components associated with the translocon complex. Receptors may be 
anchored to the membrane via a transmembrane domain or bind cargo in the 
cytosol and then peripherally associate with the membrane through 
interaction with other translocon components. Receptor proteins vary in size, 
structure and in their degree of conservation161. 

The translocon pore is an aqueous channel formed by membrane-
embedded proteins which proteins assume highly stable structure162. The 
manner in which proteins insert into the membrane to form the channel can 
vary. In mitochondria, the translocon at the outer membrane of mitochondria 
(TOM) pore-forming component, TOM40, forms a β-barrel structure through 
the membrane, with several TOM40 molecules forming 2-3 pores163-166. In 
contrast, the main pore-forming component of the translocon at the inner 
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membrane of chloroplasts (TIC), Tic110, is mostly a α-helical protein167. Both 
channels are cation selective and are between 17-25 Å in size.  
Associated with the translocon is a component that serves as the energy 
source to aid translocation. The motor component may be bound on the trans 
or cis side of the membrane to pull (e.g., hsp70 of the ER in mitochondria168) 
or push (e.g., SecA at the bacterial plasma membrane169) across the 
membrane. Both of these examples are ATP-driven, however GTP-driven 
motors also exist.  
Other components that contribute to protein translocation include 
chaperones. These prevent protein cargo from misfolding, aggregating or 
interacting with other cellular proteins prior to or after translocation158, and 
commonly depend on adenosine triphosphate (ATP) or guanosine 
triphosphate (GTP) hydrolysis for their activity158.  Chaperone proteins can 
play two roles in protein translocation: Firstly, as most membrane systems 
can only transport proteins that are at least partially unfolded, chaperones 
help to maintain substrates in a translocation-competent state158,170,171. 
Secondly, in some translocons, chaperones may also provide energy for 
translocation, such as Toc159, which is not only a receptor in the 
translocases of the outer membrane of chloroplasts (TOC), it also acts as a 
GTP-driven motor that threads pre-proteins into the Toc-channel of 
chloroplasts172.  

1.5.1 The Plasmodium Translocon of Exported Proteins (PTEX)  
Although it was hypothesised that proteins cross the PVM by passing 
through a translocon, sequence homology searches for proteins that are 
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orthologues of components of known translocon systems described in 
section 1.5, failed to identify candidates1.  However, proteomic analysis of 
schizonts stage parasites revealed a lipid-raft-like detergent resistant 
membrane preparation that was enriched for proteins known to localise at the 
PVM. Thus by using specific criteria, and performing biochemical and cell 
biology analysis, de Koning-Ward et al (2009)1 were able to identify the 
malaria protein export machinery termed Plasmodium Translocon of 
Exported Proteins (PTEX), which comprises of five putative translocon 
components. These include HSP101 (heat shock protein 101, a AAA+ 
ATPase), EXP2 (a previously identified PVM protein173,174, TRX2 (a 
thioredoxin-like protein)175, and PTEX150 and PTEX88, so named based on 
their migration size by SDS-PAGE. Each of these five components is unique 
to and conserved within the Plasmodium genus. 
In initial studies of PTEX, a series of reagents were generated to 
characterise the complex, including specific antibodies recognising P. 
falciparum PTEX150 (PfPTEX150), P. falciparum HSP101 (PfHSP101) and 
P. falciparum EXP2 (PfEXP2), as well as the generation of two transgenic P. 
falciparum parasite lines in the strain 3D7, termed 3D7-150HA and 3D7-
101HA, where the endogenous genes were modified to include a triple 
hemagglutinin (HA) epitope tag at their carboxyl termini1. Expression profiles 
of HSP101 and PEX150 showed that both proteins are strongly expressed in 
late schizogony and remain at high levels through the 48 hour blood-stage 
cycle. Immunofluorescence analysis (IFA) showed that PTEX150, HSP101 
and EXP2 co-localize and are found in discrete foci at the PVM in ring-stage 
parasites. In the schizont stages, these three proteins localise towards the 
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apical end of merozoites, with EXP2, shown by immuno-electron microscopy 
to localise to the dense granules1,176.    
Of the five PTEX components, none are predicted to form a β-barrel like 
structure, nor do any possess classic transmembrane domains1. Thus no 
obvious candidates for the membrane-spanning, pore-forming component 
were identified. However, EXP2 is the PTEX component most tightly 
associated with the PVM, being resistant to carbonate extraction174, requiring 
detergent to extract it from the membrane1,176. EXP2 is predicted to have 
structural similarities with the bacterial hemolysins (pore-forming toxin) 
Cytolysin A from Escherichia coli1,177,178, an α-helical protein which forms 
oligomers and insert into the target membranes via a β-tongue hydrophobic 
hairpin179.  
Analysis of the predicted structure of P. falciparum HSP101 suggests that 
due to the conserved fold of this class of HSP100-AAA+-ATPase family180 of 
chaperones, it forms a ring-shaped hexamer. Members of this family direct 
proteins through the central pore of their ring, using energy derived from ATP 
hydrolysis to unfold protein cargo156,176. It is predicted, therefore, that 
HSP101 serves as the PTEX motor. 
The function of PTEX150 is difficult to predict, since it does not show any 
homology to any other known proteins1.  As PTEX150 interacts tightly with 
HSP101 and EXP2, it may play a structural role in the complex, or may serve 
as a receptor176. Overall, PTEX is a stable macromolecule complex of 
>1230kDa176. EXP2 has the strongest vacuolar membrane association and 
forms the tightest association with PTEX150, which in turn binds more tightly 
to HSP101176.  
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The two other components that were identified as part of PTEX but which 
remain to be validated, include TRX2 and PTEX881. TRX2 is a 19-kDa 
protein and a member of the thioredoxin protein family, containing the typical 
WCQAC motif in its active site, which can be reduced by thioredoxin 
reductase181,182. Interestingly, a GFP-TRX2 fusion protein had previously 
been localised to the mitochondrion183,184, although intriguingly TRX2 lacks a 
mitochondrial targeting sequence1,181. Subsequent independent localisation 
studies reveal that P. falciparum TRX2 localises to the PV185-187, as well as to 
an unknown parasite organelle187. PTEX88 on the other hand, has no 
homology to other known proteins and no unique motifs to predict its role, 
and thus nothing is known about its functional role in PTEX. To date, no 
reagents (antibodies or epitope tagged chimeras) have been developed to 
facilitate the study of PTEX88. To date, the proposed functions of PTEX88 
and TRX2 include a scaffolding role, recognition of cargo, or a regulatory role 
in the PTEX complex1.  
With this information in hand, the current model of protein translocation in 
the infected erythrocyte is that proteins destined for export are trafficked to 
and deposited into the vacuolar space via a classical eukaryotic secretion 
pathway, and are then recognised by PTEX by a yet unknown receptor 
(Figure 1.2).  HSP101 interacts with the substrate proteins to maintain them 
in an export competent state (which may also require the co-operation with 
other chaperone proteins) and provides the energy that enables proteins to 
be translocated across the PVM via the EXP2 pore. Once on the host 
cytosolic side, the translocated proteins are refolded and/or further trafficked, 
which likely includes further interactions with chaperones in the infected 
erythrocyte1. Plasmodium chaperones mediating these processes are yet to 
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be identified, however in immunoprecipitation experiments, a host derived 
HSP701 was found to interact with PTEX and may play a role in these 
processes. Additionally, parasite derived exported hsp40 and hsp70-x may 
also be involved188. Given the number of proteins that comprise translocons 
in other organisms and organelles189, additional components of the PTEX 
may yet remain to be identified. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Schematic model of PTEX. 
Expanded view of the PTEX complex at the PVM. Magnified schematic 
depicts EXP2 is the membrane spanning pore due to its strong membrane 
association. EXP2 is believed to interact most tightly with PTEX150, which in 
turn binds HSP101. PTEX88 and TRX2 are associated with PTEX, yet their 
composition within PTEX is unknown. 
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Although PTEX has been shown to interact with PEXEL exported proteins 
based on immunoprecipitation experiments of three exported proteins1, to 
date the evidence for the role of PTEX in protein export is circumstantial. A 
recent study using de-convolution microscopy and three-dimensional 
structures illumination microscopy demonstrated that PTEX components are 
present at the parasite periphery, and that they partially co-localise with a 
PEXEL containing exported protein, termed ring-infected erythrocyte surface 
antigen (RESA)176,190. Nonetheless, whilst this provides further support for 
PTEXs role in export, it is not conclusive proof.  Furthermore the interaction 
of PNEPs with this complex is yet to be observed. It is therefore unclear 
whether the translocation of both subsets of exported proteins into the 
erythrocyte host proceeds via the PTEX complex, or whether multiple export 
pathways may be utilised by the parasite to export proteins containing the 
PEXEL motif and PNEPs122,145. However, since PEXEL positive proteins are 
cleaved, after which they possess no discernable motif (PNEPs also possess 
no discernable motif), it may be that a singular export pathway may 
accommodate both types of exported proteins1,122,176. Either way, definitive 
proof that PTEX is responsible for the export of PEXEL positive or PNEP 
exported proteins is still required.  
 
1.6 Project aims and hypothesis  
The overarching hypothesis of this study is that PTEX is a functional 
protein export complex and that disruption of PTEX function will lead to the 
loss of protein export into the host erythrocyte. Given that exported proteins 
are essential for parasite survival and virulence, it is hypothesised that the 
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resulting disruption of PTEX function will have consequences on parasite 
growth and pathogenesis.  
To test these hypothesis, this study aims to: (i) firstly, confirm that PTEX88 
and TRX2 are in-deed PTEX components, (ii) knockout PTEX genes to prove 
essentiality of PTEX function and to identify which components are essential 
for parasite survival and (iii) functionally characterise the role of the PTEX 
machinery in parasite protein export, parasite growth and virulence.  
To further characterise the individual components that make up PTEX and 
determine their role in protein export, the model rodent malaria parasite, P. 
berghei, will be used in this study. Since PEXEL containing proteins are 
present in P. berghei, and host cell remodelling is conserved, as well as 
conservation of the genes encoding the PTEX between the species191, it is 
therefore likely that the mechanism of protein export is also conserved and it 
is likely that P. berghei is an applicable model. P. berghei, is more amenable 
to genetic manipulation than P. falciparum, and given that a rodent model is 
available for P. berghei, the in vivo consequences of blocking PTEX function 
can be assessed, including determining the contribution of PTEX to parasite 
virulence and growth. This is particularly important for validating whether 
PTEX could serve as a good anti-malarial drug target.   
 
 
 



 










Chapter 2 


Materials and Methods 






















 
 	
1.7 Materials 
Reagents and equipment used in this research was supplied from the 
following manufacturers:   
 
 Abbott       Illinois, U.S.A 
 Abcam       Cambridge, UK 
 Amresco       Solon, OH, USA  
 Axygen       Union City, CA, USA  
 Becton Dickinson     Franklin Lakes, NJ, USA 
 Bioline       London, UK 
 Bio-Rad       Hercules, CA, USA 
 BOC       Australia 
 Dako       Denmark 
 Fermentas      Ontario, Canada 
 Fisher Biotech     Waltham, MA, USA 
 Fluka Biochemika     Buchs, Switzerland 
 General Electric Healthcare (GE)  Fairfield, CT, USA  
 Genesearch      QL, Australia 
 HemoCue      Ängelholm, SWEDEN 
 Ilford       Switzerland. 
 Integrated Sciences     Georgia, USA 
 Interpath       Vic, Australia 
 Invitrogen      Groningen, The Netherlands   
 John Morris Scientific    NSW, Australia 
 Lonza       Basel Switzerland 
 Merck/Calbiochem     San Diego, CA, USA 
 Millipore       Billerica, MA, USA 
 Miltenyi Biotech     Auburn, CA, USA 
 New England Biolabs   Ipswich, MA, USA   
 Novagen       Madison, WI, USA 
 Pacific Laboratories     Redmond, WA, USA 
 Promega       Fitchburg, WI, USA 
 Proscitech      QL, Australia 
 Provet      QL, Australia 
 Roche Molecular Biochemicals   Indianapolis, IN, USA   
 Qiagen       Mel, Australia   
 SigmaAldrich     Saint Louis, MO, USA   
 Thermo Fisher Scientific    Rochester, NY, USA    
 VWR       Radnor, PA, USA 
 Whatman       Kent, UK 
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1.8 Methods 
1.8.1 Ethics statement 
All experiments involving rodents were performed in strict accordance with 
the recommendations of the Australian Government and National Health and 
Medical Research Council Australian code of practice for the care and use of 
animals for scientific purposes. The protocols were approved by the Animal 
Welfare Committee at Deakin University (Approval No.: AWC A97/10, 
A98/2010, G37/2014). 
1.8.2 DNA and protein sequence analysis  
Plasmodium gene sequences were extracted from the Plasmodium 
genome Resource database (PlasmoDB)191. In silico restriction enzyme 
digests and sequence alignments were performed using SerialCloner version 
2.0 (Serialbasics). 
1.8.3 Oligonucleotide Primers 
All oligonucleotides used in this project were obtained from Geneworks and 
are all listed in Table 2.1. 
1.8.4 DNA applications 
1.8.4.1 DNA preparation  
Small or large-scale plasmid preparations were made from 2 ml or 400 ml 
overnight bacterial cultures, respectively, and grown under agitation (200 
rpm) at 37 °C in Luria broth (Amresco) containing 100 µg/ml ampicillin.  The 
DNA was extracted and purified using an Invitrogen mini-prep kit or midi-prep 
kit as per the manufacturers instructions.  
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1.8.4.2 Polymerase Chain Reaction (PCR) amplification 
DNA was amplified by PCR using plasmid or parasite genomic DNA 
(gDNA) as template. Each 20 μl reaction contained 200 μM dNTP, 0.5 U Taq 
(NEB), 200 nM of each oligonucleotides and 10 ng plasmid or 100 ng gDNA 
template in 1 × PCR amplification buffer (NEB). Typical cycling conditions 
were an initial 2 min cycle of 95 °C, followed by 25 cycles of 95 °C 
(denaturation) for 1 min, 50 °C (annealing) for 1 min and 68 °C (extension) 
for 1-2 min (according to the expected product size). This was followed by 
one cycle at 72 °C for 5 min, after which the sample was held at 4 °C.  
Colony screening by PCR was performed using the same conditions except 
the bacterial colony was used as template DNA. Amplified DNA was then 
purified using the PureLinkTM PCR Purification Kit (Invitrogen) and eluted with 
TE (10 mM Tris, 1 mM EDTA, pH 8.0). The DNA yield was measured using 
the NanoVue Spectrophotometer according to the manufacturers instructions 
(General Electric).   
1.8.4.3 DNA digestion 
DNA (100 ng - 5 μg) was digested with restriction enzymes supplied by 
New England Biolabs, according to the manufacturers instructions. To de-
phosphorylate the cloning vectors, 1 U of shrimp alkaline phosphatase 
(Fermentas) was added to the vector and left to further incubate at 37 °C for 
1 hr.  
1.8.4.4 DNA ligation 
Vector and insert DNA were ligated with 1-5 U of T4DNA ligase in 1 × 
ligase buffer (Fermentas) at a 2:1 insert to vector ratio and incubated at room 
temperature for 15 min. A control ligation containing only vector DNA and no 
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insert was performed in conjunction to assess the frequency of self-ligation of 
the plasmid vector.  
1.8.4.5 Bacterial transformation 
DNA was transformed into Escherichia coli (E. coli) XL-10 Gold cells using 
the heat-shock method. For this, up to 500 ng of DNA was incubated for 2 
min on ice with a 200 μl aliquot of cells prepared according to “Current 
Protocols in Molecular Biology library”192 followed by incubation at 42 °C for 
45 sec. Immediately afterwards, 1 ml Luria broth (Amresco) was added to the 
cells then incubated under agitation of 200 rpm for 45 min at 37 °C to allow 
expression of the ampicillin resistance cassette.  Transformed cells were 
spread onto Luria agar (Amresco) containing 100 µg/ml ampicillin and 
incubated overnight at 37 °C. 
1.8.4.6 DNA sequencing  
DNA was sequenced by the Australian Genome Research Facility Ltd 
(AGRF) at The Walter and Eliza Hall Institute (WEHI) using the Big Dye 
Termination sequencing protocol with 20 pmol of either the appropriate 
forward or reverse oligonucleotide and 500-1500 ng template DNA used per 
reaction.  
1.8.4.7 Agarose gel electrophoresis 
DNA was routinely separated on 0.7-2.0 % (w/v) horizontal agarose gels 
using a Tris-borate-EDTA (TBE) buffer system (89 mM Tris-base, 89 mM 
boric acid, 2 mM EDTA). Loading buffer (0.01 % (w/v) bromophenol blue, 10 
mM EDTA and 10 % (w/v) glycerol) was added to sample prior to loading. A 
1 kb molecular marker (Invitrogen) was included on each run. Gels were 
electrophoresed between 80-110 V for 30 min to 3 hrs.  Agarose gels 
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contained SYBR Safe (Invitrogen) at a concentration of 1:10,000 for DNA 
visualization on a ChemiDoc XRS (Bio-Rad) UV transilluminator. 
1.8.4.8 Southern blot hybridisation 
1.8.4.8.1 Preparation of membrane 
After electrophoresis, agarose gels containing digested gDNA were 
depurinated in 0.125 M hydrochloric acid solution for 20 min, followed by 
soaking in denaturation solution (0.5 M sodium hydroxide and 1.5 M sodium 
chloride) for 30 min.  The gel was then neutralised in 0.5 M Tris and 1.5 M 
sodium chloride (pH 8.0) for 30 min and DNA subsequently transferred in the 
neutralisation buffer onto Hybond-N membrane (General Electric) via 
capillary action overnight.  Following transfer, the membrane was baked in 
an incubator at 80 °C for 2 hrs to fix the DNA to the membrane.  The 
membrane was rinsed in Milli-Q water, air-dried at room temp and stored at 4 
°C until hybridization. 
1.8.4.8.2 Digoxigenin labeled DNA probes 
Probes used for Southern blot hybridization were amplified using the DIG-
PCR Probe synthesis kit (Roche). Each 50 μl reaction mix contained 35 μM 
DIG-dUTP (PCR DIG Probe synthesis Mix) with 200 μM each dNTP, along 
with 200 nM each forward and reverse oligonucleotide and template DNA at 
a concentration of 1-50 ng.  HotStartTaq DNA polymerase (Qiagen) was 
used at a final concentration of 2.5 U with the final MgCL2 concentration at 
2.0 mM in the 1 × PCR buffer (Qiagen).    PCR cyclic conditions were an 
initial heat activation step at 95 °C for 15 min, followed by 35 cycles of 94 °C 
(denaturation) for 30 sec, 60 °C (annealing) for 30 sec and 68 °C (extension) 
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for 4 min. This was followed by a 72 °C incubation step for 20 min.  After 
amplification, samples were stored at –20 °C.  
1.8.4.8.3 Hybridisation  
The membrane containing DNA was pre-hybridised with 10 ml DIG Easy-
Hyb solution (Roche) at 37 °C for at least 1 hr. This was followed by 
hybridisation with the DIG-labeled probe (~30 ng/ml) in 10 ml Easy-Hyb 
solution at 37 °C overnight.  
1.8.4.8.4 Detection 
Following hybridization the membrane was treated to a series of washes 
at room temperature with slow rocking. An initial rinse with 2×SSC for 5 min 
was then followed by equilibration in wash buffer solution of 0.1M maleic acid 
(Sigma-Aldrich), 0.15 M sodium chloride and 0.3% (v/v) Tween-20 (Sigma) 
for 1 min.  Incubation of the membrane for 30 min in 1% (v/v) blocking 
solution (Roche) was then followed with Digoxigenin-AP antibody (Roche) 
binding at a dilution of 1:10,000 in blocking solution for 1 hr. The membrane 
was then washed in wash buffer for 30 min and equilibrated in detection 
buffer containing 100 mM Tris-HCL  (pH 9.5) (Invitrogen) and 100 mM NaCl 
for 2 min.  The membrane was drip dried then transferred to a hybridization 
bag where it was drenched in pre-warmed CSPD ready-to use (Roche) and 
immediately covered from light and left to incubate for 5 min. The membrane 
was transferred to a cassette and exposed to X-ray film (GE) for various 
exposure times (generally 5, 10, 30 min depending on signal strength).  The 
films were then developed using Ilford Ilfosol developer at a ratio of 1:9 and 
fixed with Ilford fixer at a ratio of 1:14.          
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1.8.4.8.5 Stripping probes from membrane 
Probes were stripped from the membrane by rinsing the membrane in 
Milli-Q water for 1 min followed by two separate washes with freshly 
prepared 0.2M NaOH containing 0.1% (v/v) SDS. The membrane was then 
rinsed in 2 × SSC for 5 min and stored at 4 °C. 
1.8.5 Plasmid constructs 
1.8.5.1 Epitope tagging  
To create the vectors that were used to epitope tag the endogenous P. 
berghei ANKA (Pb) PTEX genes, the following cloning procedures were 
performed. First ∼2 kb immediately upstream of the stop codon of 
PbPTEX150 (which would ultimately serve as the targeting region for 
homologous recombination into the PbTEX150 endogenous locus) was PCR-
amplified from P. berghei ANKA genomic DNA (gDNA) in roughly two equal 
parts using the oligonucleotides O62/O63 (5' targeting region) and O64/O65 
(3' targeting region) (Refer to Table 2.1 for oligonucleotide sequences). By 
sewing the two resulting PCR products together with O62/O65, this created a 
SpeI site between the two adjacent 5' and 3' sequences that would later be 
used to linearize the DNA prior to transfection. The sewn PCR product was 
then digested with NotI and PstI and cloned in place of the P. falciparum 
PTEX150 in pTEX150-HA/Str 3'1. Subsequent digestion with NotI and EcoRV 
excised the PbTEX150-HA/Str sequence together with the downstream P. 
berghei DHFR-TS 3' UTR and, after treatment with Klenow, was cloned into 
the pB3 vector (Waters et al., 1997)193 that had been digested with ClaI and 
treated with Klenow. As the backbone of this resulting vector contained a 
SpeI site, this was removed by digestion with NaeI and EcoRV that flank this 
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site, followed by re-ligation of the plasmid, to give the final epitope tagging 
construct termed pB3-150-HA/Str-DT3'. From this vector all subsequent P. 
berghei PTEX tagging constructs were made by replacement of the 
PbTEX150 5' and 3' targeting regions using SacII/SpeI and SpeI/AvrII, 
respectively, with the targeting sequences of HSP101 (amplified using 
O46/O33 and O34/O35), TRX2 (O36/O51 and O52/O53), PTEX88 (O54/O55 
and O56/O57) and EXP2 (O58/O59 and O60/O61). Prior to transfection into 
P. berghei ANKA parasites, all targeting constructs were linearized with SpeI 
to drive integration into the endogenous PTEX locus. 
1.8.5.2 PTEX gene deletion  
For targeted gene deletion of the PTEX genes, fragments of the 5' UTR 
and 3' UTR that would serve as targeting regions to drive integration into the 
endogenous locus were PCR-amplified from P. berghei ANKA gDNA using 
gene-specific primers. The 5' UTR homologous sequences were digested 
with ApaI/SacII (or HindIII/SacII in the case of the PTEX88 5' UTR), with the 
SacII site filled in with Klenow, and cloned into the pB3 vector that was 
digested with ClaI, treated with Klenow and then digested with ApaI. The 3' 
UTR targeting sequences of HSP101 (digested with EcoRV/NotI), EXP2 
(EcoRV/SmaI), PTEX88 (EcoRV/EcoRI) and TRX2 (EcoRI/SpeI) were cloned 
into the corresponding sites of pB3 containing the respective 5' UTR or, in 
the case of EXP2 and TRX2 3' UTRs, into the SpeI site that had been treated 
with Klenow. The resulting constructs were linearized with KpnI/NotI and 
used to transfect P. berghei ANKA parasites. 
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1.8.6 Protein applications 
1.8.6.1 Protein expression 
For large-scale protein expression, 10 ml Luria broth containing 100 µg/ml 
ampicillin was inoculated with E. coli transformants of interest and incubated 
at 37 °C overnight. From this overnight culture, 4 ml was removed and added 
to 400 ml Luria broth containing ampicillin in a 2 L pre-autoclaved flask.  For 
small-scale protein expression, 2 ml overnight culture was inoculated into 50 
ml Luria broth cell culture. Broths were incubated at 37 °C at 200 rpm until an 
optical density (OD) of 0.5 - 0.6 was reached. From this, 1 ml of culture was 
taken prior to induction of protein expression, representing the negative “un-
induced” control. The remaining culture was induced for protein expression 
for 2 hrs with 1 mM Isopropyl-β-D-thiogalactoside (IPTG).  After induction, a 
1 ml sample was taken from the culture as a positive “induced” control. Both 
induced and un-induced control samples were stored at −20 °C until further 
analysis.  The remaining cell culture was pelleted and the supernatant 
removed.  The cell pellet was re-suspended in 15 ml 1 × native purification 
buffer (pH 8.0) containing 50 nM NaH2PO4 and 0.5 M NaCl. Lysozyme from 
chicken egg (1 mg/ml) (Invitrogen) was added along with 1 × tablet protease 
inhibitor cocktail (Roche) and incubated for 30 min at 4 °C under agitation. 
Cells were further lysed by 18 sonication bursts for 10 sec each at an 
amplitude of 60%.  
1.8.6.2 Protein purification 
Expressed protein was purified on Ni-NTA affinity resin according to the 
manufacturers instructions (Invitrogen). After an overnight binding incubation 
at 4 °C, three washes with 20 mM imidazole (Sigma) were performed, 
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followed by elution with 250 mM imidazole for 1 hr and then again overnight.  
1.8.6.3 Protein electrophoresis  
Infected rodent blood was depleted of leukocytes by passage through a 
CF11 column (Whatman) and then lysed using 0.02% saponin for 15 min on 
ice, followed by centrifugation at 14,000 rpm for 5 min. After three washes 
with ice-cold mouse tonicity (MT) PBS containing 1× complete protease 
inhibitors (Roche), and prior to electrophoresis, the parasite pellet was 
resuspended in 1 × reducing sample buffer reducing sample buffer (4% (v/v) 
SDS, 10% (v/v) 2-mercaptoehtanol, 20% (v/v) glycerol, 0.004% (w/v) 
bromophenol blue and 0.125 M Tris HCl (pH 6.8)).  Protein samples were 
initially boiled at 100 °C for 5 min and micro-centrifuged at 14,000 rpm for 10 
min. Sample supernatant (5-15 µl) and Dual Standards (Biorad) protein 
marker (5 µl) were loaded and fractioned by electrophoresis in either 4-12% 
gradient (Invitrogen) or 10-12% SDS-PAGE gel at 150 V for approximately 1 
hr in 1 × gel running buffer (25 mM Tris base, 192 mM Glycine, 0.1% (w/v) 
SDS (pH 8.3)). Gels were stained by soaking in Imperial Protein Stain 
(Thermo Scientific) for 30 min at room temperature. The gel was then soaked 
in de-stain at a final concentration of 50% (v/v) methanol with 10% (v/v) 
acetic acid for 45 min and left overnight at 4 °C in Milli-Q water.  
1.8.6.4 Western blot analysis 
SDS-PAGE polyacrylamide gels were prepared for protein transfer onto 
0.45 µm PVDF membrane (Millipore) via the Bio-Rad wet transfer system in 
1 × Tris-glycine buffer (25 nM Tris base, 190 nM glycine, 0.1% (w/v) SDS).  
Transfer was performed at 100 V for 1 hr.  The membrane was then 
incubated in 3% bovine serum albumin (BSA) / mouse - phosphate buffered 
saline (MT-PBS) block at 4 °C, followed by overnight incubation with the 
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antibody specific to the protein being detected diluted in 3% BSA/MT-PBS 
blocking solution.  After three washes in 0.05% (v/v) Tween/MT-PBS, HRP 
conjugated secondaries (anti-rat, anti-rabbit or anti-mouse) were used at a 
1/2000 dilution in a 3 hr incubation at 4 °C.  Following a second series of 
three washes in MT-PBS, detection was performed using the SuperSignal 
enhanced chemiluminescence (Thermo Fischer Scientific) according to 
manufacturers’ instructions, by exposure to X-ray film. Where applicable, 
band densities were measured using Image J software. 
1.8.6.5 Protein immunoprecipitations 
For immunoprecipitations (IP), P. berghei infected erythrocytes depleted of 
leukocytes or P. falciparum infected erythrocytes were lysed with 0.02% 
saponin/MT-PBS. Pelleted parasite material, were lysed with either IP lysis 
buffer (Pierce) or 0.5% Triton X-100 in PBS containing complete protease 
inhibitors (Roche). After a 30 min incubation on ice, the material was passed 
10 times through a 29 G insulin needle, followed by centrifugation at 21,000 
g for 10 min at 4 °C. The supernatant was affinity purified with either goat 
anti-HA antibodies coupled to magnetic beads (Miltenyi Biotec Australia) as 
per the manufacturer’s instruction or with 150 μl anti-HA sepharose (Roche) 
for 8 hrs at 4 °C. Unbound material was collected and beads then washed 
four times with 1 ml 0.5% Triton X-100 in MT-PBS containing complete 
protease inhibitors (Roche) and once with 1 ml MT-PBS. Bound proteins 
were eluted with 50 μl 1 × reducing sample buffer and separated by SDS-
PAGE. 
For immuno-immune-detection, primary antibodies used were monoclonal 
mouse anti-HA (12CA5) (1:1000) (Roche), polyclonal rabbit anti-HSP101 
(1/200 for P. berghei, 1/500 for P. falciparum), monoclonal mouse anti-
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HSP101 (1/500), poly-clonal rabbit anti-PTEX150 (1:200 for P. falciparum), 
mono-clonal mouse anti-EXP2 (mAb 7.7, from J. McBride and described 
previously174) (1/500 for P. berghei and 1:2000 for P. falciparum). Secondary 
antibodies were horseradish peroxidase-conjugated goat anti-mouse and 
goat anti-rabbit antibodies (1:2000, Jackson IR). 
1.8.6.6 Gel excision and Nano-LC-MS/MS  
Protein bands were manually excised from separated SDS-PAGE gels 
and subjected to manual in-gel reduction, alkylation and tryptic digestion. The 
following methods were performed by Thomas Nebl (WEHI) for Nano-LC-
MS/MS. All gel samples were reduced with 10 mM DTT for 30 min, alkylated 
for 30 min with 50 mM iodoacetic acid and digested with 375 ng trypsin 
(Promega) for 16 h at 37 °C. The extracted peptide solutions were then 
acidified (0.1% formic acid) and concentrated to approximately 10 μl by 
centrifugal lyophilization using a SpeedVac AES 1010 (Savant). Extracted 
peptides were injected and fractionated by nanoflow reversed-phase liquid 
chromatography on aρ nano- UHPLC system (Easy n-LC II, Thermo Fisher, 
USA) using a nanoAcquity C18 150 mm × 0.15 mm I.D. column (Waters, 
USA) developed with a linear 60 min gradient with a flow rate of 250 nl min−1 
from 100% solvent A (0.1% Formic acid in Milli-Q water) to 100% solvent B 
(0.1% Formic acid, 60% acetonitrile, (Thermo Fisher, USA) 40% Milli-Q 
water). The nano UHPLC was coupled online to an LTQ-Orbitrap mass 
spectrometer equipped with a nanoelectrospray ion source (Thermo Fisher, 
USA) for automated MS/MS. Up to five most intense ions per cycle were 
fragmented and analysed in the linear trap, with target ions already selected 
for MS/MS being dynamically excluded for 3 min.  
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Protein identification from the LC-MS/MS data were searched against a non-
redundant protein decoy database comprising sequences from the latest 
version of LudwigNR (Human, Bovine, P. falciparum species), as well as 
their reverse sequences (249275 entries). Mass spectra peak lists were 
extracted using extract-msn as part of Bioworks 3.3.1 (Thermo Fisher 
Scientific) linked into Mascot Daemon (Matrix Science, UK). The parameters 
used to generate the peak lists for the LTQ Orbitrap were as follows: 
minimum mass 400; maximum mass 5000; grouping tolerance 0.01 Da; 
intermediate scans 1; minimum group count 1; 10 peaks minimum and total 
ion current of 100. Peak lists for each nano-LC-MS/MS run were used to 
search MASCOT v2.2.04 search algorithm (Matrix Science, UK) provided by 
the Australian Proteomics Computational Facility (http://www.apcf.edu.au). 
The search parameters consisted of carboxymethylation of cysteine as a 
fixed modification (+58 Da, for gel samples only), with variable modifications 
set for NH2-terminal acetylation (+42 Da) and oxidation of methionine (+16 
Da). A precursor mass tolerance of 20 ppm, #13C defined as 1, fragment ion 
mass tolerance of ± 0.8 Da, and an allowance for up to three missed 
cleavages for tryptic searches was used. 
1.8.6.7 Recombinant protein purification from maltose binding  
protein 
Removal of the maltose binding protein (MBP) tag was performed using 
Factor Xa (FXa), which cleaves after the arginine residue at the Ile-(Glu or 
Asp)-Gly-Arg site. For this, 1 μg of FXa was used to digest 50 μg of substrate 
overnight at 4 °C.  The sample was then concentrated by centrifuge column 
(Millipore).  The proteins were then separated by 4-12% gradient SDS-PAGE 
gel electrophoresis and the band containing the desired protein fragment was 
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excised and used to immunise rabbits for antiserum production.   
1.8.7 Plasmodium applications 
1.8.7.1 Infection of mice with P. berghei. 
The P. berghei Cl15 of the ANKA strain was used for all mouse infection 
studies. Eight week old female donor Balb/c mice were infected with 200 µl of 
infected blood from liquid nitrogen stocks of P. berghei ANKA.  To estimate 
the parasitemia of infected mice, thin blood smears were prepared by 
collection of a 2 µl drop of tail blood smeared onto a glass slide. These were 
fixed for 30 sec with methanol (Merck) and stained for 10 min with a 1/10 
dilution of Giemsa stain (Merck) per manufacturers recommendation. The 
slide was rinsed with tap water and air-dried.  The parasitemia was 
determined using a light microscope under immersion oil using the 100x 
objective counting the number of infected erythrocytes expressed as a 
percentage of uninfected erythrocytes.  A combined total of 1000 cells were 
counted for each slide. To cryopreserve parasites, P. berghei infected whole 
blood was mixed with 30% (v/v) glycerol in phosphate buffered saline (PBS)) 
in a 1:1 ratio, and aliquoted into cryovials (Thermo Fisher Scientific) before 
being frozen in liquid N2.  
1.8.7.2 Preparation of DNA for P. berghei transfection 
Between 15-20 µg of DNA was digested with 2-3 µl of the appropriate 
restriction enzyme (10-20 U/ul) overnight at 37 °C to linearise the transfection 
construct. Digested DNA was then separated in 1% agarose gel via 
electrophoresis. The appropriate DNA band was purified using the 
PureLinkTM Quick Gel Extraction Kit (Invitrogen) as per manufacturers 
instructions. DNA was concentrated by precipitation with 2.5 × vol 100% 
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ethanol, 1/10 × vol 3M NaAc (pH 5.2) and re-suspended in a final volume of 
10 µl TE (~5 µg digested DNA).  
1.8.7.3 Preparation of schizonts for P. berghei transfection 
Female Balb/C mice (6-8 weeks old) were infected with 1 × 106 PbANKA 
parasites intraperitoneally. When the parasitemia reached approximately 1- 
3%, blood was collected from the mouse between the hrs of 10:00 to 14:00 
via cardiac puncture under anesthesia with 100% isoflurane (ProVet) or in an 
atmosphere of 100% carbon dioxide. Infected blood was spun down at 1500 
rpm to remove the buffy coat and the erythrocytes were then added to 150 ml 
complete RPMI1640 culture medium containing L-glutamine (Invitrogen), 
supplemented with 5% sodium bicarbonate, and containing 25% (v/v) heat 
inactivated Fetal Bovine Serum (Bovogen). Parasites were incubated for 90 
sec in an atmosphere of 5% oxygen, 1% carbon dioxide and 94% nitrogen to 
mimic the host gaseous environment then incubated 16 hrs at 36.5 °C. The 
following day, mature schizonts were purified by Nycodenz separation as 
previously described194.   
1.8.7.4 Transfection and drug selection  
Prior to transfection, 100 μl of Amaxa Basic Parasite Nucleofector ® 
Solution (Lonza) was combined with ~107 nycodenz purified schizonts and 
mixed gently with linearised DNA. The mixture was transferred to an 
electroporation cuvette (Lonza) and transfection was performed using an 
Amaxa® Nucleofector device set at program U33, to introduce the linearised 
DNA fragment into wild type parasites for integration into the genome. Once 
electroporated, 50 μl complete culture medium was added and the total 
volume (150 μl) was injected intravenously into the tail vein of a 6-8 week 
female Balb/c mouse.  
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Drug selection of transfected parasites commenced one day after the 
transfection procedure to allow parasites to complete one full developmental 
cycle.  Pyrimethamine was administered via drinking water. Pyrimethamine 
was made at a concentration of 7 mg/ml; the pH was adjusted to 3.5 – 5.0 
using 1 M HCL and then diluted 1/100 with tap water for a final concentration 
of 0.07 mg/ml.  For secondary drug selection or where required, 16mg/kg 
WR99210, dissolved in DMSO and diluted with MT-PBS, was administered 
subcutaneously 1-3 days post infection.  
1.8.7.5 Isolation of parasite DNA from whole blood.  
To obtain parasite DNA from whole infected rodent blood collected by 
cardiac puncture, the leukocytes were first removed by chromatography 
using CF11 powder (GE). Eluted red blood cells were centrifuged at 3000 
rpm and lysed in 0.15% (w/v) Saponin (Fluka BioChemika) in PBS 
(Amresco), after which free parasites were pelleted via micro-centrifuge at 
14,000 rpm. For parasite genomic DNA isolation, parasites were 
resuspended in P. berghei parasite lysis buffer (50 mM Tris , 5 mM EDTA , 
and 1.0% (w/v) SDS, pH 8.0 ).  RNase A  (Invitrogen) was added to the 
sample at a final concentration of 100 μg/ml and incubated at 37 °C for 
40min after which Proteinase K (Invitrogen) was added at a concentration of 
2 mg/ml and incubated at 37 °C for a further 45 min. The DNA was extracted 
three times using 1:1 phenol-chloroform mix (Sigma) and precipitated with 
100% (v/v) ethanol following the standard procedure in ‘Current Protocols in 
Molecular Biology’192; the pellet was then washed with 80% (v/v) ethanol, 
dried and suspended in 100 μl TE. 
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1.8.7.6 Cloning of transgenic parasites 
To ensure that transgenic P. berghei parasite lines were pure and no wild 
type P. berghei ANKA parasites were present, a serial cloning procedure was 
performed. For this, six Balb/c mice were infected intravenously with limiting 
dilutions of parasite infected erythrocytes per mouse in 100 μl PBS, using a 
26 G needle. Accurate total erythrocyte counts were obtained using a 
hemacytometer and clonal lines were confirmed by parasite genotyping. 
1.8.7.7 Parasite growth curves  
To assess whether transgenic parasites were affected in their growth 
and/or replication in comparison to wild type parasites, Balb/c mice were 
infected with 1×105 P. berghei ANKA wild type (n=14) or knockout clones 
(n=14). The parasitemia in blood smears made from each mouse was 
calculated on a daily basis from 3 days post infection. Mice were humanely 
culled when parasitemias exceeded 25%. 
1.8.7.8 Parasite virulence analysis 
As a measure of parasitic virulence, transgenic parasites were compared 
to wild type parasites in their ability to cause cerebral malaria in C57Bl/6 
mice. Three groups of six C57Bl/6 female mice at six weeks of age, were 
infected with 1×106 PbANKA wild type or transgenic parasites. The 
parasitemias from each mouse was calculated from 3 days post infection and 
thereafter on a daily basis. Mice were checked every 4 hrs for cerebral 
malaria symptoms, which included ataxia, and the lack of the ability to self-
right, from day 5 post infection. Mice were culled at a parasitemia exceeding 
25% or at the sign of cerebral malaria symptoms. 
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1.8.7.9 In vivo / in vitro growth assay 
Infected erythrocytes from three Balb/C mice were cultured for 16 hrs in 
complete RPMI medium supplemented with 25% FCS at 36.5 °C. P. berghei 
schizonts obtained from overnight cultures, were ruptured by mechanical 
action using a 29 G needle and syringe. Merozoites were purified by filtration 
through a 0.2 µm filter and then resuspended in 100 µl RPMI.   These were 
then combined 1:1 with reticulocyte rich blood from phenylhydrazine (10 
µL/g) pre-treated mice. Invasion was allowed to proceed for 30 min at 37 °C 
with during which time, the samples were vigorously shaken. The cells were 
then either cultured in vitro in complete RPMI or intravenously injected into 
naïve mice to establish synchronous mouse infections. In vivo parasites were 
monitored by blood smear at two hr intervals post invasion.   
1.8.7.10 Generation of semi-immune sera 
Semi-immune sera was generated from Balb/C mice which had been 
challenged with four consecutive malaria infections on a monthly basis by 
intraperitoneal injection of 104 parasites. Each infection was cleared by 
administration of 0.07 mg/ml pyrimethamine via drinking water when the 
parasitemia reached no more than 5%.  Ten days post final challenge, all 
mice were cardiac bled. For pre-immune sera, Balb/C mice that had never 
been exposed to a malaria infection were cardiac bled.  Blood was allowed to 
clot overnight at 4 °C after which it was then centrifuged at 3,000 rpm to 
collect the pre-immune serum.  The serum was heat inactivated at 65 °C and 
stored at -80 °C until use. 
1.8.8 Immunofluorescence analysis of P. berghei 
Erythrocytes infected with P. berghei parasites were fixed with 4% (v/v) 
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paraformaldehyde and 0.0075-0.015% (v/v) glutaraldehyde in PBS for 30 
min.  After washing, cells were permeabilised with 0.25% Triton X-100 where 
indicated, for 10 min and then washed a further 3 times, before blocking with 
1% BSA/MT-PBS (Sigma) for 30 min.  Cells were labeled for 1 hr at room 
temperature with appropriate primary and secondary antibodies specific to 
the protein of interest, followed by three washes in 1xMT/PBS after each 
step. Cells were mounted in Vectashield containing the nuclear stain 4',6-
diamidino-2-phenylindole (DAPI) (VectorLabs). Images were acquired with 
an Olympus IX70 microscope and processed using the Cell-X program. 
Further image processing was performed using Adobe Photoshop CS6.  
1.8.9 Flow Cytometry 
Flow cytometry was used to quantitate expression of P. berghei proteins 
on the surface of infected erythrocytes. Wild type and transgenic parasites 
were harvested from infected Balb/C via tail smear, and incubated in block 
(1% (w/v) casein sodium salt in RPMI buffer) for 30 min, followed by 
incubation for 1 hr in either pre-immune or hyper-immune sera diluted to 
1/20.  Samples were then centrifuged at 1,200 rpm for one minute to remove 
the supernatant followed by incubation in Goat anti-mouse IgG AlexaFluor 
647 conjugate (Invitrogen) at a concentration of 1:2000 for 1 hr. Following 
two washes, cells were incubated for 5 min in Sybr safe (Invitrogen) in block 
at a dilution of 1:2000.  Three washes completed the cell preparation before 
cell suspensions were analysed using a FACS Canto by BD. Settings were 
optimized per sample, as per manufacturers manual. All incubations were 
performed at ambient temperature. 
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1.8.10 Statistical Analysis 
Statistical analysis was performed using Graph Pad Prism version 6 
(GraphPad Software - MacKiev). Results were analysed for statistical 
significance using a two-tailed student’s t-test using parametric distribution, 
One-way ANOVA with Tukey Post hoc analysis, and a log-rank (Mantel-Cox) 
test for survival analysis.  A P value <0.05 was regarded as significant.  
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Table 2.1: Oligonucleotides used in this study 
Oligonuc-
leotide 
reference 
Target gene Sequence (5' to 3') 
O1 PbPTEX150 5' CGC GGA TCC GAT CTT AAG CAA TTA ATT CAA 
O2 PbPTEX150 5' GGA CTG CAG AAG CTC ATC GGG ATG GGT GTA 
O3 PfTRX2 5' CGC GGA TCC GAT GAT CCT TTA ACA CCC CTC 
O4 PfTRX2 5' GGA CTG CAG TAA ATG TTT TTT AAT TAA TGC 
O5 PbTRX2 5' CGC GGA TCC GAC TTC CAA TTA TCA CCA ATA G 
O6 PbTRX2 5' GGA CTG CAG TAA ATG CTT TCT AAT AGT TGA 
O7 PbTRX2 5' TAG GGC CCT TCC TAG TAA AAT TAC GAC CTT 
O8 PbTRX2 5' GCC GAA TTC CAG AGG AGT GTC AAC TGG TAT 
O9 PbTRX2 5' GAA AAC CCT AAA CAC ATT TTG TGC 
O10 PbTRX2 5' GTG TTA GAA AAG AAG TTA ATA ATT CG 
O11 PbDHFR 5' ACT GTT ATA ATT ATG TTG TCT CTT C 
O12 PbDHFR 5' GAT GTG TTA TGT GAT TAA TTC ATA C 
O13 PbHSP101 5' TAG GGC CCG CTC TTA ATG CAT TTG CTT TAT A 
O14 PbHSP101 5' GTT CCG CGG GCA ATG TTC CGT ACC ATT TCT ACT 
O15 PbHSP101 5' GAT ATC GGC TCA TTA TCA TTT GAA TCA TCA 
O16 PbHSP101 5' GCG GCC GCG TGT TGG TCT AGC TCC TAA TTC TG 
O17 PbPTEX88 5' GCC AAG CTT GAT AGC TCA ATA CAC ACT TTT GTA TTA ATA 
O18 PbPTEX88 5' GTT CCG CGG CTT TTC TAT CAA TTA TAA CTT GGT AAA T 
O19 PbPTEX88 5' GCG ATA TCG TAA CAG ATG ATG GGT ATA TCT TT 
O20 PbPTEX88  5' GCC GAA TTC CCC ATC TTT TTT TAT TTT CTA CCC 
O21 PbEXP2  5' TAG GGC CCG TGG TTA GCC TTA GAA TGT TGT T 
O22 PbEXP2  5' GTT CCG CGG GTT GTA TGC TTA TAG GTC GCA TA 
O23 PbEXP2  5' GCG ATA TCG CAA GAA ACT GAT TCT AAT GAG GC 
O24 PbEXP2  5' TAC CCG GGC ATT TAA GCA CAA AGT GGC TGT A 
O25 PbTRX2  5' TAG GGC CCT TCC TAG TAA AAT TAC GAC CTT ATC 
O26 PbTRX2  5' GTT CCG CGG CGC TAA TAT GTG CTT CAT GAT GA 
O27 PbTRX2  5' CCC GGG GAA TAA GCT ATG ATA TTA GGT ATT A 
O28 PbTRX2 5' GCC GAA TTC CAG AGG AGT GTC AAC TGG TAT A 
O29 pB3 backbone 5' CGC CAG GGT TTT CCC AGT CAC GAC 
O30 pB3 backbone 5' AGC GGA TAA CAA TTT CAC ACA GGA 
O31 PbTRX2 5' TAG CCG CGG TTC CTA GTA AAA TTA CGA CCT TAT C 
O32 PbTRX2 5' TAT GGG CCC CGC TAA TAT GTG CTT CAT GAT GA 
O33 Pb101_5’R (Spe) 5' AGC CAC TAG TCA AAG GCA TAC CGG AAT CTC TT 
O34 Pb101_3’F (Spe) 5' CCG GTA TGC CTT TGA CTA GTG GCT CAT TAT CAT TTG AAT CAT C 
O35 Pb101_3’R (A) 5' GAC CCT AGG TGA CAA TGA AAG GTT AAT AAC AAT GT 
O36 PbTRX2_5’F(S) 5' GAG CCG CGG AAT AAC AAC GTT TTG GAG C 
O37 PbTRX2 5' TAT AAT AGA AAT TCA TCA TGA AGC A 
O38 PbTRX2 5' TAA TGT AAC TAT TTT TTT TTT CAT ATA ATA 
O39 PbTRX2 5' TTT GCG GCC GCT CTA TAA ATG CTT TCT AAT AGT TGA TGT 
O40 Nanoluc  5' TAT CCT AGG ATG GTC TTC ACA CTC GAA 
O41 Nanoluc  5' TTA CTC GAG TTA CGC CAG AAT GCG 
O42 GFP 5' TGC GCT AGC ATG AGT AAA GGA GAA GAA CT 
O43 EF1α  5' CGA CAT ATG GAT CCC CCT ATG TTT TAT AAA ATT 
O44 HA 5' CCG GGA CGT CGT ACG GGT ATG C 
O45 PbPTEX150 5' GGA AGT GTT AGT GGT AAT GGT AGC G 
O46 PbHSP101 5' GAG CCG CGG AAT AAG ATA ATA TTA TTT GTC GAT GAA 
O47 PbPTEX88 5' GCC AAG CTT GAT AGC TCA ATA CAC ACA CTT TTG TAT TAA TA 
O48 PbEXP2 5' TTA CTG CGG ATT CAC AAT TAT TGC 
O49 PbTRX2 5' GAA AAC CCT AAA CAC ATT TTG TGC 
O50 PbTRX2 5' TCA GCT AGC CGC TAA TAT GTG CTT CAT GAT GA 
O51 PbTR2 5' TGT TAC TAG TCC AAT CTT GGC ATC TTG TTG T 
O52 PbTRX2 5' GCC AAG ATT GGA CTA GTA ACA AAG CAG CAC GGA TTA TAT AA 
O53 PbTRX2 5' GAC CCT AGG TAA ATG CTT TCT AAT AGT TGA TGT TAA TTC 
O54 PTEX88 5' GAG CCG CGG AAC AAT GAT CAA ATG TAT TAT ACA GG 
O55 PTEX88 5' CAT GAC TAG TTT ACA TTA GGA GAT GTT GAA AAA TGA T 
O56 PTEX88 5' TCC TAA TGT AAA CTA GTC ATG TTC AAG TAC TTG TCC AAA AG 
O57 PTEX88 5' GAC CCT AGG TTC ATG CAA ATA GTA ACT CAT TGT C 
O58 PbEXP2  5' CAC CCC GCG GGT GGT TAG CCT TAG AAT GTT G 
O59 PbEXP2  5' ATT TAC TAG TGT TGT ATG CTT ATA GGT CGC A 
O60 PbEXP2  5' GCA TAC AAC ACT AGT AAA TAT TGT AAA ATG TGA CGC ATA TA 
O61 PbEXP2  5' GAC CCT AGG AGC CTC ATT AGA ATC AGT TTC TT 
O62 PbTEX150  5' CAT GCG GCC GCG GTG GAA GTG GAA GTG GAA GTG 
O63 PbTEX150  5' CAT TAC TAG TGG CAT ATG GTG ATA AAT CAT AGA AC 
O64 PbTEX150  5' CAC CAT ATG CCA CTA GTA ATG AAG ATA AGG ATT TCT CAA CA 
O65 PbTEX150  5' CGA CTG CAG CCC TAG GTT CAT CTT CAT CTT CAT CCT CTG G 
O66 PbTRX2  5' ACT ACG CGT GAA TAA GCT ATG ATA TTA GGT ATT A 
O67 PbTRX2  5' TAA CCG CGG CAG AGG AGT GTC AAC TGG TAT A 
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1.9 Introduction 
Most of what is currently known about protein export in malaria parasites 
comes from work undertaken in P. falciparum.   With respect to PTEX, its 
initial identification was described in P. falciparum and to date comprises of 
five protein components, three of which have been confirmed as genuine 
PTEX members (PTEX150, HSP101 and EXP2).  Whilst PTEX88 and 
TRX2 co-affinity purified with these three components1, PTEX88 and TRX2 
still remain tentatively assigned as members of PTEX because validation 
that this interaction is genuine is missing.   
Whilst the genes encoding the PTEX components are conserved across 
all Plasmodium species, providing some indication as to their importance, 
this does not necessarily imply the five orthologues interact to form a 
complex in other species as they do in P. falciparum. Importantly, whilst 
PTEX has been proposed as a protein translocation system, functional 
proof that it is directly responsible for parasite protein export is lacking.  
This chapter aims to characterise the PTEX orthologues present in P. 
berghei, including whether PTEX88 and TRX2, along with PTEX150, 
HSP101 and EXP2 form a complex at the PVM.  This species of 
Plasmodium was chosen as it supports the overarching aim of dissecting 
the role of PTEX in pathogenesis, which requires an in vivo model of 
malaria infection.  
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1.10 Results 
1.10.1 PTEX components are expressed in P. berghei  
PlasmoDB191 was used to identify the P. berghei orthologues of the P. 
falciparum PTEX components. Sequence alignments of each PTEX protein 
sequence from P. falciparum and P. berghei was then performed by Pairwise 
Sequence Alignment (EBI database), with between 46.2% to 90.6% amino 
acid identity observed between the P. berghei and P. falciparum PTEX protein 
sequences. HSP101 is the most highly conserved protein between the two 
species (Table 3.1). Similar to the P. falciparum PTEX components, all of the 
5 PTEX orthologues in P. berghei have a signal sequence, which would be 
required for PV localisation. The putative P. berghei PTEX proteins are 
predicted to be a similar weight to the P. falciparum orthologue and the same 
features are observed in proteins from both species. For example HSP101 
contains two ATPase domains, EXP2 contains conserved acidic repeats and 
TRX2 harbours a thioredoxin motif. Also, both P. falciparum and P. berghei 
PTEX88 and EXP2 have conserved cysteine residues (Figure 3.1). There is 
also evidence that the five PTEX genes are transcribed and expressed in P. 
berghei blood stages195 where protein export is known to occur. 
In order to confirm these bio-informatic, transcriptomic and proteomic data, 
as well as to localise the putative P. berghei PTEX proteins within the 
parasite, several transgenic P. berghei parasite lines were generated in which 
each putative PTEX component was epitope tagged at the C-terminal end 
with a triple hemagglutinin (HA) and single Strep-Tactin II (Strep) epitope tag.  
Attempts to generate antibodies to several of the components were also 
undertaken.   
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1.10.2 Generation of reagents to P. berghei PTEX components 
Whilst rabbit polyclonal anti-PTEX antibodies have been 
generated against the P. falciparum PTEX proteins, PfPTEX150, PfHSP1011 
and PfEXP2174,196, none had been developed for P. falciparum PTEX88 and 
TRX2.  Moreover, no antibodies existed against the P. berghei PTEX 
orthologues. However, due to the regions where the P. falciparum antibodies 
were targeted to, and the tight homology between the Plasmodium PTEX 
orthologues shown in Figure 3.1, the P. falciparum anti-PTEX antibodies 
have the potential to be cross reactive against the orthologous protein in P. 
berghei.  
Thus, the first step of this Chapter was to determine if the existing anti-
PfPTEX antibodies were cross reactive against the putative P. berghei PTEX 
components, before deducing if the generation of new anti-PbPTEX reagents 
was required.  To achieve this, protein extracted from asynchronous PbANKA 
parasites was separated by SDS-PAGE, and probed in a Western blot with 
the available anti-PfHSP101, anti-PfEXP2 or anti-PfPTEX150 antibodies. As a 
comparative positive control for antibody reactivity, P. falciparum 3D7 lysate 
was run alongside the PbANKA wild type lysates.  
Figure 3.2 shows that the anti-PfHSP101 detects P. falciparum HSP101 
protein just under 100 kDa as expected, but also detects a P. berghei protein 
orthologue running slightly higher, consistent with a predicted mass of the P. 
berghei orthologue being 103.06kDa. Figure 3.2 also shows that the anti-
PfEXP2 detects the ~33 kDa EXP2 protein in P. falciparum lysate, as well as 
a protein in P. berghei above 25 kDa. This is smaller than the predicted 
molecular weight of the putative P. berghei EXP2 protein of ~31 kDa, 
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however, no other protein species were detected. Thus both the protein 
species detected by the anti-PfHSP101 and anti-EXP2 antibodies are likely to 
be the P. berghei orthologues of PfHSP101 and PfEXP2. Anti-PfPTEX150 did 
not recognise any protein species in the P. berghei lysate (Data not shown). 
Thus, taken all together, these experiments revealed that P. falciparum 
HSP101 and EXP2 antibodies could be used in P. berghei to detect the 
orthologous PTEX components by Western Blot (Figure 3.2). In contrast, anti-
PfPTEX150 did not recognise any P. berghei protein species and antibody 
generation specific to the P. berghei orthologue was required. The reactivity of 
existing P. falciparum antibodies against the P. berghei orthologues is 
summarised in Table 3.2.  
 
1.10.2.1 Attempts to generate antibody reagents against PTEX150 
and TRX2 
Given that the PfPTEX150 antibody was not cross-reactive against P. 
berghei, it was apparent that new P. berghei specific antibodies to PTEX150, 
as well as TRX2 and PTEX88, to which no antibodies are available for either 
species, were required. However, as part of this thesis, only PbPTEX150 and 
both PfTRX2 and PbTRX2 were targeted for antibody generation, as PTEX88 
was being characterised in greater detail as part of another research project.   
To express PbPTEX150 for antibody production, a region of the putative P. 
berghei PTEX150 gene constituting 470 base pairs of PbPTEX150 (Figure 
3.1) was PCR amplified from PbANKA genomic DNA using the 
oligonucleotides O1/O2. The resulting fragment was digested with BamHI and 
PstI and cloned into the corresponding sites of the pB3 vector193 (Figure 3.3a). 
Likewise, to express PfTRX2 and PbTRX2 for antibody production, a region of 
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either TRX2 gene constituting 372bp of PfTRX2 and 315bp of PbTRX2 
(Figure 3.1) was PCR amplified from either P. falciparum 3D7 or P. berghei 
ANKA genomic DNA, with the oligonucleotides O3/O4 or O5/O6 respectively, 
digested with BamHI and PstI and cloned into the corresponding sites of pB3 
(Figure 3.3a).  These regions of TRX2 lack the predicted signal peptide 
sequence but comprise the conserved thioredoxin domain (WCQAC). This 
cloning strategy incorporates a maltose binding protein (MBP) tag at the N-
terminal end of PbPTEX150, PfTRX2 and PbTRX2 recombinant protein to 
maintain the solubility of the recombinant protein, and a 6-histidine (6xHis) tag 
at the C-terminal end to facilitate protein purification. The resulting plasmids 
were sequenced to ensure the coding region of PbPTEX150, PbTRX2, and 
PfTRX2 were error free and in-frame with MBP.  
To express each PTEX protein, plasmids were independently transformed 
into E. coli BL21 bacterial cells, which were then grown to log phase and 
induced for protein expression with 1M Isopropyl B-D-1thiogalactopyranoside 
(IPTG). The recombinant Pb-MBP-PTEX150-His and Pb-MBP-TRX2-His 
protein was then purified from the BL21 cells using an amylose resin and 
after a series of washes, the purified fusion proteins were eluted with10 mM 
maltose, resulting in 9.5 mg of PfTRX2, 7 mg of PbTRX2 and 8 mg of 
PTEX150 protein. The integrity of the recombinant protein was subsequently 
assessed by SDS-PAGE and Coomassie staining.  For the PbPTEX150 
purification, the predominant protein species observed in the eluate was at 
about 63 kDa, which is consistent with the predicted molecular weight 
including the MBP-His tag (Figure 3.3b). For the PfTRX2 and PbTRX2 
purification, the predominant protein species observed in the eluate was at 
about 59 kDa and 56, which was also consistent with the predicted molecular 
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weight including the MBP-His tag of 59.26 and 56.78 kDa respectively 
(Figure 3.3c, 3.3d). Unspecific protein species were not readily detectable in 
the elution fractions, suggesting the purification had been successful.   
To generate polyclonal antibodies against PbPTEX150, PfTRX2 and 
PbTRX2, the recombinant protein was used to immunise rabbits and rats. 
Sera obtained from kill bleeds of animals that had received three 
immunisations unfortunately failed to detect a protein species in P. berghei or 
P. falciparum protein lysate at the expected molecular weight for TRX2 or 
PTEX150, and instead only recognised MBP (data not shown).  With the 
PTEX150 recombinant protein, degradation was observed after short-term 
storage, and thus further attempts to generate antibodies against this protein 
were ceased. With the TRX2 recombinant protein, given that the MBP tag is 
significantly larger than TRX2 (43 kDa versus 14 kDa), it is likely that an 
immune response was predominantly induced towards the MBP portion of 
the recombinant protein rather than the target TRX2 protein.   
Thus to ensure that only antibodies specific to either P. falciparum or P. 
berghei TRX2, and not to MBP were generated, 3 mg of the recombinant 
TRX2 protein was cleaved from the MBP tag with Factor Xa enzyme (FXa) 
prior to immunisation. As can be seen from Figure 3.4, full-length MBP-
TRX2-6xHis protein runs at 43 kDa whilst cleaved TRX2-6xHis protein runs 
at approximately 14 kDa. However, un-cleaved full-length MBP-TRX2-6xHis 
protein was still present after an overnight incubation with FXa, indicating the 
enzyme was not efficient and did not completely cleave all the recombinant 
protein during this time. Therefore, in an attempt to purify TRX2 further, the 
gel fragment present at 14 kDa containing only the TRX2 protein was 
excised, solubilised and used to immunise a second batch of naïve rabbits. 
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Again, the sera from the second round of immunisations did not yield specific 
antibodies against either P. falciparum or P. berghei TRX2 protein as 
Western blot analysis of SDS-PAGE P. falciparum or berghei lysate failed to 
detect the expected protein species of 14 kDa. To determine if the sera 
contained even a low concentration of anti-TRX2 antibodies, IgG antibodies 
were purified and concentrated from the sera with Protein A - agarose beads. 
When this IgG purified antibody was probed against parasite protein lysate, it 
only resulted in lower detection of unspecific protein species and 
unfortunately TRX2 specific reactivity was not observed. 
 
1.10.2.2 Peptide antibody development against TRX2 
Considering previous attempts to generate antibodies against recombinant 
TRX2 protein failed, an alternative method to generate antibodies against 
TRX2 was performed. Here, commercial antibodies were raised by Abmart 
against short PfTRX2 peptides, selected for their epitope structure using 
Protein Surface Epitopes Targeted by Monoclonal Antibody Library (SEAL). 
The selection of nine independent epitopes was based on the likelihood that 
one might be reactive. Initially, P. falciparum TRX2 was chosen as the target 
species using this approach. If it proved to be successful, attempts using P. 
berghei specific epitopes would be considered since none of the peptides 
were predicted to be cross-reactive between P. falciparum and P. berghei. A 
total of nine peptide sequences were selected against PfTRX2 (Figure 3.5), 
and peptide monoclonal antibodies were generated (Abmart).  Initially, two of 
the monoclonal antibodies detected a faint protein species at the expected 
size of TRX2 by Western blot analysis (data not shown), however, numerous 
attempts to repeat this observation failed.  Further, IgG purification of the 
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antibodies against recombinant PfTRX2 protein did not enhance detection 
ability by Western blot analysis (data not shown).   
 
1.10.2.3 Epitope tagging of PTEX components  
Due to the unsuccessful attempts at generating polyclonal, monoclonal or 
peptide antibodies against the putative P. berghei PTEX proteins, an 
alternative method to characterise the PTEX components in P. berghei was 
explored. Accordingly, a series of transgenic P. berghei ANKA parasite lines 
were created in which the genes encoding the endogenous putative P. 
berghei ANKA PTEX components were tagged with a triple-HA and Strep-
Tactin II epitope tag, using a 3' replacement strategy. Even though the anti-
PfHSP101 and anti-PfEXP2 cross-reacted against P. berghei lysate, the P. 
berghei EXP and HSP101 components were included in the epitope tagging 
process as a control for the antibodies, as well as to provide extra tools for 
analysis.  This approach inserted the epitope tags at the C-terminal end of the 
protein without endogenous protein disruption (Figure 3.6a). To achieve this, 
approximately 2 kb of the 3' end of the target gene without the stop codon was 
cloned into the SpeI and AvrII of a modified epitope tagging construct termed 
pB3-150-HA/Str-DT3', upstream and in frame of the epitope tags. Flanking 
regions were designed to facilitate gene integration such that the full epitope-
tagged PTEX gene would be expressed under its endogenous promoter.  
Each of these five PTEX tagging constructs were sequenced to ensure the 
tag was in frame with the PTEX coding sequence (CDS). To facilitate 
integration, the plasmids were linearised within the target sequence at an 
engineered SpeI site, leaving ~1 kb of target sequence on either side of the 
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restriction cut site. Linearised DNA (1-2 µg) was transfected into schizont 
stage PbANKA parasites, which were then intravenously injected into naïve 
Balb/c mice. After mice were treated with pyrimethamine to select for 
transfectants, parasite growth was observed across all lines and at about 
seven days post infection when the parasitemia of infected mice reached 
approximately 5 % parasitemia, infected blood was harvested so that parasite 
genomic DNA and protein material could be isolated.   
To determine whether correct gene targeting had occurred, diagnostic PCR 
was performed, using primers designed to distinguish between integrated and 
wild type parasites. The expected amplicon sizes representing 3xHA/Strep 
epitope-tagged PTEX genes were recovered (Figure 3.6b). To check for 
clonality, the presence of the corresponding wild type PTEX gene was 
assessed using the oligonucleotide combinations of O45 (150-HA), O46 (101-
HA), O47 (88-HA), O48 (EXP2-HA) and O9 (TRX2-HA) with O44, which 
revealed that wild type parasites were present in each line. However, further 
cloning of parasites was not performed as transfected parasites could be 
discriminated by the presence of the HA tag. Subsequent confirmation of 
successful epitope tagging was obtained by Western blot analysis using 
mouse anti-HA antibodies against protein lysates made from transgenic 
parasites. Migration of the tagged PTEX protein species in all transfected 
parasite lines was in accordance with the predicted molecular mass and no 
labeling was observed in the un-transfected wild type control lysate (Figure 
3.7a). Further to this, transgenic PbEXP2-HA, PbHSP101-HA parasites and 
wild type parasites were also probed with anti-PfHSP101 and anti-PfEXP2 
antibody that had previously been shown in Figure 3.2 to cross-react to the P. 
berghei orthologous proteins. As expected, protein species that reacted with 
 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the anti-PfHSP101 in the transgenic parasite lysates showed an increase in 
molecular weight in accordance with the addition of the 3xHA/Strep tag. 
However, for EXP2 the shift in molecular weight changed from 26 kDa in wild 
type parasites, to 35 kDa in EXP2-HA parasites, which is more than expected 
given the size of the epitope tags (~4.5 kDa), indicating EXP2 has an unusual 
mobility profile. Also, the reactivity of the -26 kDa species in PbEXP2-HA with 
anti-PfEXP2 indicates the presence of untagged EXP2 in the parasite 
population (Figure 3.7 b). In contrast, the PbHSP101-HA parasite line shows 
no visibly detectable untagged HSP101 protein and taken together with the 
PCR results that show a weak PCR result for the wild type locus, this 
indicates there are likely to be few wild type parasites in the population (Figure 
3.7b). Importantly, the ability to successfully integrate the epitope tags into the 
loci of the PTEX genes indicates that all the PTEX genes in P. berghei are 
amenable to gene targeting. 
 
1.10.3 P. berghei PTEX orthologues localise to the PVM 
After generating the P. berghei PTEX HA-tagged parasite lines, the 
localisation of the PTEX components were analysed by immunofluorescence 
assay (IFA).  This was performed on ring-stages parasites fixed with ice-cold 
acetone/methanol. For each parasite line, labeling with a rat anti-HA antibody 
and the anti-PfEXP2 antibody was performed (Figure 3.8). The PbEXP2-HA 
fixed parasites importantly showed that staining for HA and PbEXP2 co-
localised, with a punctate labeling pattern observed outside the parasite 
periphery (Figure 3.8a top panel), similar to that observed with P. falciparum 
in which EXP2 localises to the PVM1.  This observation corroborates that the 
 

PbEXP2-HA parasite line was appropriately HA epitope tagged, and that the 
anti-PfEXP2 antibody was indeed recognising endogenous EXP2 in P. 
berghei, despite the unexpected size of PbEXP2 observed in Western blots. 
In contrast, the anti-PfHSP101 antibody, which proved to be cross-reactive 
against P. berghei by Western blot analysis, did not clearly label Pb101-HA 
under IFA conditions (data not shown). Therefore, anti-PfHSP101 antibodies 
could not be used to colocalise HSP101 with other PTEX components on the 
PTEX-HA tagged parasite lines by IFA. As can be observed from Figure 3.8a, 
four of the PTEX proteins, PbPTEX150-HA, PbHSP101-HA, PbEXP2-HA, and 
PbPTEX88-HA, co-localised with PbEXP2. Therefore, it could be concluded 
that these proteins localise at the PV/PVM. This observation is consistent with 
previous localisations of PfPTEX150 and PfHSP101, but importantly, this is 
the first time PTEX88 has been localised in any Plasmodium species. The 
localization of TRX2 was less distinct and difficult to detect overall due to very 
weak labeling with the anti-HA antibody, perhaps due to the lower level of the 
expression of TRX2-HA protein. Whilst TRX2 did appear to be present with 
EXP2 in the early ring stages of the parasites blood stage, as the parasite 
matured into trophozoite stages, the localization of TRX2-HA appeared more 
internalized and towards the parasite periphery internal to the PVM. TRX2-HA 
localisation was also investigated in schizont stages generated from rings and 
trophozoite stages harvested from infected mice and further cultured in vitro. 
IFAs revealed TRX2-HA displayed punctate apical labeling in schizonts, 
reminiscent of the labeling pattern observed with other PTEX components in 
P. falciparum1 and PbPTEX150-HA included as a control (Figure 3.8b).  
Taken together, the IFAs confirmed that the PTEX orthologues in P. berghei 
are expressed and mostly co-localise at the PVM.   
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1.10.4 P. berghei TRX2 and PTEX88 interact with other PTEX 
components 
Whilst co-localisation of the P. berghei PTEX orthologues at the PVM is 
consistent with being functionally equivalent to their P. falciparum orthologues, 
the IFAs performed above do not provide evidence that the components 
actually interact in P. berghei. Accordingly, co-immunoprecipitation 
experiments were performed to determine if the P. berghei PTEX orthologues 
interact with each other. Protein lysates from trophozoite or schizont stages 
expressing the P. berghei HA-tagged PTEX orthologues, or PbANKA wild type 
parasites, were affinity purified with rabbit anti-HA antibody coupled to 
magnetic beads and purified under native conditions. Post purification, the 
eluates were separated by SDS-PAGE and Western blots were probed with 
mouse anti-HA, anti-PfHSP101 or anti-PfEXP2 antibodies. As expected, the 
anti-HA antibodies did not detect any protein in wild-type lysate, but each of 
the five HA-tagged proteins of expected molecular masses were present in 
the elution fraction of the HA-epitope tagged transgenic parasites (Figure 
3.9a). 
In addition, affinity purification of PbPTEX150-HA, PbPTEX88-HA and 
PbTRX2-HA resulted in the co-precipitation of HSP101 (Figure 3.9b) and 
EXP2 (Figure 3.9c). Again, no signal was detected in the wild-type lysate 
eluates immunoprecipitated with anti-HA antibody. This indicates that the 
detection of PbHSP101 and PbEXP2 in the anti-HA eluates is specific. The 
observations that the PbPTEX150-HA and PbEXP2-HA immunoprecipition co-
precipitated with HSP101, and that PbPTEX150-HA and PbHSP101-HA co-
precipitated with PbEXP2, is consistent with results in P. falciparum that show 
these proteins interact1.  Significantly, these experiments also revealed for the 
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first time, that that PbTRX2-HA and PbPTEX88-HA also specifically interact 
with HSP101 and EXP2 (Figure 3.9b and c).   
A significant limitation with this analysis was the use of cross-reactive 
antibodies, originally designed for the P. falciparum PTEX orthologues.  Whilst 
these antibodies are able to specifically and accurately detect P. berghei 
HSP101 and EXP2, the detection is significantly weaker than their P. 
falciparum counterparts, most likely due to the differences in the coding 
sequences between the species. Further to this, only HSP101 and EXP2 
could be probed for due to the failure to generate specific reagents against 
PTEX150, PTEX88 and TRX2. Therefore, reciprocal immunoprecipitation 
experiment, such as an EXP2-HA pull-down followed with anti-PTEX88 
detection, could not be performed to further validate the results.  
Due to these limitations, further proteomic approaches were undertaken to 
confirm that TRX2 and PTEX88 interact with other PTEX proteins, as well as 
potentially finding other novel interacting partners of TRX2. Although both 
PTEX88-HA and TRX2-HA lines were available, only the TRX2-HA pull down 
was performed due to time restraints. Specifically, the elution fraction of the 
PbTRX2-HA or PbANKA wild-type parasites derived from anti-HA pull-downs, 
were separated by SDS-PAGE and resolved proteins were enhanced for 
visualization in situ with Sypro Ruby (Figure 3.10). Differences between 
protein species in the wild type and TRX2-HA protein fractions were observed. 
Corresponding gel fragments were excised from the wild type and PbTRX2-
HA pull-downs in circumstances in which a protein species appeared in the 
PbTRX-HA fraction but not in the PbANKA fraction as the former were 
presumed to contain protein species that interacted specifically with TRX2-
HA.  
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All samples were processed by capillary liquid chromatography coupled 
online with tandem mass spectrometry (LC-MS/MS) for peptide identification. 
Overall, gel slices excised from the TRX2-HA immunoprecipitation eluate 
yielded twenty-seven unique peptides to P. berghei PTEX orthologues, 
including PbHSP101, PbPTEX88 and PbEXP2, with 9% sequence coverage 
for each protein. In contrast, no PTEX peptides were detected in the 
corresponding P. berghei wild-type control (Figure 3.11a).  These results 
further validate the immunoprecipitation experiments performed in P. 
falciparum. Interestingly, other proteins previously shown to affinity purify with 
P. falciparum PTEX components were also isolated (Figure 3.11b).  These 
included the parasitophorous vacuolar protein 1 (PV1)197 and heat shock 
protein 70 (HSP70)1. Twelve additional proteins bound exclusively to TRX2-
HA and were not present in the wild type eluate. Since their interaction is 
specific to TRX2, these proteins are potentially new or interacting components 
of PTEX.   Non-PTEX peptides were recovered in matching bands of both the 
wild type and TRX2-HA eluates, consisting of mainly putative ribosomal 
proteins that are typically involved in the cellular process of translation, (eg: 
PbANKA_123250) and these represent proteins that have bound non-
specifically to the anti-HA resin.  
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1.11 Discussion  

The initial discovery of PTEX in P. falciparum was achieved using a range 
of proteomic, biochemical and cell biological approaches. In P. falciparum, 
PTEX comprises of PTEX150, HSP101 and EXP2, with TRX2 and PTEX88 
remaining tentatively assigned constituents until their interactions with PTEX 
could be confirmed to be specific1. Further studies in P. falciparum have also 
validated the interactions between PTEX150, HSP101 and EXP2176.  
Herein, database searches for the PTEX gene orthologues in other 
Plasmodia species revealed that the five PTEX genes are conserved across 
the genus, including P. berghei. Thus, if it could be confirmed that the putative 
PTEX components in P. berghei form a complex at the PVM in a similar 
fashion to that observed in P. falciparum, this would enable the functional 
dissection of PTEX in virulence and survival in vivo using P. berghei in a 
rodent model of infection.  
Whilst specific antibodies have been generated against P. falciparum 
HSP101, EXP2 and PTEX150, only the anti-HSP101 and anti-EXP2 
antibodies were found to be capable of recognising the P. berghei PTEX 
orthologues by Western blot to permit further characterization of these proteins 
in P. berghei. Of these two antibodies, only the one directed against EXP2 
reacted against P. berghei in IFA. Thus several different attempts were made 
in this study to generate reagents that were capable of recognizing the 
remaining putative PTEX components in P. berghei by either Western blot 
analysis or IFA but unfortunately all attempts proved unsuccessful. It should 
be noted that although recombinant P. falciparum TRX2 has been successfully 
used by Sharma et al 186 to generate polyclonal antibodies, in our hands these 
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antibodies failed to react against native parasite protein by Western blot 
analysis. The difficulty in generating antibodies to TRX2 or the other PTEX 
components may be because the portion of the recombinant protein that was 
expressed is not very immunogenic. Alternatively, the native PTEX protein 
within the parasite may only be weakly expressed, rendering its detection 
difficult. 
As a consequence of the failure to generate specific antibodies that could 
be used to characterize the putative PTEX components in P. berghei, all five 
PTEX proteins were instead epitope-tagged at their C-terminal end with a 
3xHA/Strep tag, allowing the use of anti-HA antibodies for further studies. 
Importantly, the ability to tag each putative P. berghei PTEX component 
validated that the locus is amenable to gene targeting. IFA performed on each 
of the P. berghei transgenic PTEX-HA parasite lines from ring to late 
trophozoite stages revealed that PbPTEX150, PbHSP101 and PbPTEX88 co-
localise with EXP2, the latter being the PTEX component most tightly 
associated with the PVM in P. falciparum. This indicates these components in 
P. berghei localise to where export machinery is expected to reside. However, 
the localisation of TRX2 during the ring stage could not be completely 
resolved, as in addition to co-localising with EXP2, PbTRX2-HA was also 
found within the parasite cytosol and potentially to an unknown structure. 
Nonetheless, PbTRX2-HA was also detected in schizonts, along with 
PbPTEX150, where it specifically located towards the apical end of each 
developed merozoite, consistent with TRX2 being carried in with the rest of the 
PTEX complex during parasite invasion1. Both the PVM and apical 
localisations observed here are in keeping with previous studies that show 
TRX2 is expressed in schizonts and present at either the PV/PVM during early 
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ring stages186,187. Thus, whether the presence of TRX2 within the parasite 
infers a function in addition to its putative role in PTEX at the PVM remains 
unknown. 
Using the newly generated HA-epitope tagged parasite lines as well as the 
anti-PfHSP101 and anti-PfEXP2 antibodies, it could be validated by 
immunoprecipitation experiments coupled with either immune-blot analysis or 
mass spectrometry that PTEX150, HSP101 and EXP2 interact to form a 
complex in P. berghei. Importantly, this study was also able to confirm that 
PbPTEX88 and PbTRX2 are also part of the PTEX complex. Analysis of non-
PTEX proteins that were identified as unique to the TRX2-HA pull-down and 
absent from the wild type negative control, revealed PbTRX2-HA also 
potentially interacts with the parasite vacuole protein 1 (PV1). This protein is 
unique to Plasmodium198 and localises to the PV space197, providing further 
support for the localization of TRX2 at the PV. P. falciparum PV1 is amenable 
to gene tagging but attempts to disrupt the PfPV1 gene have been 
unsuccessful, indicating it is an essential protein197.  So far the function of PV1 
is unknown, but its association with PTEX warrants further investigation as it 
may potentially be another bona fide PTEX component. 
Although the mass spectrometry analysis of proteins that affinity purified 
with TRX2-HA has shown interaction with other PTEX proteins and HSP70, a 
potential chaperone, it failed to yield any obvious novel proteins that may be 
the direct substrate of TRX2. Thus, without further experimentation on TRX2 
(and indeed PTEX88 and PTEX150) its function within the PTEX complex 
still remains a mystery.   
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Table 3.1: Comparisons between the P. falciparum and the orthologous 
P. berghei PTEX protein 
 
aProtein similarities expressed as a percentage and generated by a Pairwise Sequence Alignment 
(Needleman-Wunsch alignment algorithm). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PTEX 
Component 
Gene I.D 
P. falciparum 
Gene I.D 
P. berghei 
Protein 
Identity 
(%) 
Protein  
Similarity 
(%)a 
PTEX150 Pf3D7_1436300 PbANKA_100850 30.1% 46.2% 
HSP101 Pf3D7_1116800 PbANKA_093120 81.5% 90.6% 
EXP2 Pf3D7_1471100 PbANKA_133430 61.0% 76.7% 
PTEX88 Pf3D7_1105600 PbANKA_094130 44.0% 65.7% 
TRX2 Pf3D7_1345100 PbANKA_135800 48.7% 75.9% 
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Table 3.2: Reactivity of P. falciparum antibodiesa 
 
 
PTEX 
component 
Reactivity of 
antibody against  
P. falciparum 
Reactivity of 
antibody against  
P. berghei 
Antibody generation 
attempted in this study 
PTEX150 ** IFA -   IFA • No 
*** Western analysis **Western analysis 
HSP101 ** IFA -   IFA • P.berghei PTEX150-
polyclonal *** Western analysis *  Western analysis 
EXP2 *** IFA *** IFA • No 
*** Western analysis ***Western analysis 
PTEX88 N/A N/A • No 
TRX2 N/A N/A • P. falciparum TRX2 
polyclonal 
• P. falciparum TRX2 
monoclonal 
• P. berghei TRX2 
polyclonal 
 
a
Comparative table showing antibodies against P. falciparum PTEX proteins and their cross-reactivity to the 
P. berghei orthologue. Symbols represent strength of antibody recognition (N/A, no antibody available; - no 
interaction, * weak interaction, ** medium interaction, ***strong interaction) 
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Figure 3.1: Schematic of the P. falciparum PTEX components and 
the orthologous proteins in P. berghei.  
Colour codes correlate to distinguishing features and similarities 
between the two species. The protein length in amino acids (aa) is 
indicated. The regions to which antibodies were generated for PTEX150 
and TRX2 are indicated by the green lines.   
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Figure 3.2: Anti-PfHSP101 and anti-PfEXP2 cross-react with P. 
berghei.   
Western blot analysis of parasite proteins extracted from P. berghei 
ANKA and P. falciparum HSP101 parasites and separated by SDS-
page using either (a) anti-PfHSP101 (1/250) or (b) anti-PfEXP2 
(1/500) antibodies. The asterisks indicate P. berghei PTEX protein 
species where the antibody raised against P. falciparum is cross-
reactive. 
 
+'())!&%'#)$!
 +
+
 

 
  	

 





"    
	
(&$!%%*

(&$!%%*



"   

 



"  
	
(&$!%%*
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3:  Expression of recombinant PTEX150 and TRX2 
protein.  
a) Schematic representation of the plasmid used to express PTEX150 
and TRX2 in E. coli. MBP: maltose binding protein; 6xHIS: 6x histidine 
fusion protein. The green arrow indicates transcription start and red 
stop indicates transcriptional terminator. Jagged lines indicates the 
Factor Xa cleavage site IE/DGR b) Large-scale protein expression and 
purification of P. berghei PTEX150, c) P. falciparum TRX2 and d) P. 
berghei TRX2 recombinant protein separated by SDS-page and 
stained with Coomassie. (-) Un-induced BL21 samples, show no 
production of fusion protein without the addition of IPTG, where as (+) 
samples induced with 1mM IPTG display efficient recombinant protein 
expression in BL21 E. coli cells. E1 and E2 indicate elution fractions of 
protein purified on nickel column. Arrowheads indicate expected 
molecular weight of the fusion proteins.  
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Figure 3.4: Cleavage of recombinant PTEX150 and TRX2 protein.  
a) Schematic representation of recombinant PTEX protein after 
incubation with Factor Xa resulting in the separation of the MBP fusion 
tag and the PTEX protein. MBP: maltose binding protein; 6xHIS: 6x 
histidine fusion protein. Broken jagged lines indicates the Factor Xa 
cleavage site b) Representative SDS-PAGE gel of post-cleaved 
recombinant TRX2 protein stained with Coomassie displays three 
protein populations; uncut MBP-TRX2-6xHIS at 57kDa, MBP at 43kDa 
and TRX2 at 14kDa, the latter of which was excised from the gel for 
rabbit immunisations.   
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Figure 3.5: Sequence alignment between P. falciparum and P. 
berghei TRX2.  
Sequences in blue boxes represent the nine peptide P. falciparum 
sequences selected for monoclonal antibody generation.  Peptides 
were selected using Monoclonal SEALTM Library Design Kit software 
and based on the most exposed regions of the sequence. Amino acid 
colour indicates residue classification. Degree of sequence 
conservation indicated by stars (identical residue; double dots (similar 
aa); single dot (weakly similar aa). 
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Figure 3.6: Generation of P. berghei transgenic parasites 
expressing epitope tags.  
a) The targeting constructs were designed to integrate into the 
respective P. berghei PTEX locus by single-crossover recombination, 
such that the complete open reading frame was reconstituted while 
simultaneously introducing a combined C-terminal triple haemagglutinin 
(HA) and a single Strep-II (Str) epitope tag. The predicted structure of 
the endogenous locus before and after 3' integration is shown. Yellow 
box, 3xHA/Strep epitope tags; SM, Toxoplasma gondii DHFR-TS 
selectable marker cassette; wavy lines, plasmid backbone; green arrow, 
transcription start site; stop, transcription terminator; SacII, linearization 
site. b) Diagnostic PCR to detect integration into the PTEX locus. 
Oligonucleotide combinations O45-O49/O233R were used to detect 
incorporation of the epitope tags into transgenic PbPTEX150 (150-HA), 
PbHSP101 (101-HA), PbTEX88 (88-HA), PbEXP2 (EXP2-HA) and 
PbTRX2 (TRX2-HA). 
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Figure 3.7: Expression of P. berghei transgenic parasites with 
epitope tags.  
a) Western blot analysis of parasite proteins extracted from WT and 
transgenic P. berghei parasites harvested from infected mice using anti-
HA antibodies. b) Western blot analysis of WT and transgenic PbEXP2-
HA and Pb101-HA using the indicated antibodies reveal that the anti-
PfEXP2 and anti-Pf101 recognize a predominant protein species in WT 
P. berghei extracts at about the predicted molecular weight, while 
slightly higher species are observed in the transgenic parasite lines due 
to the incorporation of the epitope tags. 
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Figure 3.8: P. berghei PTEX components colocalise and have 
PV/PVM localization.  
Double-labeling IFA performed on (a) fixed rings stages or (b) fixed 
schizont stages of P. berghei PTEX-HA transgenic parasites using the 
antibodies as indicated. BF: Bright field. ×1000 original magnification for 
all IFA images. 
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Figure 3.9: The five putative PTEX components form a complex in 
P. berghei, including PTEX88 and TRX2.  
Immunoblot analysis of immunoprecipitations (IP) performed on P. 
berghei ANKA wild-type (WT) and transgenic HA-tagged parasite 
lysates using anti-HA antibody (-HA) for the IP and probed with (a) 
anti-HA, (b) anti-Pf101 or (c) anti-PfEXP2. Supernatant (SN) was 
collected after parasite lysate was centrifuged and the flow fraction 
represents unbound supernatant material. The presence of PTEX 
components in the elution fraction of immunoprecipitations performed 
on HA-tagged parasites and their absence in the P. berghei wild-type 
(WT) control indicates the interaction is specific. Note that in the 
uncloned PbEXP2-HA transgenic population the EXP2 antibody 
detects both epitope-tagged and untagged EXP2 that associate in 
oligomers. 
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Figure 3.10: PbTRX2-HA interacts with unique protein species.  
Elution fractions of P. berghei wild type (WT) and PbTRX2-HA parasite 
lysate pull downs with anti-HA, separated by SDS-page and stained 
with Sypro ruby. Unique protein species observed in the TRX2-HA 
fractions were excised along with the WT control and subjected to 
capillary liquid chromatography coupled online with tandem mass 
spectrometry (LC-MS/MS) for peptide identification.  
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Figure 3.11: PbTRX2-HA associates with PTEX & non-PTEX 
proteins.  
a) Schematic representation of peptide sequence coverage of 
interacting PTEX partners of PbTRX2-HA represented as a percentage. 
No PTEX peptides were detected in the control WT fractions. b) 
Representative graph of all unique peptides interacting with PbTRX2-
HA that were not observed in WT.  Included on the right-hand side are 
several peptides that were detected in both pull-downs and thus are 
likely to be interacting non-specifically with TRX2. 
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Dissecting the role of the PTEX 
components and assessing parasite 
growth and virulence 
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1.12 Introduction  
A study by Maier et al (2008)140 showed that approximately 25% of 
exported proteins could not be genetically targeted for disruption, indicating 
they are essential to the parasite. Thus any process which facilitates export 
of these proteins would also be expected to be essential. 
Given the suspected role PTEX has in the protein export pathway, it is 
hypothesised that parasites lacking a functional PTEX would not survive. 
However, not all constituents of other translocons found in nature are 
essential for function and they can still translocate proteins even if some of 
the accessory components have been genetically disrupted. This chapter, 
therefore, aimed to genetically disrupt all five PTEX components to serve two 
purposes. Firstly, confirmation of the essentiality of PTEX to parasite survival 
would corroborate the essential role it is anticipated to have in protein export. 
Those PTEX genes that cannot be disrupted are therefore likely to make 
good anti-malaria drug targets. Secondly, if any PTEX components are 
amenable to gene deletion, this would indicate these components play an 
accessory role in PTEX function. Nonetheless, it would allow phenotyping of 
the resulting transgenic parasite lines to assess the consequences of altering 
PTEX function on parasite growth and virulence.   
Attempts to genetically disrupt each PTEX gene was undertaken in P. 
berghei. Not only are transfections more efficient in this species compared to 
P. falciparum, if transgenic parasites could be derived, the mouse model for 
P. berghei allows assessment of PTEX’s role in parasite virulence and 
survival in vivo. In Chapter 3, it had been validated that PTEX is present as a 
complex in P. berghei, and importantly, that each PTEX gene is amenable to 
 
targeting as they could be successfully HA-epitope tagged. In this Chapter, 
the construction of linear PTEX targeting vectors and their transfection into P. 
berghei ANKA parasites is described, along with the analysis of recovered 
transgenic parasites in growth and virulence assays.  
 
1.13 Results  
1.13.1 Generation of PTEX knockout constructs   
The PTEX targeting vector constructs were made using the pB3 
plasmid193, which comprises an ampicillin selectable marker to facilitate 
selection of plasmids in E. coli and a Toxoplasma gondii DHFR selectable 
marker (TgSM) cassette to select for transgenic parasites using the drug 
pyrimethamine. Appropriate restriction enzymes either side of the TgSM 
allowed for plasmid cloning (Figure 4.1). Final targeting constructs comprised 
the 5' and 3' UTR sequences of each respective P. berghei PTEX gene to 
facilitate homologous recombination and replacement of the endogenous 
PTEX gene. The 5' and 3' PTEX targeting sequence flanks were obtained by 
PCR amplification of wild type P. berghei ANKA genomic DNA using 
oligonucleotides O13/O14 and O15/O16 (HSP101), O21/O22 and O23/O24) 
(EXP2), O17/O18 and O19/O20 (PTEX88) and O25/O26 and O27/O28 
(TRX2) (Table 2.1). The PTEX150 knockout construct was not created in this 
study as it has been previously described1. The PCR products were digested 
with ApaI/SacII or BamHI/XbaI, respectively and cloned into the 
corresponding sites of the pB3 plasmid. The resulting constructs were 
transformed into E. coli and transformants that grew under ampicillin 
selection were screened by PCR to assess if the ligation had been 
 
successful. This was performed using oligonucleotides corresponding to 
either the 5' or 3' targeting sequence in conjunction with either 
oligonucleotide O30 or O29, respectively, which bind to the plasmid 
backbone. PCR positive clones were then subjected to further diagnostic 
restriction enzyme digest to confirm the 5' and 3' targeting sequence had 
been cloned (data not shown). Consequently, large-scale plasmid 
preparations were performed to provide enough DNA for P. berghei 
transfection.  
To facilitate double-crossover homologous recombination into the P. 
berghei genome, plasmid DNA was linearised by digestion on either side of 
the targeting sequence with KpnI and XbaI. Addition of PvuI ensured the 2.87 
kb backbone fragment was reduced to two smaller fragments to ensure no 
fully intact plasmids were present that could replicate as episomes within the 
parasite (Figure 4.1). Using the Amaxa transfection system, wild type 
schizonts were transfected with 2 μg of each linearised DNA fragment under 
the pre-set U33 program.  Each transfection mix was administered 
intravenously into a single Balb/c mouse and 24 hrs post infection, mice were 
administered pyrimethamine drug water ad libitum to select for transgenic 
parasites.   
 
1.13.2 Analysis of P. berghei transfectants  
After positive selection with the antimalarial drug pyrimethamine, parasites 
transfected with a non-linearised PTEX knockout construct, which serves as 
a positive control, were visible in blood smears between days 5 to 7 post 
infection. However, after four weeks of drug selection, parasites transfected 
 
with the HSP101 targeting construct could never be recovered and after two 
further unsuccessful transfection attempts, pursuits to generate a HSP101 
knockout in P. berghei were relinquished. P. berghei parasites transfected 
with PTEX150, PTEX88, EXP2, and TRX2 knockout constructs all grew 
under pyrimethamine drug selection, however, the growth rate of these 
parasites were slow and occurred over a three week timeframe post 
transfection. At a parasitemia of 2-7%, infected blood was collected by 
cardiac bleed and parasite genomic DNA was extracted for analysis by PCR 
and Southern blot to determine if integration of the PTEX knockout construct 
into the PTEX locus had occurred (Figure 4.2a).  Genotyping by diagnostic 
PCR for integration at the 5' and 3' ends revealed PTEX150, EXP2 and 
PTEX88 were refractory to gene deletion in three independent gene 
knockout attempts and parasites contained only episomal versions of the 
targeting construct (data not shown). These results were confirmed by 
Southern blot analysis of genomic DNA probed with either the 5' or 3' 
targeting regions (Figure 4.2b). Since the genes encoding HSP101, 
PTEX150, EXP2 and PTEX88 were all amenable to genetic targeting via 3' 
UTR replacement for the HA tagging strategy (Chapter 3, Figure 3.6), their 
refractoriness to gene deletion indicates that these four PTEX components 
are likely to be core translocon components whose expression is essential 
for parasite survival in the blood stages of malaria infection. Alternatively, 
these genes may provide a significant advantage in blood-stage growth, such 
that parasites containing a disruption in one of these PTEX genes became 
overgrown by wild type parasites possessing episomes.  
 
 
1.13.3 The P. berghei TRX2 gene can be genetically deleted  
Parasites transfected with the TRX2 knockout construct could be obtained 
on two separate occasions and were visible in Giemsa smears made at 
approximately 14 days post transfection. In contrast to the other four PTEX 
components, diagnostic PCRs on gDNA extracted from parasites transfected 
with the TRX2 knockout construct revealed correct integration had occurred 
on both occasions, with the presence of a 1.1kb (O9/O12) and 1.1kb 
(O10/O11) fragment indicative for 5' and 3' gene integration respectively 
(Figure 4.3).  As expected, no DNA fragment using these oligonucleotide 
combinations was observed in wild type genomic DNA as only one primer in 
each pair is located in the endogenous locus.  The resulting transgenic 
parasites were termed PbΔTRX2_1 and PbΔTRX2_2. To further confirm the 
integration of the TRX2 knockout plasmid, as well as if wild type parasites 
were still present, Southern blot analysis of PbΔTRX2_1 and PbΔTRX2_2 
genomic DNA digested with BglII and EcoRI was performed, using 
Digoxigenin labeled probes generated against the 5' and 3' TRX2 flanking 
regions by PCR using oligonucleotides O25/O26 and O27/O28, respectively.  
The absence of a 4.9 kb species confirmed the loss of the wild type gene 
whilst the appearance of either a 5.8 kb (5' targeting sequence as probe) or a 
1.4 kb species (3' targeting sequence as probe), respectively, corresponds to 
the expected gene knockout integration event (Figure 4.4a).  
 
1.13.4 Creation of clonal P. berghei TRX2 gene knock out parasites 
Prior to phenotypic analysis of the transgenic PbΔTRX2 lines, it was 
important to ensure that the transfectants were clonal and devoid of low 
 
numbers of contaminating wild type parasites that could not be detected by 
the diagnostic PCR or Southern analysis.  Accordingly, cloning of 
PbΔTRX2_1 and PbΔTRX2_2 was performed by intravenous injection of 
limiting dilutions of one to two parasites per each mouse. Of the six mice 
infected for each line, 83% and 50% of the mice became infected, 
respectively.  To confirm which mice contained either wild type or knockout 
parasites, Southern blot analysis was performed on the isolated gDNA using 
the 5' or 3' PbTRX2 targeting sequence as probes (Figure 4.4b). All resulting 
clones harboured the disrupted TRX2 locus, indicating the TRX2 knockout 
parasites were clonal. Clone 1 of PbΔTRX2_1 and clone 3 of PbΔTRX2_2 
were chosen for further analysis and will be referred to as PbΔTRX2_1.1 and 
PbΔTRX2_2.3 from here on. 
 
1.13.5 Attempts to complement the P. berghei TRX2 knockout 
parasites  
In order to validate that the loss of TRX2 protein was the cause of any 
phenotypic change that may be observed in the PbΔTRX2 knockout 
parasites in future experiments, an attempt to complement the TRX2 
knockout was undertaken.  For this, a gene replacement strategy was 
performed, whereby the TRX2 gene would be re-introduced into the 
endogenous TRX2 locus under the transcriptional control of its native 
promoter, and thus the genotype would be restored (Figure 4.5). To create 
the TRX2 knockout complement vector (PbΔTRX2c) a 3.0 kb fragment 
containing 1 kb of the P. berghei TRX2 5' UTR, the complete TRX2 CDS and 
its 3' UTR was obtained by PCR amplification of wild type P. berghei 
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genomic DNA using oligonucleotides O25/O28. The PCR product was 
digested with ApaI/EcoRI, followed by the 3' overhang removal to allow blunt 
cloning into the pL0006 plasmid.  Following ligation and transformation, 
positive clones were confirmed by diagnostic PCR and restriction enzyme 
digestion, after which two of the clones were sequenced to ensure the TRX2 
CDS contained no mutations. The pL0006 plasmid comprises the human 
dihydrofolate reductive-thymidine synthase (hDHFR-TS) selectable marker 
gene cassette that encodes resistance to WR99210, which is administered 
via sub-cutaneous injection for three consecutives days post infection at 0.12 
mg per injection.  After four separate transfection attempts of the 
PbΔTRX2_1.1 with the complement plasmid, no parasites were recovered, 
regardless of whether the construct had been linearised to drive 
recombination into the PbΔTRX2 locus or not.  
The lack of viable parasites in either the experimental (linearised plasmid) 
or control transfections (non-linearised plasmid), indicated that the PbΔTRX2 
parasites were not coping with either the pressure of the second transfection 
or drug selection. Since a TRX2 complement parasite line was unable to be 
generated, subsequent phenotyping experiments were performed on both 
independent PbΔTRX2 knockouts simultaneously. Having two independent 
parasite lines behaving similarly maintains confidence that observations 
made in subsequent assays can most likely be attributed to the loss of the 
TRX2 protein, rather than as a result of a transfection anomaly, acquired 
mutations or other phenomenon. 
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1.13.6 The loss of TRX2 affects P. berghei growth in vivo 
It was originally noted that when the PbΔTRX2 clonal lines were used to 
infect Balb/c mice for genotyping analysis, these parasites grew consistently 
slower than wild type parasites.  Thus, to determine the rate of the growth 
defect observed in the PbΔTRX2 transgenic parasite lines, comparative 
growth experiments using Balb/c mice were performed. Twelve 6-week old 
naïve mice per group were infected with 1×105 P. berghei ANKA wild type, 
PbΔTRX2_1.1 or PbΔTRX2_2.3 parasites via intraperitoneal injection. Over 
the course of the experiment, the percentage parasitemia was determined by 
counting a minimum of 1000 erythrocytes in Giemsa-stained thin blood 
smears made on a daily basis.  While parasites were visible by blood smears 
in all infected mice, already by day five the wild type cohort displayed a 
significant increase in parasitised erythrocytes (Figure 4.6). On the other 
hand, mice infected with either of the PbΔTRX2 clones displayed 
parasitemias around half that of wild type throughout the course of the 
infection.  However, despite their delayed growth in mice, the PbΔTRX2 
clones were ultimately able to generate high parasite loads.  Beyond day 9-
post infection, comparative analysis between groups could no longer be 
accurately performed as mice infected with wild type had to be humanely 
culled due to high parasite burdens. For instance, at day 11-post infection, 
the wild type parasitemia percentages averaged at 33.6%   4.3, with 
survival of the cohort only at 42%.  This was compared to 100% survival for 
both the PbTRX2 clones with parasitemia ranging between 21.3%  3.2 
and 24.2%2.4. Indeed, comparative infection experiments of the parasite 
lines in Balb/C mice confirmed that loss of TRX2 had a significant impact on 
growth.  
 

To further examine the PbΔTRX2 growth delay and pinpoint where the 
defect was likely occurring, synchronous in vivo infection assays were 
performed. For this, new invasion events were monitored over three cycles of 
infection; beyond this it is unreliable as the infection becomes naturally 
asynchronous. Accordingly, wild type and PbΔTRX2_1.1 infected blood 
containing mostly ring-stage parasites from Balb/c mice infected between 5-
10% parasitemia was cultured in complete RPMI media for 16 hrs. Cultures 
were then harvested and purified schizonts were mechanically ruptured to 
release merozoites.  The homogenous mix was then filtered twice through a 
0.22 µm syringe filter to purify the individual merozoites. Merozoite 
preparations, devoid of contaminating schizonts were added to freshly 
extracted naive mouse erythrocytes and invasion was allowed to proceed for 
30 min at 37 °C under vigorous shaking.  Equal numbers of erythrocytes 
infected with wild type or PbΔTRX2 parasite lines were then intravenously 
administered into individual Balb/c mice and blood smears were analysed 
every 2 - 4 hrs for the next three cell cycles. 
While newly invaded ring-stage parasites were observed 23 hrs after 
infection with wild type parasites, PbΔTRX2_1.1 took an extra 5 hrs to 
reinvade erythrocytes and to start the second blood cycle (Figure 4.7). A 
similar delay was observed during the second cycle, such that the 
PbΔTRX2_1.1 now lagged about 8 hrs behind the wild type parasites. 
Furthermore, despite similar numbers of wild type or PbΔTRX2 infected 
erythrocytes being administered to mice, the parasitemia of PbΔTRX2_1.1 
were less than half that of wild type parasites during the second cycle, 
indicating that either parasites were dying or being cleared by the immune 
system.  
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1.13.7 Assessment of PbΔTRX2 growth in vitro 
As trophozoite and schizont stages sequester in the host microvasculature 
in the in vivo experiments described above, analysis of these parasite stages 
is not possible. Therefore, to look at growth of all parasite stages, an in vitro 
invasion assay was repeated, but on this occasion, purified merozoites that 
had newly invaded erythrocytes were kept in culture in complete media, 
rather than injected into mice, until mature schizonts formed. At every two hrs 
following invasion (T=0), thin smears of the cultures were made.  The close 
sampling of the time points ensured the morphology of the developing 
parasites could be monitored and enabled examination of the stage of the 
cycle at which the loss of TRX2 has its greatest impact (Figure 4.8a). Within 
each time point, parasites were counted and scored according to their 
development and morphology as indicated in Figure 4.8b.   
A total of one hundred parasitised erythrocytes were counted, with results 
represented as the percentage of different stages in the population over time. 
The most obvious delays occurred at the beginning and end of the cell cycle 
(Figure 4.8c). At 4.5 hrs post invasion, only 2.9 % of wild type parasites 
remained at early ring-stage, whereas 75 % of PbΔTRX2_1 and 30 % of 
PbΔTRX2_2 were still at this stage. By 7.5 hrs post infection, the majority of 
wild type had progressed into early trophozoite stage (73 %), with no early 
rings remaining whereas 33 % and 13 % of PbΔTRX2_1 and PbΔTRX2_2, 
respectively, had still not moved beyond the early ring stage. Likewise, by 24 
hrs post infection, when 83 % of the wild type parasites had already entered 
the schizont stage (43 % early and 40 % late schizonts), only 15 % of 
PbΔTRX2_1.1 and 20% of PbΔTRX2_2.3 were at a similar stage of parasite 
development, with low numbers of late schizonts formed, if any. However, 
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
examination of the mature schizonts used to prepare the merozoites for the 
in vitro invasion assay did not reveal a difference in the number of 
merozoites per schizont between the wild type and PbΔTRX2_1.1 (Figure 
4.8d).
 
1.13.8 Loss of TRX2 leads to alterations in parasite virulence 
Since PTEX is implicated in the export of virulence proteins and PbΔTRX2 
clones are shown to consistently cause reduced infection rates, a correlation 
between disruption of PTEX and reduced parasite virulence was explored.   
To assess this, C57/Bl6 mice were used for infection experiments comparing 
wild type and PbΔTRX2 knockout lines, each infected with 1x106 parasites 
via intraperitoneal injection. C57/Bl6 mice were chosen because when 
infected with P. berghei ANKA they succumb to a severe lethal form of 
malaria, termed experimental cerebral malaria or ECM. In humans cerebral 
malaria is associated with a multitude of neurological symptoms and 
extensive underlying pathology. Typically, cerebral malaria symptoms 
observed in mice and scored in this study include starring of fur, ataxia, 
hunching and paralysis, with symptoms typically occurring between days 6-
10 post infection. Upon displaying the symptoms described, mice are 
humanely culled as the cerebral malaria onset is irreversible and death 
occurs within hours.  Mice that do not succumb to cerebral malaria by this 
time become affected by anemia due to high parasite loads.   
In this study, the C57/Bl6 mice infected with wild type parasites rapidly 
succumbed to cerebral malaria symptoms around 7 days post infection, 
whereas mice infected with the PbΔTRX2 clones showed a delay in 
 
developing ECM, if at all (Figure 4.9a). For example, by day 7 post infection, 
83% of mice from the wild type group had to be culled because of the ECM 
symptoms they displayed. In comparison, mice infected with either the 
PbΔTRX2_1.1 and PbΔTRX2_2.3 at day 14 had only a 33 % and 66 % death 
rate, respectively. It was at this point that the experiment was ceased, 
however, as it was difficult to establish whether the death of PbΔTRX2 
infected mice deaths was due to cerebral malaria or in fact anemia (Figure 
4.9b). A log-rank (Mantel-Cox) test was used to calculate statistical 
significance suggesting that comparisons between the both the wild type and 
PbΔTRX2_1.1 and wild type and PbΔTRX2_2.3 survival curves were 
significant (P<0.001).  
The parasitemia of the infected C57/Bl6 mice were also examined and the 
ΔPbTRX2 clones showed delays in parasitemia similar to what was observed 
in Balb/c mice (Figure 4.6 and 4.7). While wild type mice exhibited a mean 
parasitemia of 9.1% ± 0.9 on day 6-post infection (1 day prior to developing 
ECM), by day 9 post infection when all but one wild type mouse had been 
culled, mice infected with PbΔTRX2_1 exhibited a mean parasitemia of only 
5.0% ± 0.5 and mice that survived infection with PbΔTRX2_2 had a mean 
parasitemia of 5.6% ± 1.6 (Figure 4.9b). Moreover, even when the PbΔTRX2 
clones reached higher parasitemia, this did not influence their ability to cause 
ECM. Together the comparative infection experiments of the parasite lines in 
C57/Bl6 mice confirmed that the loss of TRX2 had a significant impact on 
parasite virulence. 
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1.14 Discussion 
Whilst the PTEX machinery is a promising anti-malaria drug target, it is 
important to validate which components of PTEX are essential for parasite 
virulence and survival as these would serve the best targets for future drug 
development. In order to achieve this, attempted gene knockouts of all five 
PTEX genes in P. berghei were undertaken via a homologous recombination 
strategy. This study revealed that P. berghei HSP101, EXP2, PTEX150 and 
PTEX88 could not be genetically disrupted after multiple attempts and thus 
they are likely to all be essential or are at least required to significantly 
enhance parasite growth and survival. In contrast, Matz et al (2013)199 were 
able to derive transgenic P. berghei lacking PTEX88 and although these 
parasites were viable, they exhibited significant growth defects. In their case, 
the PTEX88 knockout parasites harboured a fluorescence cassette, enabling 
them to be positively selected using flow cytometry, which was not the 
approach taken here.  
Based on the prediction that HSP101 provides the crucial energy source 
for protein unfolding prior to translocation through the putative pore-forming 
component, EXP2, it was not unexpected to find that HSP101 and EXP2 are 
essential Plasmodium proteins and indeed a recent study has shown that 
inducible knockdown of HSP101 in P. berghei is lethal to the parasite200. 
Likewise, PTEX150 has not been able to be genetically deleted in P. 
falciparum1 and inducible knockdown of PTEX150 in P. falciparum is lethal, 
thus the inability to knockout PTEX150 in P. berghei is consistent with these 
results. However, the lack of orthologues and distinctive protein domains for 
PTEX150 as well as for PTEX88 outside the Plasmodium genus precludes 
assignment of their function at this stage. Nonetheless, based on the make-
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up of other translocon systems in prokaryotes and eukaryotes, which usually 
comprise chaperones, receptors and structural components, in addition to 
the pore-forming component and the molecular motor189, we envisage that 
PTEX150 and PTEX88 most likely serve as structural components of PTEX 
or potentially act as a receptor for cargo to dock prior to translocation across 
the PVM. 
In contrast, the fifth PTEX component, TRX2, was able to be genetically 
disrupted with successful parasite recovery, and thus P. berghei TRX2 is a 
non-essential PTEX component. However, the marked reduction in growth 
and virulence phenotypes of parasites lacking TRX2 confirms this protein 
plays an important blood-stage role and suggests TRX2 plays a key 
regulatory role in PTEX function. Although the two PbΔTRX2 clones varied 
slightly in their potential to cause ECM as well as in their growth rates, it is 
important to note that both independent PbΔTRX2 clones consistently grew 
significantly slower and displayed altered virulence when compared with the 
wild type line on all occasions. The reasons for the difference between the 
lines is unclear but may be related to the number of times the clones had 
been passaged.  Additionally, PbΔTRX2 parasites displayed consistent 
growth delays in vivo, potentially as a result of infected erythrocytes being 
cleared more efficiently by the spleen, particularly if TRX2 contributes to the 
export of virulence proteins that are involved in sequestration.  Importantly, 
the reduced growth rates in vivo as measured from blood parasitemia, do not 
appear to be the result of fewer merozoites produced per schizont, indicating 
the TRX2 disruption does not affect the parasites ability to reach schizont 
stages, but rather, PbΔTRX2 parasites took longer to progress through the 
cell cycle (as indicated by both in vitro and in vivo experiments) and fewer 
 
PbΔTRX2 parasites also made it through each cycle in vivo. Whether this is 
a result of some parasites dying each cycle due to poorer nutrient uptake or 
increased clearance of infected RBC by the spleen for example awaits 
further investigation. Interestingly, the most obvious growth delays of the 
PbΔTRX2 parasites occurred during schizont and ring stages, which 
correlates with when TRX2 expression is initiated and when PTEX is 
predicted to be functional, respectively. Although repeated attempts to 
genetically complement PbΔTRX2 parasites by using a second selectable 
marker were unsuccessful (probably due to the initial poor health and growth 
of the PbΔTRX2 parasites), it should be noted that both independent 
PbΔTRX2 clones consistently demonstrated similar phenotypes in each 
assay.  
TRX2 is a small  13 kDa protein that belongs to the thioredoxin family of 
proteins that acts to reduce disulphide bonds in substrate proteins via a 
conserved CXXC active site182. Recombinant P. falciparum TRX2 has been 
shown to reduce insulin in vitro186, indicating that it has redox activity. 
Interestingly, both chloroplasts and mitochondria use redox signals to 
regulate protein translocation across their respective membranes201. For 
example, in chloroplasts, redox signals modulate the formation and reduction 
of inter- and intra-molecular disulphide bonds of translocon components at 
the outer membrane to regulate protein import. Additionally, the redox state 
of the stroma is sensed by the translocon at the inner chloroplast membrane 
and when there is a high demand for redox-related proteins, the efficiency of 
translocation of this subset of proteins is adjusted accordingly201,202. As EXP2 
and PTEX88 contain numerous conserved cysteine residues (Figure 3.1), 
 
PTEX could also be regulated in a redox fashion to adjust protein export into 
the host cell cytosol, with TRX2, the most obvious candidate to perform this 
function. Since some of the exported proteins are predicted to be involved in 
nutrient uptake, this could account for the PbΔTRX2 clones exhibiting 
reduced growth rates. Alternatively, TRX2 may control the formation of 
disulphide bonds in a particular subset of exported cargo and thus regulate 
the ability of these proteins to be exported. Although exported cargo 
containing disulphide bonds in P. berghei have not been characterised, in P. 
falciparum, such cargo could include PfEMP1 and STEVORS, which play a 
role in parasite virulence. Future studies will require identification of the TRX2 
substrate proteins to elucidate which of these alternate functions TRX2 may 
have in the PTEX complex or whether TRX2 performs another function 
altogether.  
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Figure 4.1:  Construction of pB3-PTEX knockout constructs.  
Schematic of the original pB3 plasmid for constructing the knockout 
plasmids. The plasmid contains a Toxoplasma gondii DHFR selectable 
marker cassette (TgSM) and an ampicillin selectable marker (AMP). 
The 5' and 3' untranslated regions (UTRs) specific to each of the five 
PTEX genes were PCR amplified and cloned into the appropriate 
restriction enzyme sites. The final targeting construct was linearised at 
KpnI, XbaI and PvuI restriction enzyme sites prior to transfection.    
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Figure 4.2:  HSP101, PTEX150, EXP2 and PTEX88 are not 
amenable to gene deletion.  
a) Schematic of the P. berghei targeting constructs designed to 
integrate into the respective endogenous PTEX locus by double 
crossover recombination.  The predicted structure of the endogenous 
locus before and after integration is shown. TgSM indicates 
Toxoplasma gondii DHFR selectable marker cassette; b) Southern blot 
analysis of genomic DNA extracted from P. berghei wild type (WT) and 
parasites surviving pyrimethamine selection. Digestion with BglII or 
BglII/EcoRI and hybridized with either probes made from the 5' or 3' 
targeting sequence reveal that the endogenous gene (E) remained 
intact and bands indicative of an integration event (In) were not 
observed. Molecular weights are indicated. 
 

$% $%)'
#%)'
	"$%"%)(%$'(&)(
	#%)'(&!$( &(!%$
	
Tg SM
Tg SM

"
"



"
 
 
	 
	 
 6

	

6

	
	
6

	

6

	
	
*	 
	*



++

++
+ 
+

"


 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Genetic disruption of TRX2 P. berghei. 
a) Schematic of the P. berghei endogenous locus, the final P. berghei 
TRX2 knockout targeting construct and the P. berghei TRX2 locus after 
integration. Black arrows indicate oligonucleotides used for diagnostic 
PCRs. Restriction enzyme sites BglII(B) and EcoRI (E) and expected 
Southern DNA fragment sizes are indicated. b) Diagnostic PCR for 5' & 
3' integration of genomic DNA extracted from pyrimethamine resistant 
parasites.  
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Figure 4.4: Confirmation of the P. berghei TRX2 gene knockout  
a) Southern blot analysis of genomic DNA extracted from P. berghei 
wild type (WT) and TRX2 knockout transfectants (PbΔTRX2_1 and 
PbΔTRX2_2) digested with BglII and EcoRI and hybridised with either 
the 5' (left panel) or 3' (right panel) targeting sequence as a probe. 
Molecular weights are indicated, with (E) indicating endogenous and 
(IN) indicating integration locus. b) Southern blot analysis of P. berghei 
wild type (WT) or PbΔTRX2 positive clones digested with EcoRI/BglII 
and probed with either the 5' (Ieft panel) or 3' (right panel) targeting 
sequence as a probe. 
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Figure 4.5: Construction of a P. berghei TRX2 complement 
plasmid. 
Schematic of the P. berghei endogenous locus, the final P. berghei 
TRX2 knock-in targeting construct (PbΔTRX2KOc) and the expected P. 
berghei TRX2 locus after integration.  
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Figure 4.6: Loss of TRX2 in P. berghei leads to reduced parasite 
loads in vivo. 
Comparative growth analysis of P. berghei wild type and both PbΔTRX2 
clones in infected Balb/C mice (n=12). The cross indicates number of 
deaths. Error bars represent SEM and statistical significance was 
calculated using a two-tailed t-test. *P<0.05, **P<0.01.   
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Figure 4.7: Loss of TRX2 in P. berghei results in a longer 
parasite cycle in vivo. 
In vivo growth analysis of PbΔTRX2 parasite line in which invasion had 
been synchronized in vitro prior to intravenous inoculation in mice. The 
solid red and blue dashed arrows indicate the time points at which new 
invasion events of wild type (WT) and PbΔTRX2_1, respectively, could 
be detected.  
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Figure 4.8: Loss of TRX2 leads to altered growth phenotypes in 
vitro.  
a) Giemsa-stained blood smears taken throughout the asexual blood 
cycle. In vitro growth analysis over 24 hrs of P. berghei parasite lines 
following synchronous invasion in vitro. The first invasion events were 
observed at 0.5 hrs post invasion (p.i.). b) Representative morphology 
of parasites that were used for scoring the stage of growth. c) 
Representative panel of either wild type or PbΔTRX2_1 infected 
erythrocytes seen in Giemsa smears from invasion to schizont 
development in vitro. The stages are expressed as a ratio observed in 
100 infected erythrocytes counted. d) Column graph depicting the 
number of merozoites formed per mature schizont (n = 50). 
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Figure 4.9: Loss of TRX2 in P. berghei leads to altered virulence 
and growth phenotypes in C57/Bl6 mice.  
a) Growth curves and b) survival curves (n = 14) of P. berghei ANKA, 
PbTRX2_1.1 and PbΔTRX2_2.3 (n = 12) in C57/Bl6 mice. Data were 
pooled from two separate experiments. Error bars represent SEM. A 
two-tailed t-test was used to calculate statistical significance between 
wild type and PbΔTRX2 clones. ***P<0.001. 
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Chapter 5 
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Functional evidence that PTEX is involved 
in parasite protein export 
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1.15 Introduction 
Chapters three and four of this thesis have demonstrated that the five-
membered PTEX complex is present at the PVM in P. berghei and confirmed 
its importance to parasite survival and/or growth and virulence through 
attempts to delete the respective PTEX genes. Yet despite the strong 
circumstantial evidence that PTEX is the protein export machinery, direct 
proof for a functional role of PTEX in parasite protein export is absent.   
This Chapter aims to characterise PTEX function and its relationship with 
protein export. It will closely investigate the difference in the protein export 
levels between wild type parasites and a transgenic parasite line that has a 
disruption in the accessory PTEX component, TRX2.   
To achieve these aims, the development and optimisation of methods for 
assessing parasite protein export in P. berghei is required, as only a limited 
number of antibodies are available to exported proteins in this species.  
These assays are necessary to directly quantitate individual exported 
proteins as well as protein export at a more global level. 
 
1.16 Results 
 
1.16.1 The deletion of P. berghei TRX2 deletion does not affect the 
export of the endogenous PEXEL proteins PBANKA_122900 
& PBANKA_114540  
To determine whether disruption of TRX2 affects parasite protein export, 
specific antibodies against known endogenous exported proteins, 
 

PbANKA_114540 and PbANKA_122900 were used against wild type and 
PbΔTRX2 parasites in immunofluorescence analysis. Both of these proteins 
contain the PEXEL motif (RxLxE/Q/D) and localise to punctate structures in 
the erythrocyte cytosol95 (Figure 5.1a). Following incubation of wild type 
parasites fixed with 4 %PFA/0.01 % glutaraldehyde in rabbit sera containing 
antibodies to either PbANKA_114540 or PbANKA_122900, and subsequent 
labeling with anti-rabbit Alexa Fluor 488 antibodies, punctate labeling was 
observed within the infected erythrocyte cytosol (Figure 5.1b). A similar 
labeling pattern was observed when PbΔTRX2 parasites were analysed by 
IFA, although there was a slight fluorescence reduction in the host cell 
cytosol of PbΔTRX2 infected erythrocytes (Figure 5.1b).  However, 
quantitation of the cell fluorescence levels in both the erythrocyte and 
parasite cytosol by calculating the corrected total cell fluorescence (CTCF) 
using ImageJ revealed that there was no significant difference in the amount 
of labeling with anti-PbANKA_122900 (Figure 5.1c) or anti-PbANKA_114540 
(Figure 5.1d) between wild type and PbΔTRX2 infected cells. Moreover, 
there was no accumulation of either protein at the PV or PVM, indicating 
these two proteins could be successfully exported beyond the confines of the 
PVM and into the cytosol of erythrocytes infected with PbΔTRX2.   
 
1.16.2 P. berghei TRX2 knockout parasite lines expressing an 
episomally-expressed exported reporter protein  
To develop alternative ways of assessing protein export in the PbΔTRX2 
parasite line, a reporter construct was generated and introduced into wild 
type and PbΔTRX2 parasites. The reporter construct encodes an exported 
 
chimeric GFP. This reporter construct comprises the N-terminal coding 
sequence of KAHRP containing its signal sequence plus PEXEL motif 
(RxLxQ) fused in frame to GFP, with expression driven under the P. berghei 
EF1α promoter and the transcriptional terminator derived from the P. berghei 
Calmodulin gene. This reporter has been previously shown to be exported in 
PbANKA wild type parasites95. The construct also contains the human DHFR 
cassette to enable selection of parasites transfected with this construct using 
the drug WR9910. This reporter construct is termed p35.EF1α.K+GFP.CAM. 
After transfection of PbANKA wild type and PbΔTRX2 with 
p35.EF1.α.K+GFP.CAM and drug selection on day 1 and 3 post infection, 
after drug treatment, wild type parasites containing the GFP expression 
construct were already visible in peripheral blood smears at day 8 post 
infection. However, PbΔTRX2 parasites were not visible until day 16, by 
which time the transfected wild type lines had already been culled as the 
mice exhibited high parasitemias.  
So that the transgenic parasite lines could be imaged for GFP export at 
the same time to ensure consistency between the analysis, wild type and 
PbΔTRX2 WR9910-resistant parasites containing the episome after the 
secondary transfection were instead infected from liquid nitrogen stocks into 
naïve Balb/C mice. At six days post infection, inspection of fluorescence in 
wild type parasites showed they expressed and exported GFP into the 
erythrocyte cytosol (data not shown). In contrast, the levels of GFP 
expression in the cytosol of PbΔTRX2 infected erythrocyte was clearly 
reduced, although it was also noted that GFP expression could not be 
detected in the parasite cytosol either (data not shown).  This lack of 
fluorescence indicated that GFP might be poorly expressed by the PbΔTRX2 
 
parasites rather than the parasite having a reduced capacity to export 
proteins. This observation could be attributed to the PbΔTRX2 parasites 
growing slowly and fluorescence measured after drug administration when 
parasitemias are low, and thus the nearly undetectable fluorescence in 
PbΔTRX2 was most likely due to the episome being lost through parasite 
replication.  Due to the limitations of this reporter assay, further approaches 
were sought to determine if there were changes in export capacity between 
wild type and PbΔTRX2 parasites.  
 
1.16.3 Generation of a P. berghei TRX2 knockout parasite line 
containing an integrated exported GFP reporter gene. 
After multiple attempts to transfect the PbΔTRX2 parasite line with an 
episomal exported GFP reporter failed, an attempt was made to regenerate 
the PbTRX2 knockout parasites again, however, this time integrating an 
exported GFP reporter construct simultaneously. This would eliminate the 
need for a second transfection and secondary drug selection.  
To generate the TRX2 knockout/exported GFP reporter construct, pFRT-
2A-mCherry/KAHRPL-GFP (derived from p3'regFRT203)  was modified to 
include regions of homology specific to the P. berghei TRX2 gene sequence 
(Figure 5.2a). The wild type exported GFP-expressing construct contained 
the PbTRX2 5' UTR region, which was amplified from P. berghei using 
oligonucleotides O31/O32 and incorporated into the vector at SacII and ApaI 
sites. This construct already contained the GFP coding sequence in frame 
with the N-terminal sequence of KAHRP, including its signal sequence and 
PEXEL motif under the regulatory control of the P. berghei HSP70 promoter.  
 
Downstream of GFP, the P. berghei TRX2 3' UTR, which had been amplified 
by PCR with oligonucleotides O66/O67, was cloned into the MluI and SacII 
restriction enzyme sites (Figure 5.2a). The construct was linearised with 
SacII such that the TRX2 5' and 3' UTRs would facilitate double homologous 
integration into the PbTRX2 locus when transfected into PbANKA wild type 
parasites, leading to disruption of TRX2 locus and insertion of the GFP 
reporter. In addition, a second construct was created in which the entire 
PbTRX2 CDS under its endogenous 5' UTR promoter was PCR amplified, 
using oligonucleotides O31/O39 and cloned into the SacII and NotI site of 
p006/FRT (Figure 5.2b).  Downstream of this, the P. berghei 
thrombospondin-related anonymous protein (TRAP) (PBANKA_134980) 3' 
UTR was inserted. Integration of this construct into the P. berghei TRX2 
endogenous locus would result in the replacement of TRX2 with a fully 
functional TRX2 gene and integration of the exported GFP reporter, to serve 
as a positive control for imaging analysis.  
PbANKA wild type parasites transfected with either reporter construct 
could be recovered after pyrimethamine selection. Parasites containing the 
TRX2 replacement/reporter construct were visible in peripheral blood smears 
at day six post infection, while the parasites harbouring the TRX2 
knockout/reporter construct were visible at day 10. These parasite lines are 
subsequently referred to as WT+GFP and PbΔTRX2+GFP, respectively. 
Diagnostic PCRs on gDNA extracted from WT+GFP and PbΔTRX2+GFP 
using oligonucleotide O9/O43 and O42/O10, revealed integration had 
occurred in both lines, with the presence of a 3.4 kb or 1.5 kb and 1.6 kb 
species indicative for 5' and 3' gene integration respectively (data not 
shown).  As expected, no DNA fragment was amplified in the wild type 
 
fractions with these oligonucleotide pairs, however, primers specific for wild 
type gDNA (O39/O10) amplified the expected 1.16 kb fragment in the wild 
type control (data not shown). 
Southern blot analysis of WT+GFP and PbΔTRX2+GFP genomic DNA 
digested with EcoRI/BglII or NdeI/BglII was performed, where Digoxigenin 
labeled probes were generated against the 5' TRX2 flanking regions using 
oligonucleotides O5/O6. In the EcoRI/BglII digestion, the absence of a 4.8 kb 
species representing the wild type locus and appearance of either a 5.8 kb 
for WT+GFP or a 3.9 kb for PbΔTRX2+GFP species was observed. In the 
NdeI/BglII digestion, the absence of a 5.3 kb species representing wild type 
and appearance of either a 7.2 kb for WT+GFP or a 3.9 kb for 
PbΔTRX2+GFP species was observed (Figure 5.2c). These bands 
correspond to the expected sizes for gene replacement or gene knockout 
event, respectively. 
 
1.16.4 Live-cell fluorescent imaging of wild type or TRX2 knockout 
parasites expressing an exported GFP reporter  
As PbΔTRX2+GFP parasites still exhibited a growth delay compared to 
WT+GFP, a synchronous time course assay was performed with WT+GFP 
and PbΔTRX2+GFP to analyse GFP expression. For this, two naïve mice 
were infected with liquid nitrogen stocks of WT+GFP and PbΔTRX2+GFP 
and administered pyrimethamine drug treatment for five days. Both mice 
were then cardiac bled and infected blood was cultured until parasites 
reached schizont stage.  To ensure synchronicity, purified schizonts were 
mechanically ruptured to release merozoites by gently passing the 
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homogenous cells through a 0.22 µm filter twice. Merozoites were then 
allowed to invade naïve mouse erythrocytes by vigorous shaking at 37 °C. 
Cells were washed in media, and centrifuged gently to pellet the erythrocytes 
and to remove un-invaded merozoites.  Invasion of naïve red cells was 
efficient for both wild type and knockout parasites, with counts of invasion 
events revealing that the rate of invasion was comparable between the two 
lines (data not shown).  
Infected erythrocytes were then put back into in vitro culture at 37 °C and 
sampling and live cell imaging was performed every 6 hrs (Figure 5.3). At the 
first time point of 8 hrs post invasion, wild type parasites were exporting GFP 
into the host cell and by 11 hrs, when parasites were at trophozoite stage, 
intense GFP fluorescence was observed in the erythrocyte cytosol. Contrary 
to this observation, PbΔTRX2 parasites appeared to have limited GFP export 
in the first 8 hr time point, with the majority of GFP still present at the parasite 
vacuole. However, upon further parasite development, knockout parasites 
appeared to export the GFP in a similar fashion as wild type parasites, such 
that by 16 hrs post invasion, when parasites were at mid to late trophozoites, 
GFP was exported beyond the PVM and into the host red cell cytosol.  
Together this suggested that in the initial stages of infection, PbΔTRX2+GFP 
parasites showed slower protein export, but by the time the parasites made it 
to trophozoite stage, they could export GFP just as efficiently as wild type 
parasites. 
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1.16.5 Generation of parasites harboring an exported Nanoluc 
reporter construct 
Unlike with GFP, the detection of the protein Nanoluc is exquisitely 
sensitive, thereby permitting very low levels of Nanoluc protein to be 
measured. This opened up the possibility to transiently transfect wild type 
and PbΔTRX2 parasites with an exported Nanoluc reporter, which would 
enable protein export to be compared between the two lines within 1-2 
cycles. Two versions of the Nanoluc constructs were designed; 
pEF1α.PfKAHRP+.NL.CAM, which is expected to be exported due to the 
presence of the KAHRP signal sequence and PEXEL motif (Figure 5.4a), 
and  pEF1α.NL.CAM, where Nanoluc is retained within the parasite (Figure 
5.4b). In both constructs, Nanoluc expression is driven under the PbEF1α 
promoter and the 3' UTR is that from the P. berghei Calmodulin gene.  
Nanoluc was PCR amplified from pNL1.1[Nluc] (Promega) using 
oligonucleotide O40/O41. The 534 base pair Nanoluc amplicon product was 
cloned into the existing p35.EF1.α.K+GFP.CAM95 in vector pl0035204 plasmid 
at the AvrII and XhoI restriction enzyme sites replacing the GFP.  
To test if the PbΔTRX2 parasite line was defective in exporting Nanoluc 
protein, both wild type and PbΔTRX2 parasites were cultured and grown for 
transfection procedure as previously described194. Each parasite line was 
split before transfection, so that half the prepared parasites were transfected 
with either circular pEF1α.K+.NL.CAM or pEF1α.NL.CAM. Consequently, 
four new parasite lines were generated; wild type with exported Nanoluc 
(WT+NL), wild type with non-exported Nanoluc (WT-NL), PbΔTRX2 with 
exported Nanoluc (PbΔTRX2+NL) and PbΔTRX2 with non-exported Nanoluc 
(PbΔTRX2-NL).  
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As a positive control, wild type parasites were also stably transfected with 
the Nanoluc constructs and treated with pyrimethamine rather than 
WR99210 post-transfection. This line was used for differential lyses 
optimization (described below) to test the fluorescence intensity of the 
Nanoluc protein. Wild type parasites containing either episome 
(PbWT±NL_PYR) grew normally compared to wild type parasites without an 
introduced construct.  From preliminary analysis, high levels of Nanoluc 
activity in excess of 1x106 RLU was measured in 2 μl of blood infected with 
wild type parasites that were stably expressing either the exported or non-
exported Nanoluc.  
To maintain the plasmids within the parasite after transfection, WR9910 
was administered by sub-cutaneous injection at days 1 and 3 post 
transfection. Whilst this approach was taken with the episomal GFP 
construct, as previously described, the parasitemia levels do not need to be 
high to detect Nanoluc. Even though the PbΔTRX2±NL parasite lines grew 
slower than the PbWT±NL parasites, it did not affect the measurement of 
Nanoluc protein, as results were expressed as a ratio between the 
PbΔTRX2+NL and the PbΔTRX2-NL control. At days 2-4 post-transfection, 
parasites were harvested from mice by tail bleeds (5 μl), allowing multiple 
sampling at different time points.   
To differentiate between Nanoluc in the parasitophorous vacuole or host 
cell fraction, also referred to as non-exported or exported Nanoluc, 
respectively, a pore-forming toxin, equinatoxin (EQII) was used to 
compromise the red cell membrane without destroying the parasite 
membranes. This process releases the soluble host cell cytosolic fraction of 
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exported Nanoluc without impacting the parasite vacuolar membrane, 
thereby maintaining non-exported Nanoluc within the parasitophorous 
vacuole.  To release the Nanoluc within the parasite, the pellet fraction was 
washed and then completely lysed by hypotonic lysis. Equal amounts from 
each fraction and from each parasite line were taken and combined with 
NanoGloR for quantification of illumination.   
Tail blood from both WT+NL and PbΔTRX2+NL at comparable 
parasitemias of 0.5-1 % were sampled when parasite development was 
between mid-rings to late trophozoite stages, followed by measurement of 
Nanoluc activity using a luminometer (Bertholdt). To calculate the export 
percentages, the relative light units (RLU) determined from the host cell 
fraction was divided by the total RLU obtained from the parasite cytosol 
fraction. Data from three separate experiments, where asynchronous 
parasites were sampled, was collated and is shown in Figure 5.4c, whereby 
the wild type and PbΔTRX2 export percentages show that no significant 
difference (p=0.0897) was observed between the two parasite lines.  
 
1.16.6 Measurement of global protein export in P. berghei using 
semi-immune sera  
So far, the assays described above measure the export of single parasite 
proteins or reporter genes. As PbΔTRX2 parasites are viable, it is likely the 
parasites are still able to export proteins, therefore the ability to distinguish 
export at the individual protein levels may be difficult. However, the 
cumulative export response may be expected to be much greater and thus to 
assess this, a global protein export assay was undertaken. This involved 
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quantifying proteins exported to the infected erythrocyte surface using semi-
immune sera made specifically against P. berghei infected erythrocytes, in 
which antibodies are made to parasite derived antigens presented on the 
erythrocyte surface.  
To test the reactivity of the newly generated semi-immune sera, PFA fixed 
wild type and PbΔTRX2 infected erythrocytes were assessed for labeling 
with either non-immune (negative control) or semi-immune sera (Figure 
5.5a). Wild type infected red cells do not exhibit surface staining when 
exposed to sera from naïve mice that have never been exposed to a malaria 
infection. However, when the same wild type infected sample was exposed 
to semi-immune sera (Figure 5.5b), intense labeling was present at the 
erythrocyte cell periphery, indicative of recognition of parasite surface 
antigens. Whilst the PbΔTRX2 infected erythrocytes still reacted to the semi-
immune sera, the level of labeling observed was greatly reduced (Figure 
5.5c).   
 To quantify the level and differences of surface labeling of 
erythrocytes infected with wild type versus PbΔTRX2 using semi-immune 
sera, flow cytometry was used. For FACS analysis, wild type and PbΔTRX2 
infected erythrocytes at similar parasitemias ranging from 2-4% were 
obtained from the tail vein of infected Balb/c mice. Samples were collected 
from asynchronous infections, when parasites were between mid-rings to 
mid-trophozoite stage. Triplicate blood samples were incubated with either P. 
berghei semi-immune or non-immune sera diluted 1:20 in blocking solution 
(1% casein/RPMI). After three washes with block solution, cells were 
incubated for one hr with goat anti-mouse IgG AlexaFluor 647 diluted in block 
solution. Samples were then washed a further three times followed with a 
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brief incubation in Sybr safe nucleotide stain. Cell preparations were 
analysed with a FACS Canto II (BD Biosciences). Quantitative FACS 
analysis of erythrocytes harvested from asynchronously infected mice show 
that the two independent clonal populations of PbΔTRX2 knockout parasites 
exhibit significantly reduced levels of surface labeling with P. berghei semi-
immune sera compared with wild type parasites.  Over six assays, (with each 
parasite line prepared in triplicate), wild type export was normalised to a 
hundred percent export ability, and export in knockout parasites was 
expressed relative to this. PbΔTRX2_1 and PbΔTRX2_2 displayed a 
reduction in export ability of about 50% and 25% respectively (Figure 5.6).  
Whilst a comparable parasitemia between the different sample sets were 
used for the above analysis, there was the potential for bias given that the 
PbΔTRX2 grows slower and thus less mature stages that potentially have 
exported less were examined in the PbΔTRX2 lines. Therefore to ensure that 
FACS analysis was performed on the most comparable parasite stages, a 
synchronous time-course assay was performed. For this, synchronous 
mouse infections were initiated by injecting a high number of filter-purified 
merozoites into the tail vein of mice. At the second infection cycle, the 
parasitemia across the two infections were about 1-2% for wild type and 
PbΔTRX2 and still synchronous. Blood samples for FACS analysis were 
taken from the same infection cycle, but repeated at six-hr intervals between 
the wild type and PbΔTRX2_1, so that export of wild type and the slower 
growing PbΔTRX2 could be analysed at similar stages of growth.  
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To monitor the parasite growth and development between the lines, 
Giemsa smears were taken at the time FACS analysis was performed 
(Figure 5.7a). This revealed that at the same time point, the development of 
PbΔTRX2 was less advanced than the wild type and more comparable to the 
wild type time point taken 6 hrs earlier. Therefore the level of export 
observed at 15 hrs post infection for the PbΔTRX2 was compared to that of 
wild type measured at 8 hrs post infection. Even when this was taken into 
consideration, the surface labeling of the PbΔTRX2 parasites was 
significantly reduced when compared to wild type parasites in independent 
experiments by about 50% (n=6) (Figure 5.7b).  
 
1.16.7 Structural and morphological changes to P. berghei infected 
erythrocytes 
Host cell remodeling by P. falciparum also involves structural and 
morphological changes to the erythrocyte, such as the appearance of knobs 
on the surface of P. falciparum infected red cells. Considering that a P. 
falciparum orthologue of KAHRP is not expressed in P. berghei, it is not 
known whether P. berghei infected erythrocytes show obvious morphological 
changes to the erythrocyte by scanning electron microscopy. However since 
P. berghei infected cells can evade the immune system by sequestering, it is 
possible that changes to the P. berghei infected erythrocyte surface do occur 
and hence altering PTEX function may lead to loss of this phenotype, which 
could be explored by comparing wild type and PbΔTRX2 strains.    
The difficulty with assessing modifications to an infected erythrocyte is the 
need to ensure only infected cells are isolated and imaged. Hence, for this 
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analysis the infected erythrocyte population needed to be enriched to yield 
>90% purity.  To achieved this, infected erythrocytes were cultured in vitro 
until the majority were mid to late trophozoite. Erythrocytes harboring 
trophozoite stage parasites were specifically isolated using a MACS 
magnetic column, while uninfected erythrocytes and ring stage parasites 
were eluted. As can be seen in Figure 5.8a, uninfected erythrocytes appear 
smooth when imaged by SEM. However, when wild type infected cells were 
compared to uninfected erythrocytes there were morphological differences. 
Generally, infected red cells were rigid, lumpy and contained surface 
protrusions. Whilst observations here showed fewer protrusions than has 
been previously observed in P. falciparum, the surface of PbANKA infected 
erythrocytes were clearly different to that of uninfected cells. Thus, this 
method was then used to look at the overall effect of deletion of TRX2 on the 
morphology of erythrocytes. The PbΔTRX2 parasitised cells appeared to be 
most comparable to uninfected red cells, with a reduced degree of surface 
protrusions and cell rigidity when compared to wild type.  However, on 
occasion, PbΔTRX2 parasitised cells did appear to contain randomised 
protrusions. This effect could be attributed to the reduction of overall protein 
export or even a subset of specific proteins responsible for this protrusion 
effect that are not being exported in the PbΔTRX2 parasite line. One hundred 
random erythrocytes from each parasite line were quantitated for their 
surface protrusion, resulting in wild type infected cells containing 
approximately 85% more protrusions than observed on PbΔTRX2 infected 
cells, which when analysed by unpaired t-test was significant 
(P<0.0001)(Figure 5.8b).  
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1.17 Discussion 
The third aim of this research project involved addressing the functional 
contribution of PTEX to protein export. Whilst P. berghei provides many 
benefits in studying the malaria pathogen in vivo, phenotypic analysis of a P. 
berghei PTEX knockout is difficult without a large bank of antibody reagents, 
including to exported proteins. Attempts to phenotypically compare wild type 
and PbΔTRX2 parasites were problematic since assays to measure changes 
in protein export in P. berghei were not developed and thus novel reagents 
and methodologies first had to be established.  
Unfortunately, the ability to examine the export phenotypes of the 
PbΔTRX2 clones by transfection of chimeric exported (versus non-exported) 
GFP reporter constructs were unsuccessful as the PbΔTRX2 parasites, 
which grow slower than the wild type, struggled to survive and maintain 
episomes. To circumvent this, the TRX2 knockout was re-derived such that a 
GFP reporter cassette was integrated into its genome. Whilst expression of 
exported GFP was apparent in both the wild type and PbΔTRX2 parasites, a 
delay in GFP expression and export into the host erythrocyte was observed 
in the parasite line lacking TRX2. The delay in GFP expression relayed to 
about 4-6 hours, which was in keeping with the growth delay of the PbΔTRX2 
parasites described in Chapter 4.  Thus, whether the reduced GFP 
expression in the PbΔTRX2 parasites is the result of the parasites growing 
more slowly and having less time to export proteins or whether the slower 
growth stems from a reduction in protein export is difficult to discern. 
Ultimately, by trophozoite stages, the PbΔTRX2 parasites were able to export 
similar levels of GFP as wild type parasites. Interestingly, no GFP 
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accumulation was observed within the PV, which would be expected if there 
were a block in the export process. 
Only recently have P. berghei PEXEL-containing proteins been 
identified109,147 and demonstrated to be exported by IFA or by live cell 
imaging.  In this study two antibodies that recognize the endogenous 
exported proteins, PbANKA_114540 and PbANKA_122900, which both 
harbour PEXEL motifs, were used to study protein export (C. K. Moreira, B. 
Naissant, A. Coppi, L. Bennet, E. Aime, B. Franke-Fayard, C. J. Janse, I. 
Coppens, P. Sinnis and T. J. Templeton, personal communication). While 
both anti-PbANKA_114540 and anti-PbANKA_122900 recognised parasite 
exported proteins in the host erythrocyte, there did not appear to be any 
significant affect on export of these proteins in PbΔTRX2 infected cells.  
All together, observations made with the endogenous antibodies and both 
GFP and Nanoluc reporter constructs indicated that there was no overall 
significant change in the export of the individual proteins. However, since the 
PbΔTRX2 parasites are viable, it is not surprising that parasites would still be 
able to export proteins but export efficiency could be affected. However, even 
a slight decrease in export potential or delay in export may be difficult to 
identify at the individual protein level. Compounding this is that as the role of 
TRX2 in the complex is still unknown and thus it is highly possible that only a 
particular subset of protein cargo would be affected by a TRX2 deletion or 
that TRX2 only plays a more significant role under particular environmental 
conditions that parasite is faced with (for example, febrile episodes when the 
parasite undergoes heat shock). Thus, without reagents to a wide variety of 
different exported proteins, these experiments became rather limited. 
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With this in mind, further investigation into export deficiency in the 
PbΔTRX2 parasite line led to the development of semi-immune sera as this 
would provide a means to measure the global set of exported parasite 
proteins exposed on the erythrocyte surface. Overall results using the semi-
immune sera by IFA and FACS analysis clearly demonstrated that there was 
a reduction in global protein export in the PbΔTRX2 parasites.  To further 
corroborate that the changes observed were due to export deficiency rather 
than a slower growing PbΔTRX2, the synchronous time course assay was 
developed whereby export levels were analysed when parasites were at 
comparable stages, ensuring no bias was given to PbΔTRX2 parasites that 
were not at their maximum export potential.  Even when taking the growth 
delay into account, the PbΔTRX2 parasites displayed a reduced export 
phenotype of about 50% when compared to wild type parasites. These 
findings are in keeping with the suspected role of TRX2 as an accessory 
PTEX member.  Since parasites lacking TRX2 are still viable, they have the 
potential to export proteins, but whether they are capable of exporting all 
cargo albeit at reduced levels or whether only a particular non-essential 
subset of proteins is blocked from being exported awaits further investigation.  
Along with establishing the loss of parasite protein export in a line with a 
defect in PTEX, determining whether this affect in protein export results in 
morphological changes to the infected erythrocyte was explored. Whilst 
normal erythrocyte morphology is affected in P. falciparum infections, no 
such changes have been described for P. berghei. Much of this is due to the 
dogma that KAHRP is responsible for the erythrocyte protrusions, and 
without KAHRP present in the P. berghei genome, no other known proteins 
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have been considered to alter the morphology of P. berghei-infected cells. 
Whilst the specific cause and mechanisms are unknown in P. berghei, 
infected erythrocytes have been shown to sequester147. With this in mind, it is 
not unreasonable that P. berghei also expresses cytoadhesive ligands on the 
erythrocyte surface that enables the parasite to sequester and that this also 
alters the morphology of the infected erythrocyte. Interestingly, preliminary 
scanning electron microscopy showed that P. berghei wild type infected cells, 
exhibited surface protrusions and a deformed morphology whereas the 
PbΔTRX2 infected erythrocytes were morphologically more similar to 
uninfected cells.    
Taken together, this work demonstrates that blocking optimal PTEX 
function through the genetic deletion of TRX2 leads to a reduction in global 
parasite protein export and if this includes a reduction in the expression of 
cytoadhesive ligands on the infected erythrocyte surface, this may also 
explain why fewer C57/Bl6 mice infected with PbΔTRX2 succumbed to 
cerebral malaria than mice infected with wild type P. berghei.  It may also 
explain the reduced growth rates in vivo as the parasites may have been 
more rapidly cleared from the circulation. It would therefore be interesting to 
look at the spleens of infected mice and sections of tissue harvested from 
organs such as the brain, lung and adipose tissue, to investigate the capacity 
of the PbΔTRX2 parasites to sequester in vivo.  
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Figure 5.1:  P. berghei TRX2 deletion does not affect the ability to 
export two identified endogenously expressed exported PEXEL 
proteins.  
a) Schematic representation of the localisation of PBANKA_122900 & 
PBANKA_114540 in a P. berghei-infected erythrocyte. b) Representative IFA 
of intraerythrocytic parasites, showing no obvious blockage of export of 
PEXEL proteins PBANKA_122900 & PBANKA_114540 in PbΔTRX2 infected 
cells compared to wild type. c & d) Quantitation of fluorescence intensity 
(CTCF) of images presented in (b) shows no significant differences between 
PbΔTRX2KO compared with wild type infected erythrocytes (n=100). Error 
bars represent SEM for all replicates. 
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Figure 5.2: Generation of a P. berghei TRX2 knockout encompassing a 
GFP reporter.  
a) Schematic of the targeting constructs designed to integrate an exported 
GFP reporter into the endogenous P. berghei TRX2 locus by double 
crossover recombination. The predicted structure of the endogenous locus 
before and after integration is shown. b) Schematic representation of the 
complemented gene replacement. Integration of either construct into wild 
type parasites results in GFP that should be exported based on the KAHRP 
signal sequence and PEXEL motif (KsP).   hDHFR indicates human DHFR 
selectable marker cassette. c) Southern blot analysis of genomic DNA 
extracted from P. berghei WT, WT+GFP and PbΔTRX2+GFP parasites after 
pyrimethamine selection. Digestion with EcoRI/BglII or NdeI/BglII and 
hybridised with the 5’ targeting sequence probe show that the endogenous 
gene (E) is present in wild type parasites but is missing in both transgenic 
parasites, and bands indicative of an integration event (I) were observed at 
the predicted sizes in WT+GFP and PbΔTRX2+GFP. Molecular weights are 
indicated.   
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Figure 5.3: Time-course of GFP expression and export in transgenic 
parasites.   
Representative images of live cell GFP expression of either wild type or 
PbΔTRX2 infected cells, taken at sequential time-points after parasite 
invasion. In PbΔTRX2, an initial delay of GFP export is observed at 8hrs post 
infection, however by 16hrs post infection, GFP export in the P. berghei 
TRX2 knockout parasites is equivalent to that of wild type. BF, Bright field. 
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Figure 5.4: Schematic of the constructs designed for episomal 
expression of Nanoluc in P. berghei.   
a) Exported Nanoluc (with PEXEL and signal sequence) and b) Non-
exported Nanoluc (no PEXEL or signal sequence). hDhFR SM indicates 
human DHFR selectable marker cassette; Green arrows indicates 
transcription start and red stop indicates the transcription terminator. KsP 
indicates KAHRP signal sequence & PEXEL motif. c) Nanoluc (NL) export 
calculated as a percentage of NL in erythrocyte cytosol divided by the total 
NL expressed.  Exported NL measured as a percentage between wild type 
and PbΔTRX2 (n=16) parasites harboring NL expression plasmid showing no 
significant difference in export capacity.  
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Figure 5.5: Generation of semi-immune sera against P. berghei 
infection. Representative IFA of wild type infected erythrocyte surface 
expressed antigens reacted with a) non-immune or b) semi-immune sera. c) 
The PbΔTRX2 infected cell surface is partially recognised by the semi-
immune sera. The original magnification for all IFA images was ×1000. 
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Figure 5.6: Disruption of P. berghei TRX2 leads to reduced protein 
export on the erythrocyte surface.  
Ratios of the erythrocyte surface labeling was determined from 
asynchronous infections by flow cytometry using non-immune sera staining 
as a baseline (for background labeling) and with wild type export 
percentages set at 100%. Quantitative FACS data shown graphically of wild 
type (n=7) and PbΔTRX2_1 (n=7) and PbΔTRX2_2 (n=6) whereby parasites 
with the TRX2 gene deletion exhibit significantly reduced levels of surface 
labeling with P. berghei semi-immune sera compared with wild type parasites 
(*P=0.05; **P=0.01; ***P=0.001, unpaired t-test). 
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Figure 5.7: Disruption of P. berghei TRX2 leads to reduced protein 
export in synchronous infections.  
a) Giemsa smears showing the stages of parasite development at time points 
relative to when wild type parasites had invaded erythrocytes. PbΔTRX2 
parasites exhibit significantly reduced levels of surface labeling with P. 
berghei semi-immune sera compared with wild-type parasites. b) 
Quantitative FACS analysis of erythrocytes harvested from synchronous 
mouse infections initiated by injection of purified merozoites into the tail veins 
of mice. Surface labeling of infected erythrocytes with semi-immune sera was 
performed at time points relative to when the wild-type parasite line 
reinvaded erythrocytes for the second cycle post invasion. Taking into 
consideration that disruption of TRX2 leads to slower growth by about 6 hrs, 
the surface labeling of PbΔTRX2 parasites at a stage of growth comparable 
to that of wild type parasites is also significantly reduced (n=3 independent 
experiments). (*P=0.05; **P=0.01; ***P=0.001, unpaired t-test). 
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Figure 5.8: Surface modification of infected erythrocytes 
a) Representative images after scanning electron microscopy of uninfected, 
PbANKA wild type or PbΔTRX2 infected erythrocytes. Differences observed 
between the uninfected and wild type infected cell surface in the form of 
knob-like protrusions extending from the erythrocyte membrane. PbΔTRX2 
infected cells resemble the uninfected control. b) No of protrusions counted 
on the surface or either wild type or PbΔTRX2 infected erythrocytes 
observed under SEM, showing a significant reduction in protrusions on the 
erythrocyte surface of PbΔTRX2 infected cells. Data pooled from multiple 
samples prepared on different days (n=100). 
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Using a number of different approaches in this study, it could be confirmed 
that orthologues of the P. falciparum PTEX orthologues exist in the rodent 
malaria species, P. berghei. Additionally, it provided validation that that 
PTEX88 and TRX2 are bona fide constituents of PTEX. This confirmation 
provided a solid grounding for further analysis of P. berghei PTEX 
components in vivo, to assess their role in both parasite virulence and 
survival and to confirm whether PTEX is indeed responsible for exporting 
parasite proteins.     
Despite multiple attempts to genetically disrupt P. berghei EXP2, HSP101, 
PTEX150 and PTEX88, all were unsuccessful. In contrast, TRX2 could be 
genetically deleted on numerous occasions. These findings are consistent 
with those of Matz et al199, with the exception that they were also able to 
knockout P. berghei PTEX88 in addition to TRX2, most likely because they 
employed much more sensitive parasite recovery methods that involved the 
selection of fluorescent knockout parasites by FACS sorting. Given that 
EXP2, HSP101 and PTEX150 could be epitope-tagged, the inability to 
knockout these genes suggests that they are essential to the parasite. 
Formal proof of this has come from a recent paper that used gene 
regulatable systems developed for P. falciparum and P. berghei to 
knockdown expression of PTEX150 and HSP101, respectively200. In the case 
of PTEX150, a transgenic parasite was derived in which the PTEX150 locus 
was modified to incorporate a glucosamine-inducible glmS ribozyme within its 
3' UTR. Upon addition of glucosamine to the culture media, cleavage of the 3' 
UTR by the ribozyme hastened degradation of PTEX150 mRNA, leading to 
parasite death. In the case of HSP101, transgenic parasites were derived in 
which the HSP101 coding sequence was placed under the transcriptional 
 
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control of an anhydrotetracycline (ATc)-regulated transactivator element205, 
and thus HSP101 mRNA levels could be regulated by the addition of ATc to 
the drinking water of mice. Similar to the PTEX150 knockdown, reduction of 
HSP101 transcript levels was lethal to the parasite. Similar analyses have 
been performed for P. berghei EXP2 by de Koning-Ward (unpublished), 
however, given how abundant the levels of EXP2 transcript are in the 
parasite, it has been difficult to obtain efficient knockdown of EXP2 
expression for phenotypic analysis.  
The ability to generate a P. berghei TRX2 knockout reveals that at least in 
this species, TRX2 is a non-essential PTEX component, and therefore, very 
unlikely to make a suitable drug target. Nonetheless, the PbΔTRX2 parasites 
provided a valuable tool to dissect the role of PTEX in protein export as 
despite having a slower growth rate, the genetic modification was not lethal 
to the parasite. Whilst the export assays performed on the PbΔTRX2 line did 
not yield noticeable changes in the localization of endogenous proteins that 
are normally exported into punctate structures in the erythrocyte cytosol, the 
PbΔTRX2 parasites did have an overall reduction in global protein export 
even when delayed growth was taken into consideration. Given that the 
PbΔTRX2 parasites also exhibited a delay in their ability to export a GFP 
reporter, it is likely that loss of TRX2 leads to a reduced efficiency of overall 
export, although it cannot be ruled out that TRX2 may also play a role in 
exporting a particular subset of proteins that were not specifically 
investigated here.  Importantly, when the export assays developed in this 
study were used to measure export deficiencies in the P. berghei HSP101 
inducible knockout parasites, Pbi101KD, the export results were very striking 
and consistent with anticipated levels of export when comparing disruption of 
 
	
an essential PTEX component to a non-essential gene. Not only did Pbi101 
KD have a much greater reduction in global parasite protein exported to the 
infected erythrocyte surface (Supp Figure 1), there were also clear 
differences between the export of individual PEXEL proteins, 
PbANKA_114540 and transmembrane domain positive, PbANKA_122900 as 
observed by IFA when exposed to different ATc regimes (Supp Figure 2). 
Moreover, knockdown of HSP101 also resulted in retention of a PEXEL-
negative protein EMAP1 (PbANKA_083680) at the PV and this protein was 
not observed at its typical location at the erythrocyte membrane109 (Supp 
Figure 2). These assays, in combination with the assays undertaken on the 
P. falciparum PTEX150 knockout have provided the definite proof that PTEX 
is not only involved in the export of soluble cargo, but in the export of both 
PNEPs as well as transmembrane-domain containing proteins. Thus, PTEX 
is a central player in the protein export process and thus represents an 
Achilles’ heel of the parasite.  
Despite export being drastically affected by PTEX disruption, limitations 
still exist in the experimental capabilities of phenotypically characterising the 
PTEX inducible knockouts as any change to PTEX that has a profound effect 
on protein export has dire consequences to parasite survival. Thus 
deciphering the function of individual PTEX components has not yet been 
definitely solved. Looking at other translocons that exist in nature has 
enabled predictions as to what they may be. Generally, whilst other 
translocons found in nature are unique, they share a number of unifying 
features, albeit whether they found in eukaryote organelles (eg. ER, 
mitochondria, chloroplasts or peroxisomes) or in prokaryotes, that include 
receptors to recognise cargo to be translocated, a membrane-spanning 
 


component that provides paasge through the membrane, energy (ATP, GTP 
or a membrane potential) to facilitate the translocation process as well as 
chaperones to unfold and refold cargo. Additionally, they comprise of 
components that are not essential for the translocon to operate, but which 
help to regulate activities such as translocon assembly or their configuration 
in an open or closed state, or the translocation of particular proteins under 
certain conditions. For example, genetic deletion of some members of the 
TOC complex of chloroplasts, have yielded minimal or no change in 
translocation phenotype. Deletion of Toc64, a translocon component that is 
peripherally associated through its interaction with Toc34206-208 in the 
chloroplasts of both in Physcomitrella patens and Arabidopsis209,210, resulted 
in a change in the shape of chloroplast in moss. However the gene deletion 
in either species did not exhibit any changes to protein translocation209. 
The inability to knockout EXP2 is consistent with the original proposal by 
de Koning-Ward et al1 that this component forms the pore in the PVM. 
Analysis of chemical extraction fractions demonstrated that EXP2 associates 
most strongly with the integral membrane-associated fraction both in 
schizonts1 and ring-stage parasites176, suggesting EXP2 is directly 
membrane-associated when PTEX presumably functions176. EXP2 also 
displays a homo-oligomer confirmation indicative of its predicted pore-like 
structure176. Nonetheless, evidence that EXP2 is the pore is still 
circumstantial and further work is required to dissect exactly how EXP2 
associates with the membrane and if it is in fact indeed capable of forming 
pores through a membrane similar to HlyE, as previously proposed1 or some 
other mechanism. 
Translocation of proteins in P. falciparum requires energy157. Inhibitors that 
 

deplete ATP in the erythrocyte cytosol resulted in an arrest of secretion of 
glycophorin-binding protein (GBP). Addition of ATP reversed the phenotype 
and resulted in the translocation of GBP157.  In PTEX, the energy source is 
most likely provided by HSP101 activity based on its active AAA+ ATPase 
domain211 and the essentiality of this protein to both protein export and 
parasite survival is in keeping with this200. ATPases are associated with 
diverse cellular functions and play essential roles in different cellular activities 
like proteolysis, membrane trafficking, cytoskeletal regulation, protein 
folding212. They are found in all organisms and typically assemble into 
hexameric ring structures that are involved in energy dependent 
macromolecule remodeling180. Plasmodium HSP101 is also predicted to form 
a hexameric structure1 that undergoes conformational change after binding 
and hydrolysis of ATP213,214 to unfold protein cargo prior to translocation 
across the PVM. Thus, HSP101 likely functions in the opposite manner to the 
related ClpC chaperone211 (also termed HSP93), found in plant and algal 
chloroplasts, which docks onto Tic40/Tic110 in the TIC protein translocon 
system on the trans side of the membrane to ratchet proteins for import 
through the translocon208.  
Additionally, protein export in Plasmodium parasites requires proteins to 
be unfolded156. Thus, PTEX is similar to most other translocation machineries 
(eg, ER, chloroplast, mitochondria, and bacterial secretion systems) that 
require cargo to be in a loosely folded conformation so that they can cross 
the target membrane158,170,171. In contrast, the thylakoidal system of bacteria 
or the twin Arg translocation (Tat) pathway, have the ability to transport tightly 
folded proteins215. In other systems, misfolding, aggregation of cargo and the 
prevention of undesired interactions with other cellular proteins158, relies on 
 

the presence of chaperones to bind to the synthesized proteins and these 
commonly depend on ATP hydrolysis for their activity158,216.  For example, 
DnaK and DnaJ are well-established cytosolic chaperones in prokaryotes217.  
DnaK binds the protein to be translocated to prolong its translocation 
conformation thus increasing the time for engagement of the signal sequence 
with the translocon channel158,218,219.  Proteomic analysis of the Plasmodium 
vacuolar content revealed an abundance of chaperones198 and whilst 
HSP101 may itself have a chaperone role, it may also require the assistance 
of other proteins to keep the cargo in a competent state for export. 
While the role of PTEX150 within PTEX remains unknown, 
immunoprecipitation data suggests it interacts with both EXP2 and 
HSP101176 and thus it may serve as a structural component. Keeping the 
PTEX complex together would be consistent with the essential nature of 
PTEX150 and the detrimental consequences that PTEX150 deletion has on 
protein export. PTEX150 may serve as a platform for HSP101 to dock onto or 
it may act as a receptor that receives cargo. The role of PTEX88 in the 
complex also remains unknown.  There are no distinguishing features in this 
protein by which to predict function. Although it can be genetically deleted199, 
parasites grow very poorly, indicating that whilst it is non-essential it is likely 
to still make a significant contribution to PTEX function. Further assessment 
of the PTEX88 gene deletion parasite line is required, with a specific focus on 
protein export and how the gene deletion affects the stability and structure of 
the PTEX complex. 
Despite the fact the TRX2 could be genetically deleted and parasites could 
be phenotyped to determine the consequence on protein export, virulence 
 

and survival, at this point, it is still not possible to ascertain the specific role of 
TRX2. This will require the identification of its substrate protein/s. However, 
since TRX2 is a non-essential PTEX component, its role in PTEX is most 
likely to be regulatory. TRX2 could help to regulate the efficiency of PTEX by 
the formation of disulphide bonds within EXP2 or PTEX88 to maintain PTEX 
in an open or closed confirmation. Alternatively, it may regulate the export of 
cargo for export that contain disulphide bonds, by helping with unfolding prior 
to export. The export of proteins containing disulphide bonds, was not 
examined in this study, as the identification of such proteins are unknown in 
P. berghei and consequently there are no reagents available that specifically 
recognise these in P. berghei. It remains to be seen if deletion of TRX2 in P. 
falciparum is permissible and if the export of proteins such as STEVOR, 
RIFIN and PfEMP1, all of which contain disulphide bonds, is affected.  
Using the export assays described in this study, functional evidence that 
PTEX is responsible for parasite protein export has been formally proven, 
especially with the HSP101 knockdown parasite line, in which export of both 
PEXEL and PNEPs was completely blocked200. This is direct evidence that 
the role of the PTEX molecular machine is to translocate all proteins destined 
for the host cell across the PVM into the host cytosol, and directly or 
indirectly, for parasite proteins expressed on the infected erythrocyte surface. 
However many questions about PTEX assembly and the mechanism of 
action still remain unanswered. PTEX has been described as being a five 
member complex, however like other translocons, it may actually comprise of 
more interacting partner proteins, some of which may only transiently interact 
with PTEX and thus may be difficult to identify. It also remains unknown how 
proteins destined for export reach PTEX or are specifically recognised by 
 

PTEX, and whether there are multiple receptors that recognise distinct cargo. 
Along with this, chaperones are commonly required to refold the proteins 
translocated across a membrane and in Plasmodium, these may be either 
parasite derived or recruited from the host, however the identity of these 
have yet to be confirmed.   
As PTEX provides a common portal for protein export, blocking its function 
with the use of drugs would block the export of hundreds of parasite proteins 
with diverse functions. From this study, the three essential components of 
PTEX, PTEX150, HSP101 and EXP2, would represent the best drug targets. 
However it is unknown which of these are in fact the most druggable. 
Affecting the ATPase activity may block HSP101, however inhibitors would 
need to be stringently selective against parasite HSP101 and not block the 
function of host HSP100 proteins, which are typically well conserved. For 
EXP2, the oligomerisation could be targeted to retard its ability to form a pore 
and the subsequent passage of exported proteins. It is less clear for 
PTEX150 how its function can be blocked with drugs, but like EXP2, this 
protein is completely unique to malaria parasites, and thus it is worthwhile to 
pursue drugs that target these proteins. Importantly, drug-targeting PTEX 
would be sufficiently novel to circumvent cross-resistance to existing anti-
malaria drugs.  
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Supplementary Figure 1: Knockdown of P. berghei HSP101 blocks 
export of PEXEL and PNEP proteins.  
a) Surface labeling of parasite antigens on Pbi101 KD parasites harvested 
between days 1 and 2 post infection from mice pretreated with ATc was 
substantially decreased compared with infected erythrocytes not exposed to 
ATc as measured by FACS. b) Staggered parasite sampling with ATc 
treatment given for 12 or 24 hrs (n=8; error bars represent s.e.m.; ***P , 
0.001, using unpaired t-test). Boxes and whiskers delineate all data points, 
with whiskers indicating minimum and maximum values.  
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Supplementary Figure 2: Surface labeling of parasite antigens  
a) Asynchronous Pbi101 KD parasites grown to high parasitemia followed 
with ATc treatment for either 12 or 24 h (n 5 8; error bars represent s.e.m.). 
Representative IFA of 100 Pbi101 KD intraerythrocytic stages, showing that 
exposure to ATc blocks export of PEXEL (top and middle panels) and PNEP 
(bottom panel) proteins. Yellow bar in all diagrams, signal sequence; red bar, 
transmembrane domain; black bar, glycosylphosphatidylinositol anchor. DIC, 
differential interference contrast. b) Expression of MSP8 is not affected by 
ATc treatment. Scale bars, 5μm. 
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